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VIII. Summary 
 
The lipid kinase VPS34 is an essential mediator of multiple aspects of intracellular trafficking via 
the formation of phosphoinositide-3-phosphate (PI(3)P) on membranes, this is critical to 
mediate efficient trafficking of cargo by endocytosis. In addition, VPS34 kinase activity is 
essential for inducing autophagy in combination with the protein kinase ULK1. Autophagy acts 
as a catabolic pathway that is up regulated in response to stress, but is negatively regulated by 
the master growth protein kinase mTOR. This study sought to identify novel control mechanisms 
that may mediate the regulation of VPS34 between the pathways of endocytosis and autophagy. 
During nutrient rich conditions a binding protein of VPS34, UVRAG, was identified to be 
phosphorylated. Further analysis has identified that phosphorylation is mediated by mTOR and 
that this occurs at two sites, S550 and S571. Multiple lines of evidence suggest that 
phosphorylation does not alter the stoichiometry or localisation of the complex nor does it 
mediate recruitment of additional factors. Phosphorylation of UVRAG acts to increase lipid 
kinase activity in vitro and cellular PI(3)P levels by ~ 2 fold, mutation of S550 and S571 to alanine 
residues abrogate this increase in activity. Examination of autophagy, receptor mediated 
endocytosis and recycling have demonstrated no effect of UVRAG phosphorylation upon their 
rate of trafficking. Mutation of UVRAG phosphorylation sites however leads to a significant 
lysosome abnormality that is demonstrated by a dispersed phenotype. Preliminary analysis 
suggests that this may occur due to abnormalities in the process of autophagic lysosome 
reformation, a process that is dependent upon the activity of mTOR. This suggests a previously 
uncharacterised role of PI(3)P in lysosomal regulation and adds to current understanding of 
regulation between VPS34 and mTOR. Additionally data presented here examines a novel 
PI3KC3 inhibitor that demonstrates profound selectivity over other PI3K isoforms and lipid 
kinases. This will be important to further examine the functional role of VPS34 and UVRAG. 
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1 Introduction 
 
1.1 Endocytosis  
1.1.1 The Cell Surface 
 
The plasma membrane defines the edge of a cell and is a dynamic structure that physically acts 
to separate and protect cellular contents, be it part of a uni- or multicellular organism, from a 
fluctuating exterior environment. Cells require basic nutrients such as sugars and proteins for 
survival, when available in excess cells are able to utilise these to grow and divide. The plasma 
membrane barrier however means that specialised processes are required for the uptake of 
components from the exterior environment. Multiple mechanisms exist to internalise ‘cargo’ 
and can be broadly referred to as the process of ‘Endocytosis’ (Doherty & McMahon 2009). 
Traditionally endocytosis was thought simply to traffic cargo to the lysosome, an acidic 
degradative organelle, to break down material (Duve & Wattiaux 1966). Through intensive study 
our understanding has vastly increased to appreciate that endocytosis is inextricably linked with 
intracellular trafficking and signalling to mediate all aspects of cellular logistics (Sigismund et al. 
2012). Endocytosis ultimately governs the relationship of a cell with its exterior environment 
and this is crucial for survival. Alterations in the exterior environment can result in periods where 
nutrients are no longer freely accessible, it is during these times that the cell must efficiently 
identify that resources are limited and respond by implementing changes to allow survival until 
fresh nutrients become available. Part of this process involves reducing anabolic activities whilst 
simultaneously activating catabolic pathways, failure to do so and continuing growth under 
these circumstances would be catastrophic and ultimately lead to cell death (Tsukada & Ohsumi 
1993). Understanding the interaction of cells with their exterior environment and how this 
regulates cellular pathways to determine growth is of fundamental importance, particularly as 
impaired endocytosis and growth signalling are commonly associated with human disease such 
as cancer. 
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This chapter will examine further the processes of endocytosis and intracellular transport, in 
addition the pathways of cell catabolism upon nutrient restriction will be explored. Most 
importantly, our current understanding of the mechanisms utilised by the cell to modulate and 
regulate these pathways will be discussed. 
1.1.2 The Endocytic Pathway 
 
 
Figure 1.1 - Mechanisms of Endocytosis 
Adapted from (Conner & Schmid 2003) . Demonstrates the mult iple mechanisms util ised by cells 
to internal ise cargo and the size of endocytic vesicle produced.  
 
The process of endocytosis can be divided into two primary groups dependent on whether it 
mediates the uptake of particles (Phagocytosis – ‘Cell eating’) or uptake of solutes and fluid 
(Pinocytosis – ‘Cell drinking’). Pinocytosis can be further sub-divided based upon uptake 
mechanism, whereby fluid-phase endocytosis refers to the non-selective bulk fluid uptake by 
the cell. Receptor-mediated endocytosis (RME) by comparison utilises high affinity receptors to 
bind specific ligands (Besterman & Low 1983) and this includes the well characterised epidermal 
growth factor receptor (EGFR) and the transferrin receptor (TR) (Karin & Mintz 1981; Sullivan et 
al. 1976). Upon ligand binding, receptors cluster and are internalised by clathrin-mediated 
endocytosis (CME) into small vesicles. Other forms of cellular uptake include caveolin-mediated 
endocytosis and non-clathrin endocytosis (NCE) that utilise distinct mechanisms for vesicle 
formation that also differ in size (Mayor & Pagano 2007).  
15 
 
 
 
 
Figure 1.2 - The Endocytic Pathway 
Internal isat ion of act ivated receptors by CME traff ics material to the early endosome where cargo 
is  sorted for recycling or degradation.  Material can undergo ‘ fast’  direct recycling to the plasma 
membrane or ‘s low’ recycl ing v ia a recycl ing endosome. Further internalisat ion of cargo  into 
intraluminal  vesic les ( ILVs) within the late endosome commits the cargo to degradation by fusion 
with the lysosome.  
 
The breadth of internalisation mechanisms employed by a cell ensures the uptake of numerous 
cargoes that in some cases display preference for particular internalisation mechanisms (Eyster 
et al. 2009; Traub 2003). The rate of endocytic processes is also varied between cell types 
dependent upon their function, macrophages for example extensively utilise phagocytosis for 
the uptake of large debris or pathogens (Aderem & Underhill 1999). 
Internalisation of material by pinocytosis leads to a series of trafficking and sorting steps via 
vesicular structures known as endosomes to determine material that is to be recycled to the cell 
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surface or degraded at the lysosome (Steinman et al. 1983). Early endosomal structures that are 
present near the cell periphery act at the first step of cargo sorting (Steinman et al. 1983), 
receptors can be rapidly returned to the cell surface by direct trafficking or alternately a slower 
recycling pathway exists that involves trafficking to a recycling endosome prior to return to the 
cell surface (van Dam et al. 2002). Whilst at early endosomal structures receptor mediated 
signalling can still occur as the C-termini is still cytoplasmic facing (Lloyd et al. 2002). Signalling 
can be terminated by targeting the receptor for degradation by incorporation into intraluminal 
vesicles (ILVs) that bud inward at the endosome, this leads to the characteristic vesicular 
appearance of late endosomes also known as multi-vesicular bodies (MVBs) (Futter et al. 2001). 
Once internalised the receptor can no longer signal as the C-termini no longer contacts the 
cytoplasm, MVBs then ultimately fuse with lysosomes, causing the breakdown of material by 
acid hydrolases (Hershko & Ciechanover 1982).   
1.1.3 Intracellular Trafficking and the Lysosome 
 
Within the cell multiple distinct trafficking pathways exist that transport material between 
specific organelles and locations, this is essential to ensure cellular components are located at 
the regions where they are required for function. Vesicular trafficking is a complex process that 
requires many proteins, however, the process can be divided into four major steps (Figure 1.3). 
Adaptor proteins (APs) recognise cargo and recruit coat proteins to induce vesicle budding (Ford 
et al. 2001), the vesicle then undergoes scission (Bliek & Redelmeier 1993) and is trafficked 
towards the acceptor membrane (Caviston & Holzbaur 2006). Tethering proteins and Rab 
GTPases work together (Simonsen et al. 1998) to bring membranes close together that allow 
membrane fusion mediated by soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (SNAREs) (Söllner et al. 1993).  
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Figure 1.3 - Basic Steps of Vesicular Trafficking 
Figure adapted from (Cai et  al.  2007). (1) Coat proteins are recruited via adaptor proteins (AP) to 
the donor membrane, APs also bind cargo to be internal ised (Ford et al.  2001) . The vesicle is  
released from membrane by Dynamin mediated sc ission (Hinshaw & Schmid 1995) . (2)  Vesicles are 
transported to the acceptor membrane by motor proteins and microtubules (Caviston & Holzbaur 
2006).  (3)  Tethering factors and Rab GTPases bind vesicles (Simonsen et al.  1998)  to reduce the 
membrane distances to assist with (4) membrane fusion mediated by SNARE proteins (Söllner et  
al.  1993).  
Multiple cellular trafficking pathways exist (Figure 1.4) and are often characterised by distinct 
components. Adaptor protein complex 2 (AP-2) is utilised in transport from the plasma 
membrane (Gaidarov & Keen 1999) whilst AP-1 mediates Golgi to Endosome transport (Traub 
et al. 1993). Transport via the Golgi is critical for lysosomal hydrolases that are translocated into 
the lumen of the endoplasmic reticulum (ER) during synthesis and then subsequently require 
transport to the lysosome where they become active in the acidic pH of the lumen (Kornfeld 
1987). Newly formed hydrolases contain a mannose 6-phosphate tag that, following transport 
to the trans-Golgi network (TGN), is recognised and bound by mannose-6-phosphate receptors 
(M6PRs) (Dahms et al. 1989). The M6PR-hydrolase complex is then trafficked to endosomes 
where the mildly acidic pH triggers the release from the receptor (Kornfeld 1987). Hydrolases 
remain in the endosome as they mature to assist with proteolytic degradation, meanwhile the 
vacant M6PRs are transported back to the TGN to repeat this process and prevent the 
degradation of the receptor by the lysosome (Brown et al. 1986). An equivalent pathway exists 
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in yeast that transports vacuolar proteases including carboxypeptidase Y (CPY) from the ER via 
the Golgi to the vacuole (Stevens et al. 1982).  
 
Figure 1.4 - Intracellular Trafficking Pathways 
Multiple pathways exist  in the cel l in addition to the endocytic pathway (recycl ing not included 
in this f igure).  Material internal ised is  trafficked to the lysosome by the endosomes,  but these 
are interlinked with transport to and from the Golgi.  Upon formation , lysosomal hydrolases are 
delivered to the lysosome via traff icking from the Golgi,  which also acts to direct  cargo for 
secretion.  
  
19 
 
 
1.1.4 Identification of Vacuolar Protein Sorting (vps) Mutants 
 
Several pioneering genetic mutational analyses were carried out in yeast cells that examined the 
transportation of CPY to determine proteins required for transport to the vacuole. It had 
previously been identified that over-expression of CPY or mutating the sorting signal caused CPY 
to be transported from the Golgi to the plasma membrane for secretion instead of localisation 
to the vacuole (Johnson et al. 1987; Stevens et al. 1986). This phenotype was taken advantage 
of experimentally as yeast cells that secrete CPY following genetic mutation are likely to be 
deficient in trafficking to the vacuole and this approach led to the classification of eight vacuolar 
protein localisation (vpl) mutants (Rothman & Stevens 1986). This method was improved by 
fusing CPY to the enzyme invertase that is normally secreted and allows yeast growth on sucrose 
(Bankaitis et al. 1986). Fusion to CPY results in delivery to the vacuole that is only reverted to 
the secretory pathway if transport to the vacuole is impeded (Johnson et al. 1987). This approach 
improved the identification of vacuolar trafficking mutants as yeast are only viable on sucrose if 
trafficking is impaired, this led to the identification of vacuolar protein targeting (vpt) mutants 
(Bankaitis et al. 1986)(Robinson et al. 1988). Mutants can be sub-divided into three classes by 
vacuolar phenotype where class A causes no effect, class B causes vacuole fragmentation and 
class C yeast exhibit vacuole biogenesis defects (Banta et al. 1988). Further vpl mutants were 
identified by secretion of CPY and compared to previously identified vpt mutants or pep mutants 
that have decreased expression of CPY (Jones 1977; Rothman et al. 1989). Significant overlaps 
were detected between mutants and as such vpt, vpl and pep mutants were consolidated and 
renamed as vacuolar protein sorting (vps) mutants. These experiments were critical in 
establishing an initial list of essential trafficking proteins that we now understand to be involved 
in all aspects of cellular trafficking and not simply limited to vacuolar protein sorting. Current 
understanding of the 40 vps mutants identified in vpl and vpt screens is shown in Table 1. 
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VPS VPL VPT Class PEP Mammalian 
Homolog 
Complex Role 
1 1 26 B - Dynamin N/A Vesicle Scission 
2 2 - A - VPS2 (CHMP2) ESCRT-III MVB formation 
3 3 17 A 6 VPS3 CORVET Complex Tethering 
4 4 10 A - VPS4 (SKD1) VPS4-VTA1 complex ATPase 
5 5 5 B 10 VPS5 Retromer Endosome to TGN 
transport 
6 6 13 A - Syntaxin SNARE Q-SNARE 
7 7 - A 15 Unknown Unknown Unknown 
8 8 8 A - VPS8 CORVET Complex Tethering 
9 - 9 A - VPS9D1 Rab5 GEF GEF 
10 - 1 A - VPS10 CPY Transport TGN -> 
Vacuole 
CPY Receptor 
11 9 11 C 5 VPS11 Class C-VPS Complex Lysosome Fusion 
12 - 12 A - Unknown Unknown Unknown 
13 - 2 A - VPS13A-D 
(Chorein) 
N/A Unknown – Possibly 
TGN to late endosome 
14 - 14 A - CHMP2A ESCRT-III MVB Formation 
15 - 15 A - VPS15 PI3KC3 Complex Endocytosis + 
Autophagy 
16 - 16 C - VPS16 Class C-VPS Complex Lysosome Fusion 
17 - 3 B 21 VPS17 Retromer Endosome to TGN 
transport 
18 - 18 C - VPS18 Class C-VPS Complex Lysosome Fusion 
19 - 19 A - Unknown Unknown Unknown 
20 10 20 A - VPS20 (CHMP6) ESCRT-III MVB formation 
21 - 21 A - Rab5 N/A Rab 
22 14 22 A - VPS22 (EAP30) ESCRT-II MVB formation 
23 15 23 A - VPS23 (TSG101) ESCRT-I MVB formation 
24 - 24 A - VPS24 (CHMP3) ESCRT-III MVB formation 
25 12 25 A - VPS25 (EAP20) ESCRT-II MVB formation 
26 - 4 A 8 VPS26A / B Retromer Endosome to TGN 
transport 
27 - 27 A - HRS ESCRT-0 MVB formation 
28 13 28 A 12 VPS28 ESCRT-I MVB formation 
29 - 6 A - VPS29 Retromer Endosome to TGN 
transport 
30 - 30 A - BECLIN1 PI3KC3 Complex Endocytosis + 
Autophagy 
31 - 31 A - ALIX (AIP1) N/A Adaptor protein - 
MVBs 
32 - 32 A - SNF7 (CHMP4) ESCRT-III MVB formation 
33 - 33 C - VPS33 (PEP14) Class C-VPS Complex Lysosome Fusion 
34 - 29 A - VPS34 PI3KC3 Complex Endocytosis + 
Autophagy 
35 - 7 A - VPS35 Retromer Endosome to TGN 
transport 
36 11 - A - VPS36 (EAP45) ESCRT-II MVB formation 
37 16 - A - VPS37 ESCRT-I MVB formation 
38 17 - A - UVRAG PI3KC3 Complex Endocytosis 
39 18 - A - VPS39 HOPS Complex Lysosome Fusion 
40 19 - B - Unknown Unknown Unknown 
Table 1 – Vacuolar Protein Sorting Mutants, Homologues and Function 
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1.1.5 VPS34 Modulates Trafficking by PI3K Activity 
 
Vps mutants have been studied intently since identification to characterise the mechanisms by 
which they mediate trafficking. Of these proteins, VPS34 is now known to be an essential 
mediator of multiple trafficking steps and plays a key role in signalling events directing both 
endocytosis and autophagy.  
Initial characterisation of Δvps34 yeast cells demonstrated a temperature sensitive growth 
defect and that Vps34p binds to membrane structures (Herman & Emr 1990). Vps34p has 
significant homology to the catalytic domain of the lipid kinase PI3Kα and analysis in vitro 
revealed that VPS34 also contains Phosphatidylinositol 3-kinase (PI3K) activity (further 
examined in 1.1.6)(Schu et al. 1993). The vacuolar phenotype of Δvps15 and Δvps34 is very 
similar and does not cleanly fall into the defined vacuolar class types, suggesting the two 
proteins may be interlinked (Banta et al. 1988). Vps34p and Vps15p were identified to 
co-fractionate by density gradient and could also be reciprocally immunoprecipitated with one 
another, this was later determined to be mediated by the final ~ 30 amino acids at the C-termini 
of Vps34p (Budovskaya et al. 2002; Stack et al. 1993). Vps15p is a protein kinase and is 
myristoylated at the N-terminus, a modification that commonly enables membrane binding, 
however mutation of the myristoylation site had no effect upon membrane association (Herman 
et al. 1991; Madsen et al. 2010). The mechanism through which Vps15p regulates Vps34p is not 
entirely understood, although it is clear that Vps34p from Δvps15 yeast is deficient in membrane 
binding and lipid kinase activity is severely impaired (Stack et al. 1993).  Expression of a Vps15p 
kinase domain mutant restores Vps34p membrane binding, but does not rescue lipid kinase 
activity suggesting that Vps15p protein kinase activity mediates lipid kinase activity (Stack et al. 
1993). Substrates of Vps15p however have not been identified and the level of Vps34p 
phosphorylation is not altered between wild-type or Δvps15 mutants (Stack & Emr 1994). The 
mammalian homolog VPS34 was identified based upon homology to the yeast Vps34p and is 
also shown to possess PI3K activity; additionally it has been identified to interact with p150, a 
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homologue of Vps15p (Volinia et al. 1995). Blockade of PI3K activity by use of inhibitory 
antibodies impairs the trafficking of platelet-derived growth factor receptor and the formation 
of ILVs (Siddhanta et al. 1998; Futter et al. 2001). Additionally PI3K inhibition using the inhibitor 
wortmannin blocks the fusion of early endosomes (Jones & Clague 1995). Although wortmannin 
is not specific for PI3KC3 inhibition (Arcaro & Wymann 1993; Stack & Emr 1994), taken together 
the data is highly suggestive that the lipid kinase activity and formation of PI(3)P is critical for 
mediating trafficking by VPS34. This led to further study and understanding of the regulation of 
phosphoinositides in trafficking.  
 
1.1.6 Phosphatidylinositol and Phosphoinositides 
 
Phosphatidylinositol (PtdIns or PI) is a glycerolipid composed of two non-polar fatty acid chains 
connected to a glycerol backbone and phosphate group containing an inositol ring polar head 
group (Figure 1.5) and represents a minor proportion of eukaryote cellular membranes, 
contributing to less than 15% of the total lipid composition (van Meer & de Kroon 2011). The 
polar inositol head contains five hydroxyl groups, where position three, four or five can be 
phosphorylated either singly or in combination to yield seven distinct lipids referred to as 
phosphoinositides (Di Paolo & De Camilli 2006). The hydroxyl groups at position two and six are 
not phosphorylated due to steric hindrance (Figure 1.5). 
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Figure 1.5 - Structure of Phosphatidylinositol 
The structure of phosphatidylinositol is shown. Numbers in brackets represent the hydrox yl group 
number that is ut il ised for the naming of phosphoinosit ide species.  
 
All seven phosphoinositides species have been identified in mammalians and are estimated to 
account for ~ 8 % of cellular PtdIns or ~ 1 % of total lipids (Figure 1.6). The abundance of 
individual phosphoinositides species varies greatly; PI(3,5)P2 for example is present at 
concentrations ~ 125 fold lower than that of the most abundant phosphoinositide PI(4,5)P2 
(Zolov et al. 2012). 
Phosphorylation is catalysed by phosphatidylinositol kinases (PIKs) that are divided into classes 
based upon their inositol head group target. These are phosphatidylinositol-3-kinases (PI3Ks), 
phosphatidylinositol-4-kinases (PI4Ks) and phosphatidylinositol-5-kinases (PI5Ks) that 
phosphorylate inositol position 3,4 and 5 respectively (Fruman et al. 1998). PIKs selectively 
phosphorylate a single position, therefore the formation of phosphatidylinositol-bis- or 
tris-phosphate requires sequential kinase activity (Figure 1.6). PI3Ks are further divided into 
class I, II and III dependent upon their substrate preference in vivo. Class I (PI3KC1) enzymes are 
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shown to produce PI(3,4,5)P3 (Stephens et al. 1993), class II (PI3KC2) are less understood but 
appear to catalyse the formation of PI(3)P and PI(3,4)P2 (Misawa et al. 1998). VPS34 is the sole 
mammalian class III enzyme and produces the majority of cellular PI(3)P (Devereaux et al. 2013). 
Several lipid phosphatases also demonstrate specific activity towards individual phosphorylation 
sites on the inositol ring of phosphoinositides such as the 3’-phosphatase myotubularin (MTM1) 
that dephosphorylates position 3 from PI(3)P and PI(3,5,)P2 (Taylor et al. 2000) or the 
5’-phosphatase SHIP2 that catalyses PI(3,4,5)P3 to PI(3,4)P2 (Ishihara et al. 1999).  
The production of phosphoinositides is important for the generation of region specific identity 
that occurs due to spatial restriction of PIKs and phosphatases. The distribution of 
phosphoinositides can be demonstrated by utilising specific protein recognition binding 
domains (see 1.1.7). PI(4)P for example is primarily present in a perinuclear region that 
corresponds to the Golgi, PI(4,5)P2 is accumulated at the plasma membrane whilst PI(3)P is 
mainly observed with endosomes (Figure 1.7) (Gillooly et al. 2000; Hammond et al. 2009).   
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Figure 1.6 - Interconversion of Phosphoinositides 
PtdIns can be interconverted between phosphoinosit ide species by l ipid kinase or l ipid 
phosphatase act ivity.  Solid arrows represent activ ity th at has been demonstrated in cel ls,  dashed 
arrows represents activ ity that has been shown in vitro  but not in cel ls.  Arrows represent activ ity  
by lipid kinases (black) or l ipid phosphatases (red).  Values in brackets represent estimated 
percentage values of total  PtdIns in the absence of any stimulatory factors from mammalian cells 
(Devereaux et  al.  2013; Lemmon 2008; Milne et al.  2005; Zolov et al .  2012) .  
 
It must be noted that the action of lipid phosphatases is not always to simply counteract lipid 
kinase action, but can also be important for generation of distinct lipid identity. PI(5)P for 
example is not formed by phosphorylation of PtdIns in cells, instead it is generated via 
dephosphorylation of PI(3,5)P2 (Zolov et al. 2012). 
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Figure 1.7 - Distinct Localisation of Phosphoinositides 
Figure taken from (Di Paolo & De Camilli  2006) .  The PH Binding domain of PLC δ1 recognises 
PI(4,5)P2  at the plasma membrane, PH Domain of FAPP1 binds to PI(4)P in the Golgi and a 2xFYVE 
domain from HRS binds PI(3)P at  endosomes.  Experiments were carr ied out in Chinese hamster 
ovary cells.   
 
The presence of lipid identities allows the recruitment of specific effector proteins via 
phosphoinositide binding domains for essential functions at that location (1.1.7). Similarly 
alterations to phosphoinositide composition that may occur due to localisation or activation of 
PIKs will modulate recruitment of effector proteins and can therefore alter processes at the 
membrane. This is exemplified by the activation of PI3Kα by growth factors at the plasma 
membrane that leads to the rapid generation of PI(3,4,5)P3 to recruit downstream factors to 
mediate growth factor signalling (Stephens et al. 1993).    
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1.1.7 Phosphoinositide Binding Domains 
 
The pleckstrin homology (PH) domain is found in a large number of proteins and is highly 
represented amongst proteins involved in signalling and trafficking. The PH domain was 
identified based upon sequence similarity to the protein Pleckstrin (Haslam et al. 1993). 
Subsequently a small proportion of these domains were identified to be able to bind to varying 
phosphoinositide species (Harlan et al. 1994). The PH domains that interact with 
phosphoinositides generally favour interaction with those containing two adjacent phosphates 
such as PI(3,4)P2, PI(4,5)P2 and PI(3,4,5)P2 (Lemmon 2007). This is not entirely exclusive however 
and work has demonstrated that the PH domain of FAPP1 can localise to the Golgi based upon 
coincident binding of PI(4)P and ADP-Ribosylation factor 1 (ARF1) (Godi et al. 2004). 
Advancement in the understanding of trafficking in relation to VPS34 and endocytosis was made 
by the identification of binding domains that are able to interact specifically with PI(3)P (Table 
2). Early endosome antigen 1 (EEA1) was discovered to be localised to early endosomes in a PI3K 
activity dependent manner (Patki et al. 1997). Analyses identified a zinc-binding finger in EEA1 
that was distinct from traditional zinc fingers present in nucleic acid binding proteins and was 
found in several other trafficking proteins, this was named the Fab1, YOTB, Vac1 and EEA1 
(FYVE) zinc finger binding domain (Stenmark et al. 1996). The FYVE domain of EEA1 was 
subsequently identified to bind PI(3)P that localises the protein at endosomal structures 
(Gaullier et al. 1998). This study also demonstrated for the first time that FYVE domains are 
highly specific for binding to PI(3)P over other phosphoinositides and that the FYVE domain of 
hepatocyte growth factor regulated tyrosine kinase substrate (HRS) displayed similar properties 
to EEA1 (Gaullier et al. 1998). FYVE domains retain a conserved basic motif and eight conserved 
cysteine residues that co-ordinate two Zn2+ ions to stabilise the domain structure (Misra & 
Hurley 1999). Following this discovery, a phox homology (PX) domain from the vacuolar SNARE 
protein Vam7 involved in vesicle fusion was also demonstrated to bind PI(3)P (Cheever et al. 
2001; Song et al. 2001). The PX domain is found in multiple proteins including the sorting nexin 
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(SNX) family that were originally identified by their ability to assist with EGFR degradation 
(Kurten et al. 1996; Haft et al. 1998).  Other phosphoinositide binding domains are also present 
within the cell such as C2 domains that typically require calcium to mediate binding to 
phospholipids (Sutton et al. 1995).  All FYVE domains and a large proportion of PX domain 
containing proteins are specific for binding to PI(3)P, therefore their function within the cell is 
largely controlled by the activity of VPS34.  
Domain Lipid Binding Example protein Reference 
FYVE PI(3)P EEA1, HRS, DFCP1 (Gaullier et al. 1998) 
PH 
PI(3,4)P2 AKT (Thomas et al. 2002) 
PI(4,5)P2 DYNAMIN (Achiriloaie et al. 1999) 
PI(3,4,5)P3 GRP1, AKT (Gray et al. 1999; Thomas et al. 
2002) 
PX 
PI(3)P P40 PHOX, SNX2, SNX3 (Kanai et al. 2001) 
PI(5)P SNX13 (He et al. 2011) 
PI(3,4)P2 P47 PHOX (Kanai et al. 2001) 
Table 2 – Example of Phosphoinositide Binding Domains 
 
1.1.8 Cellular Trafficking Mediated by PI(3)P 
 
The dependence of PI(3)P for correct localisation of multiple FYVE domain containing proteins 
such as EEA1 or HRS has allowed further insight into the regulatory roles PI(3)P plays in the 
trafficking system (Gaullier et al. 1998). EEA1 is one of the most studied FYVE domain containing 
proteins and is a large coiled-coil protein that also contains a Rab5 binding domain next to the 
FYVE domain (Simonsen et al. 1998). Recruitment of EEA1 to membranes requires co-incident 
binding to Rab5-GTP and PI(3)P and thereby drives very specific EEA1 membrane recruitment 
(Lawe et al. 2000). EEA1 assists with fusion of Rab5 positive membranes that is thought to occur 
by tethering to allow SNARE protein pairing (Christoforidis et al. 1999). Determination of the 
FYVE domain crystal structure (Misra & Hurley 1999) combined with knowledge of the conserved 
FYVE domain sequence allows targeted mutation of conserved cysteine residues to prevent 
phosphoinositide binding, this has proven a useful tool for determining the role of PI(3)P binding 
in protein function (Ridley et al. 2001). One of the most critical advances has been the 
development of a recombinant double FYVE domain protein probe separated by a linker region 
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that can bind to PI(3)P in cells with high affinity (Gillooly et al. 2000). Addition of a protein tag 
or fluorophore to this probe allows determination of cellular PI(3)P levels based upon the level 
of probe membrane binding, this has been critical for more recent analysis into regulatory 
mechanisms and pathways that trigger more subtle changes in activity or function of VPS34 
(Furuya et al. 2010; Russell et al. 2013; Yuan et al. 2013). Similarly the PX domain from the 
protein p40phox can also be expressed recombinantly to bind PI(3)P specifically (Kanai et al. 
2001).  
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1.2 Autophagy 
 
1.2.1 Background 
 
Figure 1.8 - Forms of Autophagy 
Three subtypes of  autophagy exist.  (A) Microautophagy is thought to involve the invagination of 
the lysosome membrane to directly  take up material.  (B)  Chaperone-Mediated autophagy involves 
the specif ic targeting of  proteins by binding to hsc70 and then subsequent transport  across the 
lysosomal membrane. (C)  Macroautophagy is the most well  studied form that involves the uptake 
of cellular material inside a  characterist ic double membrane structure that then fuses with the 
lysosome for degradation.  
 
Autophagy is a catabolic cellular process that degrades intracellular material via the lysosome. 
There are several forms of autophagy: microautophagy (Figure 1.8A) that is thought to involve 
direct engulfment of cytoplasmic material by the lysosome (Mijaljica et al. 2011); 
Chaperone-mediated autophagy (CMA - Figure 1.8B) is a highly specific pathway that utilises 
heat shock cognate protein of 70 kDa (HSC70) to recognise and bind precise cargo that it then 
assists in transporting across the lysosomal membrane (Chiang et al. 1989; Dunn 1994); and 
macroautophagy that encapsulates portions of the cytoplasm in a characteristic double 
membrane structure for trafficking and delivery to the lysosome (Figure 1.8C). Macroautophagy 
(herein referred to as autophagy) has been the most studied and characterised form to date.  
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Autophagy is a highly conserved process that is also found in unicellular eukaryotes such as yeast 
and amoeba (Goldberg & St. John 1976; Takeshige et al. 1992). Whilst the process of autophagy 
has been known of since the 1960s (Duve & Wattiaux 1966), it has only been in the last two 
decades that understanding of the process has really progressed. Autophagy proceeds at a basal 
rate in cells that assists with the turnover of proteins and organelles, however in response to 
diverse cellular stresses this process can be rapidly increased (Mortimore & Schworer 1977). 
Amino acid starvation is one of the most potent inducers of autophagy and it is necessary to 
prolong cell survival by generating nutrients from the breakdown of cellular components, 
blockade of autophagy in yeast results in a severe reduction in cell survival upon nitrogen 
starvation (Tsukada & Ohsumi 1993). Inhibition of yeast vacuolar proteases by addition of the 
serine protease inhibitor phenylmethanesulfonyl fluoride (PMSF) causes accumulation of 
autophagic bodies during nitrogen starvation that can be easily identified by light microscopy 
(Takeshige et al. 1992). The ability to identify accumulation of autophagic structures by light 
microscopy provides an easy screening method and was utilised to determine autophagy 
deficient mutants. 
 
 
1.2.2 Identification of Key Autophagy Proteins  
 
Understanding of proteins required for the autophagy pathway was pioneered by mutational 
studies in S. cerevisiae that identified more than 35 genes that are responsible for deficient 
autophagy upon nitrogen starvation (Tsukada & Ohsumi 1993; Thumm et al. 1994). These 
genetic mutational analysis experiments were similar to those carried out previously for the 
identification of vpt and vpl mutants (1.1.4). Of the autophagy deficient yeast strains found, 
~20 % were due to mutation in the same gene that was termed apg1, further analysis identified 
that Apg1p is a serine-threonine protein kinase and contains homology to UNC-51 of C. elegans 
(Matsuura et al. 1997). This proved a vital stepping stone to linking Apg1p to the human and 
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mouse homolog Unc-51 like autophagy activating kinase 1 (ULK1) that contains 41 % and 29 % 
sequence identity to UNC-51 and Apg1p respectively (Kuroyanagi et al. 1998; Yan et al. 1998). 
Despite this linkage, it took almost another 10 years to confirm that knockdown of ULK1 impairs 
mammalian autophagy (Chan et al. 2007). From the apg mutants identified in yeast, Apg1p/ULK1 
has been the only kinase identified. Further study in yeast identified that Apg1p overexpression 
can rescue the autophagy defect of apg13 mutant yeast and that they form a complex required 
for cell viability upon starvation (Funakoshi et al. 1997). A third component, Atg17, was 
identified as an additional binding partner required for autophagy (Cheong et al. 2005; Kabeya 
et al. 2005). Homologs of these components have subsequently been identified in mammalian 
cells as ATG13 and FIP200 and found to form a complex with ULK1 that is required for autophagy 
(Ganley et al. 2009; Hosokawa et al. 2009; Jung et al. 2009).   
Intriguingly, analysis of the interaction between two apg proteins, Apg14p and Apg6p, revealed 
that apg6 mutants are deficient in both autophagy and CPY trafficking to the vacuole whilst 
apg14 is only defective in autophagy (Kametaka et al. 1998). Structural analysis identified Apg6p 
to be the same protein as Vps30p identified through earlier vacuolar protein screens (1.1.4) 
(Kametaka et al. 1998). Further analysis of Vps30p interacting proteins identified binding to 
Apg14p, Vps15p, Vps34p and Vps38p (Kihara, Noda, et al. 2001). One of the most interesting 
aspects is that Apg6p/Vps30p, Vps34p and Vps15p all cause combined CPY and autophagy 
defects in yeast whilst Apg14p and Vps38p are only defective in autophagy and CPY trafficking 
respectively (Kihara, Noda, et al. 2001). Immunoprecipitation of Vps38p and Apg14p individually 
are unable to interact with one another but retain a common core binding complex of Vps15p, 
Vps34p and Apg6p/Vps30p (     Figure 1.9) (Kihara, Noda, et al. 2001). This study demonstrated 
for the first time that VPS34 can form two distinct complexes, one primarily associated with 
autophagy (Apg14p – Complex I) and another primarily associated with vacuolar trafficking 
(Vps38p – Complex II).  
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     Figure 1.9 - VPS34 Complex Formation in Yeast 
 
1.2.3 The Mammalian VPS34 Complex 
 
Following the identification of Apg6p/Vps30p, the mammalian homologue BECLIN1 was 
identified based upon ~25 % sequence homology and the ability to complement the autophagy 
deficiency of apg6 mutants (Liang et al. 1999). BECLIN1 binds to VPS34 by a conserved region 
from yeast to mammals termed the evolutionary conserved domain (ECD) (Furuya et al. 2005) 
and BECLIN1 is suggested to be a haploinsufficient tumour suppressor as it is mono-allelically 
deleted in 40-75 % of sporadic breast and ovarian cancers (Liang et al. 1999). In addition, 
BECLIN1 -/+ mice have a high incidence of spontaneous tumour generation (Qu et al. 2003). 
Immunoprecipitation experiments of BECLIN1 identified UV radiation resistance associated gene 
(UVRAG) as an interacting protein via interaction of their coiled-coil domains (CCDs) (Liang et al. 
2006). UVRAG was later attributed as a Vps38p homologue in a study by Itakura et al. (2008) 
that also identified a homologue of Apg14p now termed Atg14 like (ATG14L). ATG14L and 
UVRAG both contain <15 % sequence homology with their yeast counterparts but retain >30 % 
sequence similarity (Itakura et al. 2008).  Akin to yeast, ATG14L and UVRAG are found in mutually 
distinct complexes that retain a common VPS15, VPS34, BECLIN1 (Apg6) core (Itakura et al. 2008; 
Kihara, Noda, et al. 2001). ATG14L also possesses a CCD that mediates binding with the CCD of 
BECLIN1, it is by this requirement for the same binding site between UVRAG and ATG14L that 
leads to the formation of mutually exclusive complexes (Sun et al. 2008).  The domain structure 
of VPS34 complex proteins is demonstrated in Figure 1.10. ATG14L is required for autophagy 
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similar to yeast Apg14p as knock-down drastically impairs autophagosome formation and 
autophagy (Itakura et al. 2008; Matsunaga et al. 2009). A specific region at the C-termini of 
ATG14L termed the Barkor/ATG14L autophagosome targeting sequence (BATS) has been 
determined to target the VPS34 complex to the ER by recognition of membrane curvature and 
PI(3)P in a positive feedback mechanism (Fan et al. 2011). The binding of UVRAG to BECLIN1 
increases VPS34 PI3K activity in vitro by ~2-4 fold (Liang et al. 2006; Sun et al. 2010) and knock-
down of UVRAG,BECLIN1, VPS34 or VPS15 all cause defects in the trafficking and degradation of 
the EGFR (Thoresen et al. 2010). 
Homologues of yeast complex I and II are therefore found in mammalian cells and are able to 
fulfil similar trafficking roles as those defined in yeast. Further complexity is added in the 
mammalian system however by interaction of further proteins with the VPS34 complex.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 - Domain Structure of the VPS34 Complex 
Domain structure of  VPS34 complex components where numbers indicate amino acid residues, dashed lines and protein names in re d indicate defined protein interacting 
regions. Domain abbreviat ions:  CCD = Coi led coi l domain, ECD = Evolutionary conserved domain, BATS = Barkor/ATG14L autophagosome targeting sequence , PRR = 
Proline rich region.   
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1.2.4 The Role of UVRAG 
 
The protein UVRAG was first identified by its ability to promote survival in xeroderma 
pigmentosum cells upon exposure to ultraviolet irradiation and it is presumed to be a 
haploinsufficient tumour suppressor as it is frequently found monoallelically deleted or mutated 
in colon cancers (Ionov et al. 2004; Teitz et al. 1990). UVRAG contains an N-terminal proline rich 
region (PRR), a C2 domain, a CCD and a large C-terminal domain with no defined domain 
structure (Figure 1.10). Very little was known regarding the function of UVRAG until it became 
implicated in binding to BECLIN1 via the CCD and reported to induce autophagy upon expression 
(Liang et al. 2006), however subsequent studies have failed to recapitulate an autophagic 
phenotype upon expression or depletion (Itakura et al. 2008; Knævelsrud et al. 2010). UVRAG is 
also bound by ‘RUN domain protein as Beclin-1 interacting and cysteine-rich containing’ 
(RUBICON) that acts as a negative regulator to reduce VPS34 lipid kinase activity and 
subsequently EGFR trafficking (Matsunaga et al. 2009; Sun et al. 2010). The PRR of UVRAG 
contains non-repetitive repeats, a particular class of PRR that often bind to SH3 domains of other 
proteins (Williamson 1994). UVRAG has been reported to bind to the SH3 domain of 
Endophilin-B1 (Bif-1), an N-BAR containing protein that can induce membrane curvature and is 
thought to promote autophagy (Takahashi et al. 2007; Takahashi et al. 2009). UVRAG has also 
been reported to bind to VPS11 and VPS16 as part of the class C-VPS complex that assists with 
membrane fusion at the lysosome (Table 1) (Liang et al. 2008). UVRAG is widely expressed 
throughout cells exhibiting co-localisation determined by immunofluorescence with multiple 
endosome markers (EEA1, Rab9, LAMP1), Golgi markers (GM130, TGN46), ER markers (Calnexin, 
Dsred-ER), nuclear damage markers (γ-H2AX) and also the centrosome (CEP63) that suggests 
UVRAG possesses a wide range of cellular functions beyond the established role of Vps38p in 
yeast  (He et al. 2013; Itakura et al. 2008; Matsunaga et al. 2009; Zhao et al. 2012).  
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1.2.5 Induction of Autophagy 
 
The small ubiquitin like molecule microtubule-associated protein 1 light chain 3 (LC3 - atg8 in 
yeast) is conjugated to phosphatidylethanolamine to form LC3-II that is recruited to 
autophagosomal membranes and therefore correlates with the autophagosome abundance 
(Kabeya et al. 2000). Once the autophagosome is sealed, the LC3-II retained inside is subject to 
degradation alongside the other autophagic cargo by the lysosome. Cellular LC3 levels are 
dynamic due to the constant synthesis and degradation by autophagy, inhibitors that block 
lysosomal acidification prevent LC3-II degradation but do not affect autophagosome formation 
(Yamamoto & Tagawa 1998). Therefore LC3-II that would normally be degraded accumulates 
and this is higher in cells actively undergoing autophagy, measurement of LC3-II before and after 
lysosome inhibition is commonly used as an assay to compare autophagic rate (Klionsky & 
Abdalla 2012). This has been utilised extensively to study factors that modulate autophagy. 
The activation of autophagy requires the activity of both the lipid kinase VPS34 and protein 
kinase Apg1/ULK1 at primary stages for successful formation of autophagosomes (Chan et al. 
2007; Kihara, Noda, et al. 2001). Autophagy can be activated in response to multiple cellular 
stresses that includes amino acid starvation (Mortimore & Schworer 1977), glucose starvation 
(Kotoulas et al. 2006), hypoxia (Tracy et al. 2007) and infection (Suzuki et al. 2007) . Precisely 
how all these stress pathways feed in to induce autophagy is still poorly understood. 
The discovery that inhibiting target of rapamycin (TOR) in yeast leads to the activation of 
autophagy was a significant step forward in understanding the pathways involved in regulating 
autophagy (Noda & Ohsumi 1998). It was subsequently found that TOR inhibits Apg1 activity by 
hyperphosphorylation of Apg13 to prevent interaction with Apg1 (Kamada et al. 2000). In 
mammalian cells ULK1 and ATG13 are both phosphorylated by mTOR, but this does not affect 
their binding (Hosokawa et al. 2009). The phosphorylation does however correlate with reduced 
ULK1 kinase activity and autophagy (Ganley et al. 2009; Jung et al. 2009).  
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5’AMP-activated protein kinase (AMPK) also plays a critical role in sensing energy status in 
response to ADP and AMP levels (Hardie 2011). It has also been identified to phosphorylate ULK1 
to stimulate autophagy in response to glucose starvation (Kim et al. 2011). AMPK however has 
also been suggested to negatively regulate ULK1 by inhibitory phosphorylation that is relieved 
upon amino acid starvation (Shang et al. 2011).  
It is now apparent that ULK1 is heavily phosphorylated within cells and it is possible that this 
represents connections to multiple stress pathways (Alers et al. 2012). Further work is required 
to determine the upstream kinases to many of these sites and elucidate the functional 
consequences of ULK1 phosphorylation. 
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1.3 The Mechanistic Target of Rapamycin  
 
1.3.1 mTOR complexes 
 
The mechanistic target of rapamycin (mTOR) is a serine threonine protein kinase that is 
homologous to yeast TOR and forms the active core of two distinct complexes, mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). Distinction has been drawn between the two 
complexes based upon their sensitivity to the inhibitor rapamycin, where mTORC1 is inhibited 
and mTORC2 is resistant analogous to TOR complex 1 and 2 in yeast (Loewith et al. 2002). 
mTORC1 is regulated by nutrient status and growth factor signalling and when activated 
promotes growth by phosphorylation of downstream targets including p70 S6 Kinase (S6K) and 
eIF4E-binding protein 1 (4E-BP1) that act to improve protein translation  (Hara et al. 1997; Price 
et al. 1992). eIF-4E binds to the mRNA cap to enhance protein synthesis (Gingras et al. 1999) but 
4E-BP1 can bind and sequester eIF-4E to inhibit translation (Rousseau et al. 1996). 
Phosphorylation of 4E-BP1 by mTORC1 releases eIF-4E and thereby promotes growth (Beretta 
et al. 1996). Simultaneously mTORC1 acts to repress catabolic pathways by inhibitory 
phosphorylation, such as described previously with ULK1 or transcription factor EB (TFEB) 
(Ganley et al. 2009; Peña-Llopis et al. 2011). TFEB positively regulates the expression of genes 
belonging to the coordinated lysosomal expression and regulation (CLEAR) network and 
autophagy proteins (Sardiello et al. 2009; Settembre et al. 2011).  Phosphorylation of TFEB by 
mTORC1 prevents nuclear localisation and therefore represses transcription of autophagic and 
lysosomal genes (Roczniak-Ferguson & Petit 2012; Settembre et al. 2012). Co-ordinated positive 
regulation of anabolic and negative regulation of catabolic processes therefore acts to promote 
cellular growth when mTORC1 is active (Kim et al. 2002). 
The signalling and regulation of mTORC2 is less understood, but it is known to have major roles 
in the regulation of the actin cytoskeleton and mediates protein kinase B (PKB or AKT), protein 
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kinase C (PKC) and serum and glucocorticoid induced protein kinase (SGK) phosphorylation 
(Ikenoue et al. 2008; Sarbassov et al. 2004). 
The complexes are differentiated by additional binding proteins, mTORC1 is primarily defined 
by binding of the regulatory associated protein of mTOR (RAPTOR) that plays an important role 
in substrate recognition and is the rapamycin sensitive component (Hara et al. 2002; Kim et al. 
2002). mTORC1 also contains the proline-rich Akt substrate of 40 kDa (PRAS40) that binds 
directly to RAPTOR to inhibit kinase activity, activation of growth factor signalling however leads 
to phosphorylation of PRAS40 by Akt that causes dissociation from RAPTOR (Sancak et al. 2007; 
Vander Haar et al. 2007). In contrast mTORC2 is primarily defined by binding to the rapamycin-
insensitive companion of mTOR (RICTOR) that is required for mTORC2 activity (Jacinto et al. 
2004; Sarbassov et al. 2004). Other unique components of mTORC2 include mammalian 
stress-activated protein kinase interacting protein (mSIN1) that helps to stabilise RICTOR and 
contributes to activatory phosphorylation of AKT (Jacinto et al. 2006; Yang et al. 2006). 
Additionally PROTOR-1 binds to RICTOR but it is not required for mTORC2 stability but affects 
the phosphorylation of SGK1 (Pearce et al. 2011). mTORC1 and mTORC2 complexes contain the 
protein DEP domain-containing mTOR-interacting protein (DEPTOR) that negatively reduces 
activity (Peterson et al. 2009). In addition, both complexes contain the protein mammalian lethal 
with SEC13 protein 8 (mLST8) that is required for mTORC2 function yet has no effect upon 
mTORC1 activity (Guertin et al. 2006). The composition of mTORC1 and mTORC2 is 
demonstrated in Figure 1.11.  
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Figure 1.11 - Mammalian mTOR complexes 
Components of mTORC1 and mTORC2 are demonstrated. mTORC1 contributes to anabolic  process 
via phosphorylation of  4E-BP1 and S6 Kinase whilst inhibiting catabolic  processes by 
phosphorylat ion of ULK1 and TFEB. Less is known regarding mTORC2 regulation and substrates,  
however establ ished substrates include AKT, SGK and PKC.  
 
1.3.2 Regulation of mTORC1 
 
The activity of mTORC1 is modulated by the small G-protein Ras homolog enriched in brain 
(RHEB) that increases S6K and 4E-BP1 substrate phosphorylation (Inoki et al. 2003; Tee et al. 
2003). RHEB is reported to interact with the mTOR complex independently of GDP/GTP binding 
state, however only RHEB-GTP is able to increase mTORC1 activity (Long et al. 2005). The 
interaction of mTORC1 and RHEB occurs at the lysosome and is modulated by two distinct 
nutrient dependent pathways that connect mTOR activity to cellular nutrient status (Flinn et al. 
2010). 
Receptor tyrosine kinases (RTKs) such as the EGFR or insulin receptor (IR) are activated upon 
growth factor binding and causes autophosphorylation of the cytoplasmic tail (Schmidt-Ullrich 
et al. 1997). This subsequently activates PI3Kα that utilises PI(4,5)P2 at the plasma membrane to 
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form PI(3,4,5)P3 (Stephens et al. 1993). In turn, PtdIns(3,4,5)P3-dependent protein kinase-1 
(PDK1) and its substrate AKT are recruited to the plasma membrane via their PH lipid binding 
domains and AKT is activated by PDK1 mediated phosphorylation (Alessi et al. 1997). Alongside 
relieving mTORC1 of inhibition by removing PRAS40 (Sancak et al. 2007; Vander Haar et al. 
2007), AKT also plays a key role in modulating the tuberous sclerosis complex (TSC). TSC1 and 
TSC2 form a heterodimer that act as a GTPase activating protein (GAP) for RHEB, driving it to the 
inactive RHEB-GDP state (Garami et al. 2003; Inoki et al. 2003). Active AKT however 
phosphorylates TSC2 (Potter et al. 2002) and causes the release of TSC1-TSC2 from the 
lysosome, thereby promoting the RHEB-GTP state (Menon et al. 2014). 
In addition to growth factor signalling, the level of amino acids also impacts upon mTORC1 
activation. Four Rag GTPases termed RagA-D exist as heterodimers of RagA/RagB and 
RagC/RagD and are tethered to the lysosome via a protein complex termed the Ragulator 
(Sancak et al. 2008). In the absence of amino acids Rags are present as RagA/B-GDP and 
RagC/D-GTP, stimulation with amino acids causes the state to change and is dependent upon 
the vacuolar H+ ATPase, leading to RagA/B-GTP and RagC/D-GDP (Zoncu et al. 2011). The 
Ragulator acts as a guanine nucleotide exchange factor (GEF) in a vacuolar H+ ATPase dependent 
manner that promotes RagA/B-GTP (Bar-Peled et al. 2012). The active Rag heterodimer then 
interacts and recruits RAPTOR to the lysosomal membrane (Sancak et al. 2010). This is key to 
recruitment of the mTORC1 complex to the lysosome to allow co-localisation with RHEB, as such, 
withdrawal of amino acids impairs mTORC1 activity in response to growth factor stimulation as 
mTORC1 does not localise with active RHEB (Smith et al. 2005).  
The amino acid and growth factor pathways thereby alter mTORC1 activity by modulating access 
to RHEB-GTP and are demonstrated in Figure 1.12. Activation of both pathways is required for 
maximal mTORC1 activity (Sengupta et al. 2010). Active mTORC1 is assumed to remain bound 
to the lysosomal membrane, however active mTORC1 correlates with peripheral lysosomal 
positioning that is thought to assist with substrate phosphorylation (Korolchuk et al. 2011). Upon 
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withdrawal of nutrients the Rag GTPases recruit TSC2 to the membrane to inactivate RHEB and 
causes mTORC1 release from the lysosome (Demetriades et al. 2014). 
 
 
Figure 1.12 - Regulation of mTORC1 Activity 
mTORC1 is dependent upon two distinct pathways for activation. Growth factor signall ing leads 
to the formation of PIP 3  at the cell  surface by PI3Kα activity,  this  recr uits PDK1 and leads to  AKT 
phosphorylat ion and activation. AKT removes the negative mTORC1 regulator PRAS40 by 
phosphorylat ion and causes dissociat ion of  TSC1 -TSC2 from the lysosome to prevent GAP activ ity  
towards RHEB. Amino acids impact upon the vacuolar  ATPase that promotes GEF activ ity  of the 
Ragulator complex,  forming RagA/B -GTP and RagC/D-GDP. This recruits the mTORC1 complex to 
the lysosome via interaction with RAPTOR.  
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1.3.3 Signalling, Trafficking and Human Disease 
 
Growth factor signalling plays a vital role in communicating the presence of nutrients and 
conveying growth in cells. It is perhaps not surprising therefore that mutations that cause 
dysregulation of this pathway are responsible for driving many human diseases, particularly 
cancer(Easton & Houghton 2006; Vivanco & Sawyers 2002).  
 
Figure 1.13 - Aberrant Growth Factor Signalling 
Many components in the receptor tyrosine kinase (RTK) mediated PI3K -AKT growth factor 
signall ing pathway are mutated in human cancer s.  Hyperactive signal ling is  achieved by 
upregulation or constitutive activation of  components indicated by red arrows.  Alternately loss 
of function or decreased expression of negative regulators indicated in red can lead to heightened 
signall ing.  
 
Defects in components of the PI3K-AKT signalling pathway can lead to hyperactive growth 
signalling (Figure 1.13) and many mutations have been identified in human cancers. Increased 
formation of PI(3,4,5)P3 at the plasma membrane is often observed and this can occur through 
several means.  Amplification of the PI3Kα catalytic subunit p110 gene that forms PI(3,4,5)P3 
from PI(4,5)P2 is detected in many cancers including ~40 % of ovarian cancers (Shayesteh et al. 
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1999). Alternately loss of function mutations in phosphatase and tensin homolog (PTEN), a 
3’-phosphatase that counteracts PI3Kα formation of PI(3,4,5)P3, is also observed in a multitude 
of cancers (Li et al. 1997; Steck et al. 1997). The expression of HER-2, a growth factor receptor 
related to EGFR, is increased in ~30 % of breast cancer tumours (Slamon et al. 1987). Increased 
expression of HER-2 is sufficient to promote malignant transformation (Di Fiore et al. 1987). 
Mutations in AKT that lead to constitutive activation are also demonstrated to transform cells 
and induce leukaemia in mice (Carpten et al. 2007). Similarly, tuberous sclerosis complex is 
caused by mutations and loss of function in the TSC1 or TSC2 gene that consequently enhances 
mTOR signalling and leads to the formation of multiple benign tumours (Kenerson et al. 2002).  
Upregulation of the PI3K-AKT pathway is therefore clearly affiliated with the pathogenesis of 
cancer. PI3K-AKT signalling is mediated through mTORC1 and therefore drugs targeting mTORC1 
seems an attractive target to prevent aberrant signalling. Indeed inhibition of mTOR has proven 
to be beneficial in the treatment of PTEN null cell lines in vitro and tumours from mouse models 
in vivo (Neshat et al. 2001; Podsypanina et al. 2001). Clinical trials with rapamycin analogues 
however have demonstrated limited efficacy, this may in part be due to the pro-survival 
mechanism of autophagy that we now understand to be activated by mTOR inhibition (Benjamin 
et al. 2011). The lysosomal inhibitor hydroxychloroquine (HCQ) (Fedorko et al. 1968) was 
licensed for use in malaria in 1955 (Hoekenga 1955) and is currently the only FDA approved 
inhibitor that disrupts autophagy. Combination of mTOR inhibitors with HCQ have 
demonstrated synergistic effects upon cell death in melanoma cell lines by inducing apoptosis 
(Xie et al. 2013). Data from phase I clinical trials have indicated that the combination of mTOR 
inhibition and HCQ prolongs the stable disease period of advanced melanoma compared to 
mTOR inhibition alone but potentially more potent autophagy inhibition could further improve 
patient outcome (Rangwala et al. 2014). The consequences of clinical administration of more 
potent lysosomal inhibitors however is unknown and may lead to increased toxicity, particularly 
as the lysosome is central to multiple pathways beyond autophagy. The debilitating effects of 
impaired lysosomal processing is clearly apparent in individuals affected by lysosomal storage 
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diseases (LSDs). LSDs are a group of over 50 genetic diseases caused by deficiencies in lysosome 
enzymes or transport proteins that are characterised by the progressive accumulation of 
material within the lysosome due to aberrant function (Neufeld 1991). The combined 
prevalence of LSD is ~ 1 in every 7700 live births (Meikle et al. 1999) and cause ranging symptoms 
with varying severity dependent upon the affected protein. Symptoms include kidney failure, 
hearing loss, movement disorders and delays in development (Grabowski 2008; van der Ploeg & 
Reuser 2008; Zarate & Hopkin 2008). Caution must therefore be taken in attempts to 
pharmacologically target and impair lysosome function as a therapeutic strategy. Positively 
modulating lysosomes may prove beneficial for treatment of certain diseases that accumulate 
protein such as LSDs or use in Alzheimer’s and Huntington’s that are characterised by 
accumulation of β-amyloid and Huntingtin protein aggregates respectively (DiFiglia et al. 1997; 
Masters & Simms 1985). Z-Phe-Ala-diazomethylketone (PADK) increases the formation and 
activity of Cathepsin B and has been demonstrated to reduce the β-amyloid aggregates in an 
Alzheimer’s mouse model (Butler et al. 2011). 
The importance of functional autophagy and endocytosis are clearly demonstrated in knockout 
mouse models. Impairment of autophagy in knockout mice causes death shortly after birth 
(Komatsu et al. 2005) whilst endocytosis is even more fundamental with VPS34 and BECLIN1 
knock-out mice dying during embryogenesis (~E7.5) (Yue et al. 2003; Zhou et al. 2011). 
Alternative drugs that selectively target the autophagy pathway without affecting the lysosome 
and endocytic pathways could improve clinical efficacy and carry a lower risk of side effects. 
However an improved understanding of the co-regulation of autophagy and endocytosis will be 
required to identify appropriate targets for such drugs.  
Interestingly, whilst mTORC1 has been established to regulate autophagy induction via ULK1 
(1.2.5), the regulation of VPS34 in this context is unclear. The formation of PI(3)P at early 
autophagosome sites (the omegasome) is increased upon starvation, demonstrating that 
activity or localisation of VPS34 is regulated (Axe et al. 2008). Attempts to establish regulatory 
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roles between VPS34 and mTOR to date have produced contradictory results. Inhibition of 
VPS34 activity by inhibitory antibodies causes a decrease in the phosphorylation of the mTOR 
substrate S6K (Byfield et al. 2005), suggesting VPS34 acts upstream. In contrast amino acid 
starvation and inhibition of mTOR has been demonstrated to decrease the level of cellular PI(3)P 
(Nobukuni et al. 2005) suggesting VPS34 is regulated by mTOR. Difficulty undoubtedly arises 
from the interconnection between VPS34 mediated pathways and mTORC1 with the lysosome. 
Additionally growth factor signalling activates mTORC1 but is subject to regulation by VPS34 as 
RTK signalling can be terminated by incorporation into MVBs and receptor degradation (1.1.3).  
This study aims to identify possible regulatory mechanisms of VPS34 that mediates distinction 
between endocytosis and autophagy. Improvements in the understanding of how intracellular 
pathways are connected and regulated is key for the development of future therapies. Recently 
nanomedicines have been of particular interest with over 70 in clinical trials for cancer alone, 
endocytosis is one mechanism by which drug internalisation can be achieved (Duncan & 
Richardson 2012) . Understanding the effect of disease and cancer driving mutations on 
endocytosis is key as this may be advantageous for targeted delivery of therapeutic compounds, 
similarly a defect in endocytosis may limit the uptake and impair drug efficacy. A greater 
understanding of endocytosis and trafficking is therefore essential for generating future 
therapeutic approaches. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals 
 
Acetone, ethanol, formic acid, glycerol, glycine, 4‐(2‐Hydroxyethyl)piperazine‐1‐ethanesulfonic 
acid (Hepes), Isopropanol, methanol, 2‐mercaptoethanol, potassium chloride, sodium chloride, 
sodium ethylenediaminetetraacetic acid (EDTA), magnesium acetate, sodium ethylene glycol 
tetra acetic acid (EGTA), sodium fluoride, sodium, β-glycerophosphate, sodium orthovanadate,   
adenosine 5’-triphosphate sodium salt (ATP), ammonium bicarbonate, ammonium persulphate 
(APS), bovine serum albumin (BSA), bromophenol blue, dimethyl sulphoxide (DMSO), 
iodoacetamide, phenylmethanesulphonylfluoride (PMSF), Ponceau S, sodium dodecyl sulphate 
(SDS), sodium tetraborate, N’‐tetramethylethylenediamine (TEMED), triethylammonium 
bicarbonate, Nonidet P40 and Tween 20 were from Sigma‐Aldrich (Poole,UK). Sucrose and Tris 
(hydroxymethyl)methylamine (Tris) were from BDH (Lutterworth, UK). Precision Plus protein 
markers, Bradford reagent and Transfectin™ were from BioRad (Herts, UK). 3‐[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) was from Calbiochem 
(Merck Biosciences, Nottingham,UK). Insulin-like growth factor (IGF1) was from Cell Signaling 
Technology (New Biolabs, Herts, UK). Dialysed foetal bovine serum (FBS) was from Biowest 
(Nuaillé, France). 6, 24 and 96 well tissue culture plates, cell culture dishes, cryovials and Spin-X 
columns were from Corning Incorporated (NY, USA). siRNA and buffer was from Dharmacon. 
40% (w/v) 29:1 Acrylamide: Bis-Acrylamide solution was from Flowgen Bioscience. Protein 
G-sepharose, Glutathione-sepharose, Enhanced chemiluminescence (ECL) kit, Hyperfilm MP and 
32P-labelled γ-ATP were purchased from GE Healthcare (Piscataway, USA). Dulbecco’s modified 
eagle medium (DMEM), Opti-MEM reduced serum media, Foetal bovine serum (FBS), Dulbecco’s 
Phosphate buffered serum (PBS), Trypsin/EDTA solution and L-glutamine were from GIBCO 
(Paisley, UK). Precast NuPAGE Novex SDS polyacrylamide 4-12% Bis-Tris gels, NuPAGE MES and 
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MOPS running buffer (20X), ProLong Gold and Silver Quest stain were from Invitrogen (Paisley, 
UK). Photographic developer (LX24) and liquid fixer (FX40) were from Kodak (Liverpool, UK). X-
ray films were from Konica Corporation (Japan). Polyethylenimine (PEI) was from Polysciences 
(Warrington, PA). Skimmed milk (Marvel) was from Premier Beverages (Stafford, UK). Plasmid 
Maxi kits were from Qiagen Ltd (Crawley, UK). Acetonitrile (HPLC grade) and trifluoroacetic acid 
(TFA) were from Rathburn Chemicals (Walkerburn, UK). Protran BA nitrocellulose membrane 
was purchased from Schleicher and Schuell (Anderman and Co.Ltd., Surrey, UK).  
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2.1.2 Buffers 
 
The buffers utilised for experiments in this study are detailed in Table 3. 
 
Buffer DTT PMSF PI β-Me Composition 
Acid Strip     20 mM Acetic Acid, 500 mM NaCl 
Blocking Buffer     5 % (w/v) Milk Powder, TBST 
BSA Antibody Buffer     5 % (w/v) BSA, TBST, 0.02 % (w/v) Sodium Azide 
CHAPS lysis buffer X X X  20 mM Tris pH 7.4, 137 mM NaCl, 2 mM EDTA, 10 % 
(v/v) Glycerol, 2 % (w/v) CHAPS 
Dialysis Buffer X    25mM Hepes pH 7.4, 50mM KCl 
Formaldehyde Buffer     3.7 % (w/v) Formaldehyde, 200 mM Hepes pH 7.4 
Fractionation Buffer X X X  20 mM Hepes pH 7.4, 250 mM Sucrose, 1 mM EDTA 
Gel Filtration Buffer X X X  50 mM Hepes pH 7.4, 150 mM NaCl, 1 mM EDTA 
Glutamate Buffer     25 mM Hepes pH 7.4, 25 mM KCl, 2.5 mM Mg-Acetate, 
5 mM EGTA, 150 mM K-Glutamate 
GST Elution Buffer    0.1 % (50 mM Tris pH 7.5, 250 mM NaCl, 0.1 mM EDTA, 0.3 % 
(v/v) Brij-35, 40 mM Glutathione) pH 8 
IF Blocking Buffer     PBS, 1 % (w/v) BSA 
Kinase Buffer     25 mM Hepes pH 7.4, 50 mM KCl 
Lipid Kinase Assay 
Buffer 
    10 mM MnCl2, 20 mM Tris pH 7.5, 67 mM NaCl, 0.02 % 
(w/v) CHAPs 
Milk Antibody Buffer     5 % (w/v) Milk powder, TBST, 0.02 % (w/v) Sodium Azide 
mTORC lysis buffer X X X  40 mM Hepes pH 7.4, 120 mM NaCl, 1 mM EDTA, 0.3 % 
(w/v) CHAPS 
NP-40 (0.5 %) lysis 
buffer 
X X X  50 mM Hepes pH 7.4, 150 mM NaCl, 1 mM EDTA, 10 % 
(v/v) Glycerol, 0.5 % (v/v) NP-40 
NP-40 (1 %) lysis 
buffer 
X X   50 mM Hepes pH 7.4, 150 mM NaCl, 1 mM EDTA, 10 % 
(v/v) Glycerol, 1 % (v/v) NP-40 
Opti-prep buffers     10-45% (v/v) Opti-prep, 20 mM Hepes pH 7.4, 1mM 
EDTA 
Permeabilisation 
buffer 
    PBS, 0.2 % (v/v) NP-40 
Phosphatase 
Inhibitor Cocktail 
(100x) 
    115 mM Sodium Molybdate, 400 mM Sodium Tartrate, 
1 M β-Glycerophosphate, 100 mM Sodium Fluoride, 
100 mM Sodium Orthovanadate 
Ponceau     5 % (v/v) Acetic Acid, 0.1 % (w/v) Ponceau S 
Potassium Oxalate 
Buffer 
    1 % (w/v) Potassium Oxalate, 5 mM EDTA, 50 % (v/v) 
Methanol 
Running Buffer (1x)     25 mM Tris, 51.7 mM Glycine, 3.47 mM SDS 
Sample Buffer (4x)    10 % 250 mM Tris pH 6.8, 8 % (w/v) SDS, 40 % (v/v) Glycerol, 
0.02 % (w/v) Bromophemol Blue 
Sample Buffer (5x)    12.5 % 300 mM Tris pH 6.8, 10 % (w/v) SDS, 50 % (v/v) Glycerol, 
0.025 % (w/v) Bromophenol Blue 
TBST (1x)     20 mM Tris, 150 mM NaCl, 0.1 % (v/v) Tween- 20 
Transfer Buffer (1x)     48 mM Tris, 39 mM Glycine, 1.3 mM SDS, 10 % (v/v) 
Methanol 
Table 3 – Buffers Utilised in this Study.  
Where indicated 1mM DTT, 1mM PMSF, 1x Phosphatase Inhibitor cocktai l and β -mercaptoethanol 
(β-Me) were added fresh before use.  
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2.1.3 Inhibitors 
 
Inhibitors utilised in this study and their working concentrations are indicated in Table 4. 
 
Name Target IC50 
Working 
Concentration 
Reference Company 
Cat 
Number 
CAS 
Number 
Bafilomycin A1 V-ATPase 0.6 - 1.5 nM 50 nM (Yoshimori et al. 1991) Enzo life sciences 
BML-
CM110 
88899-55-2 
KU0063794 mTOR 10 nM 1 µM 
(García-Martínez et al. 
2009) 
Tocris 3725 
938440-64-
3 
Rapamycin mTORC1 50 pM 100 nM – 1 µM (Hara et al. 2002) Merck Millipore 553210 53123-88-9 
VPS34-IN1 VPS34 25 nM 1 µM (Bago et al. 2014) Novartis N/A N/A 
VPS34-IN2 VPS34 6 nM 1 µM N/A Novartis N/A N/A 
Wortmannin PI3K 3 µM 10 µM (Stack & Emr 1994) Enzo life sciences BML-ST415 19545-26-7 
YM201636 PIKfyve 33 nM 1 µM (Jefferies et al. 2008) Biovision 2045-1 
371942-69-
7 
Table 4 – Inhibitors Utilised and IC50 Values 
 
2.1.4 Antibodies (In-House) 
 
Antibodies were generated and purified by the Division of Signal Transduction Therapy (DSTT), 
University of Dundee and are detailed in Table 5. 
 
Name Estimated MW (kDa) Species Ref WB Conc WB buffer 
LC3 14/16 Sheep S400D 1 µg/ml Milk 
mTOR 260 Sheep S683B 1 µg/ml Milk 
PRAS40 40 Sheep S115B 1 µg/ml Milk 
RAPTOR 150 Sheep S682B + 
S260D 
1 µg/ml Milk 
RICTOR 192 Sheep S654B 1 µg/ml Milk 
UVRAG 95 Sheep S323D 1 µg/ml Milk 
UVRAG P-550 95 Sheep S307D 1 µg/ml Milk 
UVRAG P-571 95 Sheep S451D 1 µg/ml Milk 
VPS34 100 Sheep S672B 1 µg/ml Milk 
Table 5 - In-House Antibodies Utilised 
  
52 
 
 
2.1.5 Antibodies (Commercial) 
 
Commercial antibodies utilised for western blotting and immunofluorescence are detailed in 
Table 6. 
 
 
Target 
~MW 
(kDa) 
 
Species 
 
Company 
Cat 
Number 
WB 
Conc 
IF 
Conc 
WB 
Buffer 
 
Comments 
4E-BP1 20 Rabbit CST 9452 1:1000  BSA  
4E-BP1 P-
T37/46 
20 Rabbit CST 9459 1:1000  BSA  
Akt P-T308 60 Rabbit CST 4056 1:1000  BSA  
Akt P-S473 60 Rabbit CST 9271 1:1000  BSA  
APPL1 80 Rabbit CST 3858 1:1000 1:500 BSA  
Anti-Mouse - Goat Thermo  1:5000  Milk HRP conjugate 
Anti-Rabbit - Goat Thermo  1:5000  Milk HRP conjugate 
Anti-Sheep - Rabbit Thermo  1:5000  Milk HRP conjugate 
ATG13 55 Rabbit Sigma SAB4200100 1:1000  Milk  
ATG13 S318 55 Rabbit Abnova PAB19948 1:1000  Milk  
ATG14L 70 Rabbit MBL PD026 1:1000  BSA  
BECLIN1 55 Rabbit MBL PD017 1:4000  BSA  
Beclin2-HRP 50 HRP Novus  
Biologicals 
NB110-
60982H 
1:1000  Milk  
DNA-PK 250 Rabbit CST 4602 1:1000  BSA  
EEA1 170 Rabbit CST 2411 1:1000 1:500 BSA  
EGFR 150 Rabbit Santa Cruz sc-03 1:1000  BSA  
ERK1/2 44/42 Rabbit CST 4695 1:1000  BSA  
P-ERK1/2 44/42 Rabbit CST 4376 1:1000  BSA  
FLAG-HRP - HRP Sigma A8592 1:2000  Milk  
FYCO1 200 Mouse Abnova H00079443-
A01 
1:1000 1:500 BSA  
FYVE-CENT 260 Rabbit CST 8532 1:1000 1:500 BSA  
GFP - Mouse Roche 11814460001 1:3000  BSA WB Only 
GFP - Rabbit Life 
Technologies 
A11122 - 1:1000  IF Only 
GSK3 a/b 51/46 Mouse Invitrogen 44610 1:500  BSA  
GSK3 
P-S9/21 
51/46 Rabbit CST 9331 1:1000  BSA  
GST-HRP - HRP Abcam Ab3416 1:2000  Milk  
LAMP1 100 Mouse Santa Cruz sc-20011 
(H4A3) 
1:1000 1:1000 Milk Detects 
Human 
LAMP1 100 Rat Santa Cruz sc-19992 
(1D4B) 
1:1000 1:1000 Milk Detects 
Mouse 
LC3 14/16 Rabbit CST 4108 1:1000  Milk WB Only 
LC3 14/16 Mouse MBL M152-3  1:1000  IF Only 
mCherry - Mouse Clontech 632543 1:1000  Milk  
mTOR 250 Rabbit CST 2983 1:1000 1:500 BSA  
P70 S6K 70 Rabbit CST 2708 1:1000  BSA  
p70 (S6K) P-
T389 
70 Rabbit CST 9205 1:1000  BSA  
RAB5 ~25 Rabbit CST 2143 1:1000  BSA  
RAB7 ~25 Rabbit CST 9367 1:1000  BSA  
RAB11a ~25 Rabbit CST 2413 1:1000  BSA  
RUBICON 130 Rabbit CST 8465 1:1000  BSA  
α-TUBULIN 52 Mouse Calbiochem CP06 1:2500  BSA  
α-TUBULIN 52 Rabbit CST 2125 1:3000  Milk  
Transferrin 
Receptor 
95 Mouse Invitrogen 136800 1:1000  BSA  
TSC2 200 Rabbit CST 3990 1:1000  BSA  
TSC2 
P-T1462 
200 Rabbit CST 3611 1:1000  BSA  
ULK1 130 Rabbit Sigma A7481 1:1000  Milk  
ULK1 P-757 130 Rabbit CST 6888 1:1000  BSA  
UVRAG 95 Mouse MBL M160-3 1:1000  BSA  
Table 6 - Commercial Antibodies utilised in this study. 
Western Blot (WB) and Immunofluorescence (IF) antibody concentrations are as indicated. CST = 
Cel l Signaling Technologies,  MBL = MBL International Corporation.   
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2.1.6 cDNA Constructs 
 
cDNA constructs utilised for experiments in this study are highlighted in Table 7. 
 
Protein Tag 
(Terminus) 
Vector Genbank ID Species Mammalian 
Selection 
DU 
Number 
Comments 
ATG14L GST (N) pEBG6P NM_014924.4 H N/A 40296  
BECLIN1 FLAG (N) pBabe AAH10276.1 H Puro 35123  
DFCP1 GFP (N) pBabe NP_067083.1 H Hyg  40185  
HRS GFP (N) pBabe AF020308.1 M Puro 40523 2xFYVE domain (147-223 
with linker) 
HRS GST (N) pGEX6P AF020308.1 M N/A 45781 2xFYVE domain (147-223 
with linker) 
LAMP1 GFP (C) pBabe NM_005561.3 H Puro 40445  
LAMP1 mCherry (C) pBabe NM_005561.3 H Puro 49491  
p40 phox GST (N) pGEX6P AB025219.1 H N/A 45823 M1-R148 
p70 (S6K) GST (N) pEBG6P NP_003152.1 H N/A 32609 D236A (Kinase Dead) 
UVRAG FLAG (N) pBabe AAH64837.1 H Hyg 35051  
UVRAG FLAG (N) pBabe AAH64837.1 H Hyg 40448 S550A+S571A 
UVRAG GFP (N) pBabe AAH64837.1 H Puro 40482 siRNA Resistant 
UVRAG GFP (N) pBabe AAH64837.1 H Puro 40467 siRNA Resistant, 
S550A+S571A 
UVRAG GST (N) pEBG6P AAH64837.1 H N/A 36657  
UVRAG GST (N) pEBG6P AAH64837.1 H N/A 40451 S550A 
UVRAG GST (N) pEBG6P AAH64837.1 H N/A 40452 S571A 
UVRAG GST (N) pEBG6P AAH64837.1 H N/A 40453 S550A + S571A 
UVRAG shRNA pSuper AAH64837.1 H + M Puro 36747 ORF1 site - 
GGACAAAGGAAGTGCATTT 
UVRAG shRNA pSuper AAH64837.1 H + M Puro 36749 5'UTR site - 
GTAATATGGCTCTTCCTTA 
SGK  GST (N) pEBG6P XP_037046 H N/A 125 K127A 
Table 7 – cDNA Constructs used in this study. 
Human (H), Mouse (M), Hygromycin (Hyg),  Puromycin (Puro).  DU Number is the clone reference 
as recorded by the Divis ion of Signal Transduction  Therapy, Dundee.  
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2.2 Cell Culture 
Cell culture media for growth and treatment of cells is detailed in Table 8, all procedures were carried out 
under aseptic conditions meeting biological safety requirements. For growth, cell lines were maintained 
in a complete media which included Dulbecco’s modified eagles medium (DMEM) and 10 % (v/v) foetal 
bovine serum (FBS).  Cells were grown at 37 °C with 5 % CO2 in a water-saturated incubator. For passaging, 
cells were washed once with Dulbecco’s phosphate buffered saline (DPBS) prior to incubation with Trypsin 
+ 0.05 % EDTA for 3-5 min at 37 °C to detach cells and split at 1:6 for maintaining growth.  
Media Name Composition of Media 
Complete Media DMEM, 10 % (v/v) FBS, 2 mM L-Glutamine, 100 units/ml 
penicillin, 0.1 mg/ml streptomycin. 
EGF Media DMEM, 10 mM Hepes pH 7.4, 0.1 % (w/v) BSA 
IF Complete Media DMEM, 10 % (v/v) FBS, 2 mM L-Glutamine, 100 units/ml 
penicillin, 0.1 mg/ml streptomycin 20 mM Hepes pH 7.4  
(No phenol red) 
IF Quench Media DMEM, 10mM Hepes pH 7.4 
IF Starvation Media EBSS, 20mM Hepes pH 7.4 
(No phenol red) 
Serum Starve Media DMEM   
Starvation Media EBSS 
TFR Media DMEM, 20mM Hepes pH 7.4, 0.1% (w/v) BSA 
Table 8 - Composition of Media used for cell culture and experiments.  
Details of  media util ised for tissue culture cel l  growth and experiments where IF = 
Immunofluorescence.  
 
 
2.2.1 Induction of Autophagy 
Autophagy was induced in cells either by amino acid starvation or chemically via mTOR inhibition (1.2.5). 
For the former, cells were washed twice and incubated in Earle’s balanced salt solution (EBSS) to deprive 
the cells of amino acids and serum. Alternatively the dual mTORC1 and mTORC2 ATP-competitive 
inhibitor KU0063794  was used to directly inhibit mTOR activity (García-Martínez et al. 2009). The 
induction of autophagy was confirmed by addition of the lysosomal inhibitor Bafilomycin A1 to monitor 
LC3 flux (1.2.5), further details of treatments are noted in figure legends. 
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2.2.2 Retroviral Generation of Stable Cell Lines 
Stable cell lines were generated via retroviral infection in accordance with biological safety regulations. 
The cDNA of interest (6 µg) was co-transfected into 293FT cells with 3.8 µg GAG/POL and 2.2 µg VSV-G 
expression plasmids (Clontech) per 10 cm dish for retrovirus production using Lipofectamine® 2000 
(Invitrogen) as per manufacturer’s protocol. The growth medium was changed at 16 h post-transfection 
and subsequently harvested at 40 h post-transfection, passed through a 0.45 µm filter, and applied 
directly on to target cells in the presence of 10 µg/ml polybrene to assist with viral infection (Hesse et al. 
1978). Following 24 h of retrovirus exposure, the growth media was changed to include selection with 
10 µg/ml puromycin (Sigma) or 100 µg/ml hygromycin B (Source Bioscience) dependent upon cDNA 
resistance marker (as indicated in Table 7). Successfully transfected cells were utilised for experiments 
following complete death of non-viral exposed cells in response to selection.  
2.2.3 siRNA Knockdown 
Endogenous UVRAG was knocked down primarily utilising the siRNA GGACAAAGGAAGTGCATTT as 
previously described (Liang et al. 2006). All siRNAs were obtained from Dharmacon. 
Name Target Region Sequence 
UVRAG ORF1 Protein Coding GGACAAAGGAAGTGCATTT 
UVRAG ORF2 Protein Coding ACTCCAGACTTGAGGCAAA 
UVRAG 5’UTR 5’ Untranslated Region GTAATATGGCTCTTCCTTA 
Table 9 - siRNA Sequences 
 
Cells were reverse transfected using Lipofectamine® RNAIMAX or TransFectin™ as per manufacturer’s 
instructions.  Cells were counted using a Countess® automated cell counter (Invitrogen) and 1x106 cells 
were plated per transfection in a 6 cm dish. Cells were incubated with siRNA in OptiMem for 16 h prior to 
changing to complete media and the cells were passaged at ~24 h post-transfection, they were then 
utilised for desired experiments between 40-70 h post-transfection. For forward transfection, protocol 
was the same utilising adherent cells. 
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2.3 Cell Lysis and Sample Preparation 
Following treatment of cells as described in figure legends, cells were lysed and prepared for subsequent 
analysis. Cells were moved onto ice and washed twice with ice-cold PBS; all remaining PBS was removed 
before the addition of lysis buffer (Table 3). Cells were scraped and transferred to eppendorfs for 
clarification by centrifugation at 21,000 x g for 10 min at 4 °C, supernatants were retained for use in 
analysis. The protein concentration of samples was determined via Bradford assay (Bradford 1976) to 
allow normalisation between samples for subsequent analysis. 
2.3.1 Western Blotting 
Samples to be analysed by western blot were diluted and normalised in 4x sample buffer to create 1x 
samples for separation by SDS-PAGE. Typically 25-40 µg of protein was loaded per sample alongside 
Precision Plus Protein™ All Blue Standards (Bio-Rad) and separated by a poly-acrylamide gel in 1x running 
buffer (Table 3). Samples were transferred to PVDF (Imobilon P – Millipore) membrane at 350 mA for 
50 min in 1x transfer buffer (Table 3) and membranes were stained using ponceau (Table 3) to check the 
quality of transfer before cutting the membrane appropriately to probe for proteins of interest. 
Membranes were incubated in blocking buffer for 20 min at RT to block membranes and reduce 
non-specific antibody binding. Membranes were washed twice with TBST (Table 3) prior to incubation in 
primary antibody for 16 h at 4 °C using concentrations indicated in 2.1.4/2.1.5 in either Milk or BSA 
antibody buffer. The primary antibody was removed and membranes washed three times for 10 min with 
TBST prior to addition of secondary HRP conjugated antibodies (Thermo) for 1 h in blocking buffer. 
Membranes were washed a further three times whilst rocking for 10 min at RT with TBST. Membranes 
were incubated with Amersham™ enhanced chemiluminescence (ECL) substrate according to 
manufacturer’s protocol and exposed to X-ray film or high sensitivity Amersham™ Hyperfilm™ dependent 
upon signal and developed using an automatic film developer (SRX-101A – Konica Minolta). 
2.3.2 Protein Immunoprecipitation 
 
Following determination of protein concentration by Bradford assay, a specific protein or complex of 
interest could be selectively isolated by immunoprecipitation (IP). For endogenous proteins, 3 µg of 
antibody was added per mg of protein lysate and 20 µl of protein G-sepharose per sample. For exogenous 
tagged proteins, FLAG agarose, GFP-TRAP agarose, GST Sepharose or S-protein agarose beads were used 
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as appropriate. An input from each lysate was also taken, usually 2-10% of total IP concentration to 
compare and allow determination of IP efficiency. Samples were incubated for 2 h rotating at 4 °C, beads 
were pelleted by centrifugation at 1000 x g for 1 min at 4 °C and washed three times with lysis buffer 
(Table 3). After the final wash, remaining buffer was aspirated to waste and 1x sample buffer was added 
to beads to precipitate off bound proteins from the beads.  IPs could then be analysed by western blot as 
detailed previously (2.3.1).  
 
2.3.3 Crude Membrane Fractionation 
 
To compare the cytosol to membrane distribution of proteins, cells were crudely fractionated by ultra-
centrifugation. Cells were treated as described in figure legends then moved onto ice and washed twice 
in ice-cold PBS, all PBS was removed before addition of fractionation buffer (Table 3). Cells were scraped 
and transferred to an Eppendorf, samples were homogenised in the absence of detergent by repeatedly 
passing through a narrow gauge needle to burst cells. The efficiency of breakage was confirmed by light 
microscope. Unbroken cells and nuclei were removed by centrifugation at 500 x g for 5 min at 4 °C. Part 
of the sample was retained as a post-nuclear supernatant (PNS), the remaining sample was then split into 
cytosol and membrane components by subsequent centrifugation at 100,000 x g for 1 h at 4 °C. The 
supernatant (cytosol) was removed and diluted in 4x sample buffer. The pellet (membrane) was 
resuspended in 1x sample buffer at an equal volume to that of the cytosol, this allowed 1:1 
(cytosol:membrane) comparison of proteins when loaded equally by western blot.  
2.3.4 Mass Spectrometry Sample Preparation 
Samples to be analysed by mass spectrometry were first separated by SDS-PAGE as described previously 
(2.3.1). Acrylamide gels were stained for protein using either Instant Blue™ coomasssie (Expedeon) or 
SilverQuest ™ silver staining kit (Invitrogen) as per manufacturer’s guidelines. To minimise contamination, 
mass spectrometry samples were handled and processed in a laminar flow hood during sample 
preparation. Protein bands to be analysed were diced into small cubes (~1 mm) and transferred to a clean 
Eppendorf per band. Gel pieces underwent sequential washes (0.5 ml for 10 min each on a vibrating 
platform) with water, 50 % acetonitrile (ACN), 100 mM Ammonium Bicarbonate (NH4HCO3) and 50 % 
ACN/50 mM NH4HCO3. Samples were alkylated in gel by addition of 75 µl 10 mM dithiothreitol (DTT) in 
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0.1 M ammonium bicarbonate for 45 min at 65°C. The supernatant was removed and 75 µl 50 mM 
Iodoacetamide in 0.1 M ammonium bicarbonate was added and incubated for 20 min at RT. Gel pieces 
were washed with 0.5 ml for 10 min with 50 mM ammonium bicarbonate and then 50 mM ammonium 
bicarbonate + 50 % (v/v) ACN. Gel pieces were then incubated with 0.3 ml ACN for 15 min at RT, which 
was removed by centrifugal evaporation (SpeedVac™, Thermo Scientific) to dry the gel pieces. To digest 
proteins, 30 µl of 25 mM Triethylammonium bicarbonate containing 5 µg/ml Trypsin was added to gel 
pieces and incubated shaking for 30 min at RT. Water was added if required to completely cover gel pieces 
and samples were left shaking at 1100 rpm for 16 h at RT in a Thermomixer® (Eppendorf) to digest 
peptides.  An equal volume of ACN was then added to the gel pieces to extract peptides and incubated at 
1100 rpm for 15 min at RT; the supernatant was removed and dried by centrifugal evaporation. During 
this time 100 µl formic acid buffer was added to the gel pieces and shaken at 1100 rpm at RT. The 
supernatant was added to the initial dried extract and dried once more by centrifugal evaporation. Once 
completed, samples were submitted to the MRC proteomics and mass spectrometry team for analysis by 
LC-MS/MS using an Orbitrap™ Classic mass spectrometer (Thermo Scientific). Proteins and 
phosphorylation sites were identified from peptides by Mascot software (Matrixscience). Phosphorylation 
sites were represented by comparison of the extracted-ion chromatogram (XIC) between samples. 
2.4 In vitro Kinase Assay 
2.4.1 Protein Purification 
Recombinant proteins for use in mTORC1 kinase assays were exogenously expressed and purified from 
HEK293 cells. Cells were transfected in 15 cm dishes at ~60 % confluency. Transfection was carried out by 
incubating 25 µg of DNA per dish in 0.5 ml of Optimem, 50 µg of Polyethylenimine (PEI) was added to a 
separate 0.5 ml of Optimem. Following a 5 min incubation, solutions were combined to allow coating of 
DNA with PEI. PEI condenses DNA into positively charged particles that can be internalised by cells via 
endocytosis, following which the DNA can escape (possibly by osmotic swelling and vesicle bursting) and 
reach the nucleus (Boussif et al. 1995). Following a further 20 min incubation the DNA-PEI solution was 
added directly to HEK293 cells in complete media and incubated for 18 h. The media was changed and 
cells grown for a further 24 h. Cells were then treated (~42h post-transfection) by washing twice and 
incubating in EBSS for 1 h to inactivate and dephosphorylate mTOR sites; Cells were moved onto ice, 
washed twice with PBS and lysed in 1% NP-40 lysis buffer lacking phosphatase inhibitors (Table 3). Lysates 
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were clarified by centrifugation at 3300 x g for 30 min at 4 °C, the cleared supernatant was used for 
immunoprecipitation with GST-sepharose beads rotating for 2 h at 4 °C. Beads were washed twice with 
1% NP-40 lysis buffer + NaCl (1M final) and twice with 1% NP-40 lysis buffer. Beads were then incubated 
with 20 µl GST elution buffer per harvested plate with occasional shaking (10s every 60s) in a 
Thermomixer® for 1 h at 4 °C. Elution buffer was removed by passing through a Spin-X® centrifuge column 
(0.22µm filter, CLS8162, Corning® Costar® - Sigma) at 2000 x g for 1 min at 4 °C. Beads were used for a 
second and third round of eluting as previous, except using 25% less elution buffer for each elution. All 
elutions were then dialysed overnight in dialysis buffer. Elutions were then checked by SDS-PAGE and 
stained with Instant Blue™ coomassie (Expedeon) as per manufacturer’s instructions to examine the 
abundance and purity. Elutions were then snap frozen in liquid nitrogen until required for use.    
 
2.4.2 mTORC1 in vitro Kinase Assay 
 
Endogenous mTORC1 was immunoprecipitated from HEK293 cells and used for in vitro kinase assays. Cells 
were grown in complete media and stimulated with 50 ng/ml insulin-like growth factor 1 (IGF1) for 30 min 
to hyper-activate mTOR prior to lysis in mTORC lysis buffer (Table 3). Endogenous mTORC1 was 
immunoprecipitated using 3 µg of anti-raptor antibody (S682B or S260D) per mg of HEK293 lysate and 
20 µl Protein G Sepharose per sample rotating for 2 h at 4 °C. The beads were pelleted by centrifugation 
at 1000 x g for 1 min at 4 °C and washed twice with mTORC lysis buffer + NaCl (0.5 M NaCl total), twice 
with mTORC lysis buffer and finally twice with kinase buffer (Table 3), all washes were 1 ml. After the final 
wash step, the total IP was split equally between reactions and ~10 µl kinase buffer was left on beads. Per 
reaction, ~1 µg of substrate was added in 20 µl of kinase buffer prior to the final addition of 10 µl ATP Mix 
[10 mM MnCl2, 20 µM ATP, 1 µCi 32P γ-ATP per reaction diluted in kinase buffer]. Reactions were agitated 
in a Thermomixer® at 1100 rpm for 30 min at 30 °C and terminated by the addition of 10 µl 5x Sample 
Buffer. Samples were ran by SDS-PAGE and transferred to PVDF membrane as previously described (2.3.1), 
membranes were then exposed to Amersham™ Hyperfilm™ to detect the incorporation of 32P phosphate 
into protein substrates. Following autoradiography PVDF membranes were incubated in blocking buffer 
for 20 min at RT and analysed by western blot to control for protein levels between separate reactions.  
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2.4.3 VPS34 in vitro Kinase Assay 
 
Cells were treated as described in figure legends prior to lysis in 0.5% NP-40 lysis buffer (Table 3). UVRAG 
in complex with VPS34 was immunoprecipitated via GFP-TRAP or FLAG agarose in exogenous expression 
experiments or alternatively endogenously utilising an anti-UVRAG antibody (S323D). UVRAG was IP’d by 
rotating lysate for 2 h at 4 °C, beads were then pelleted at 1000 x g for 1 min at 4 °C between washes. 
Beads were washed twice with 0.5 % NP-40 lysis buffer + NaCl (0.5 M final), twice with 0.5 % NP-40 lysis 
buffer and finally twice with lipid kinase assay (LKA) buffer (Table 3). VPS34 activity was assayed in vitro 
with a final reaction concentration of 10 µg phosphatidylinositol (PI) liposomes (bovine liver PI, extruded 
through a 100 nm filter – Avanti® Mini-Extruder), 5 µM ATP + 7.5 µCi 32P γ-ATP in LKA buffer. Alternatively 
for kinase inhibitor assays, 100 nM recombinant VPS34/15 (DU8692) was used in place of 
immunoprecipitated kinase. Reactions were agitated in a Thermomixer™ at 1100 rpm for 30 min at 30 °C 
before centrifugation through a Spin-X® column to separate beads,  addition of 500 µl 
Methanol:Chloroform:Hydrochloric Acid (200:100:3.5) terminated the reaction. 1x sample buffer was 
added to the beads removed by Spin-X column and retained to analyse by western blotting as a loading 
control for VPS34 levels immunoprecipitated and to normalise data. Subsequently 180 µl of chloroform 
and 300 µl of 0.1 M hydrochloric acid was added to the solvent of each sample and centrifuged at 1000 x g 
for 1 min at RT to phase split components. The chloroform lipid containing lower layer was transferred to 
a fresh Eppendorf and dried by centrifugal evaporation. Thin layer chromatography (TLC) silica 60 plates 
(Merck-Millipore) were treated with potassium oxalate buffer (Table 3) and dried to assist with 
phospholipid separation (Gonzalez-Sastre & Folch-Pi 1968). Dried lipids were resuspended in 50 µl 
chloroform, spotted onto treated TLC plates and then ran using a methanol:chloroform:water:ammonium 
hydroxide (47:60:11.2:2) solvent system to separate phosphoinositol products. Once complete the TLC 
plate was dried and the incorporation of 32P into lipids was analysed using a Fujifilm Image Reader 
(FLA-2000). Recombinant VPS34/15 (DU8692) was used as a positive control to identify and determine 
PI(3)P product formation. Quantitation was carried out using AIDA image analyzer (Raytest).  
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2.5 EGFR Degradation Assay 
To monitor cellular endocytic function, the uptake and degradation of the epidermal growth factor 
receptor (EGFR) was examined. Tissue culture cells were serum starved by washing twice and incubating 
in DMEM only for 2h or 4h to accumulate EGFR on the cell surface. At time-point 0, 30 µg/ml 
cycloheximide was added to inhibit protein synthesis (Ennis & Lubin 1964) and 50 ng/ml EGF was added 
to stimulate EGFR activation. Cells were moved back into the incubator and at time points indicated, 
moved onto ice and lysed in 0.5 % NP-40 lysis buffer as described (2.3.1). Samples were immunoblotted 
for EGFR across time-points and the abundance of the EGFR plotted relevant to time.  
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2.6 DNA Transformation and Plasmid Purification 
 
E.coli DH5α competent bacteria (Life technologies – Invitrogen) were utilised to increase yield of DNA. For 
each transformation, 20-50 ng of plasmid DNA was added to 25 µl of competent DH5α on ice for 15 min. 
Uptake of DNA was induced by heat-shock at 40 °C for 45 seconds and returning to ice for 2 min [Modified 
from (Cohen et al. 1972)]. LB Broth (250 µl) was added to each reaction and streaked out immediately 
onto LB agar plates containing 100 µg / ml ampicillin. Plates were inverted and incubated for 16 – 20 h at 
37 °C to allow colony growth. A single colony was picked and used to inoculate a culture of 250 ml LB 
Broth containing 100 µg/ml Carbenicillin in an Erlenmayer flask. Cultures were incubated at 180 rpm for 
18 h at 30 °C in a Multitron (Infors HT) bacterial shaker. Plasmid DNA was purified from bacterial cultures 
utilising a plasmid maxiprep kit (Qiagen) as per manufacturer’s protocol. Isolated DNA was analysed using 
a NanoDrop 1000 spectrophotometer (Thermo Scientific) to confirm sample yield and purity. 
2.7 Lambda Phosphatase Treatment 
Lambda (λ) phosphatase has a wide range of activity against serine, threonine and tyrosine 
phosphorylation sites in a manganese dependent manner (Cohen & Cohen 1989). Cells were lysed in 0.5% 
NP-40 lysis buffer (Table 3) and clarified by centrifugation at 21,000 x g for 10 min at 4 °C, the supernatant 
was supplemented with 10 µg Lambda Phosphatase and 5mM MnCl2 in the presence or absence of 
phosphatase inhibitor cocktail (used at 10x final). Samples were incubated at 1100 rpm for 30 min at 30 °C 
in a Thermomixer® and reactions terminated by the addition of 4x sample buffer. Samples were then 
analysed by western blotting to determine whether the mobility of proteins are affected, indicative of 
phosphorylation.   
2.8 Opti-Prep Gradient Separation 
To separate cell lysates by density, Opti-prep™ density gradient was used (D1556 – Sigma). Following 
treatment, cells were moved onto ice and scraped in membrane fractionation buffer (Table 3) before 
passing through a narrow gauge needle to homogenise cells. Nuclei and intact cells were removed by 
centrifugation at 500 x g for 5 min at 4 °C. Density gradients were prepared by sequential layering of 
40 % to 10 % Opti-prep™ (Table 3) in 5 % intervals inside thick-wall polycarbonate ultracentrifuge tubes 
with the cell lysate layered on top as the final addition. Samples underwent centrifugation at 100,000 x g 
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for 16 h at 4 °C. Layers were removed sequentially and added to 4x sample buffer for analysis by western 
blotting.  
2.9 Size Exclusion Chromatography 
Samples to be separated by size exclusion chromatography were treated as described and lysed on ice in 
0.5 % NP-40 lysis buffer. Samples were clarified by centrifugation at 21,000 x g for 10 min at 4 °C, the 
supernatant was then filtered through a 0.22 µm filter to remove any remaining protein precipitates. A 
Superose 6 column (GE Healthcare) was equilibrated in Gel filtration buffer prior to injection of 0.5 ml of 
protein lysate. Fractions were collected every 0.5 ml and western blotted as indicated, the approximate 
molecular weight of eluted proteins was subsequently determined by running a gel filtration 
chromatography standard (151-1901 – Bio-Rad).  
2.10 Immunofluorescence 
For fixed immunofluorescence experiments, cells were seeded out onto 22x22 mm glass coverslips. 
Coverslips were first washed in 100 % ethanol before allowing to air dry in a 6-well plate inside a biological 
safety cabinet. Once dry, trypsinised cells were added on top and grown for a minimum of 16 h to ensure 
cells had adhered and settled sufficiently onto the glass. Cells were then utilised for immunofluorescence 
experiments as described further below. Imaging was carried out on a Nikon Eclipse Ti widefield 
microscope using NIS Elements.  
2.10.1 Cell Fixation, Staining and Mounting 
Following treatments, cells require fixation to terminate cell processes and preserve the sample for 
subsequent microscopy analysis: 
2.10.1.1  - Formaldehyde Fixation 
In most cases following the desired cell treatment, coverslips were washed twice in PBS before fixing with 
formaldehyde buffer (Table 3) for 20 min at RT. The formaldehyde was then removed and quenched by 
washing twice and incubating for 10 min in IF Quench Media (Table 8). If cells were to be stained using 
antibodies, they were treated as described (2.10.1.3). Otherwise, cells were washed twice in PBS and 
dipped into ddH2O briefly before mounting onto coverslides using Prolong® Gold Mountant (with DAPI). 
Slides were covered and left at RT overnight to allow mountant to dry completely before imaging.  
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2.10.1.2 - Methanol Fixation 
Where indicated, cells were fixed and permeabilised with methanol. Following treatment, coverslips were 
washed twice briefly in PBS before incubating in -20 °C methanol for 2 min on ice. Coverslips were washed 
twice further in PBS to remove trace methanol before incubating in IF blocking buffer (Table 8). Antibody 
staining was then continued as described in 2.10.1.3 (without permeabilisation step).      
2.10.1.3 – Antibody Staining 
 
For staining with antibodies, after fixation coverslips were washed once with PBS and then incubated in 
permeabilisation buffer (Table 8) for 3 min to make intracellular antigens accessible. Coverslips were then 
washed twice and incubated for 15 min with IF blocking buffer (Table 8) to reduce non-specific epitope 
binding. The primary antibody was prepared in IF blocking buffer (Table 8) at concentrations indicated in 
2.1.5 (typically 1:500 – 1:1000) and added directly onto coverslips and incubated for 1 h at 37 °C. Unbound 
antibody was removed by washing three times for 10 min in IF blocking buffer. Secondary Alexa-Fluor 
conjugated antibodies (Life Technologies, Thermo) were added to coverslips (1:500) in IF blocking buffer 
and incubated for 30 min at RT; surplus antibody was removed by three further washes for 10 min each 
in IF blocking buffer. Coverslips were briefly dipped into ddH2O prior to mounting onto coverslides with 
ProLong gold® antifade mountant (with DAPI, Life Technologies). Coverslides were covered and left at RT 
overnight to fully dry before imaging.  
2.10.2 Transferrin Recycling Assay 
Cells were washed twice and incubated with TFR media containing 5 µg/ml transferrin Alexa-Fluor-594 
conjugate for 1 h at 37 °C to pre-load the cells. Cells were then washed twice and incubated with complete 
media containing 100 µg/ml holo-transferrin to prevent re-uptake of labelled transferrin. Coverslips were 
stopped at multiple time-points to monitor the turnover of transferrin. At each time-point end cells were 
washed once with acid strip buffer before fixing with formaldehyde buffer and mounting as described in 
2.10.1.1. 
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2.10.3 Phospholipid Staining 
2.10.3.1 – PX and FYVE domain probe - PI(3)P 
To create specific probes for PI(3)P within cells, the PX Domain of p40phox (DU45823) and 2xFYVE domain 
of HRS (DU45781) were utilised. Proteins were cloned, expressed and purified by the DSTT (University of 
Dundee). The probes were then conjugated to Alexa-Fluor 488 (A30006 – Life Technologies) or 
Alexa-Fluor-594 (A30008 – Life Technologies) as per manufacturer’s protocol. The labelled proteins were 
stored at 1 mg/ml in 50 % (v/v) Glycerol at -80 °C. 
2.10.3.2 – PI(3)P Staining Protocol 
 
Cells were treated as described in figure legends, cells were then moved onto ice and washed once with 
ice-cold PBS. Coverslips were washed twice with ice-cold glutamate buffer prior to brief snap freezing with 
liquid N2, coverslips were then thawed and washed twice with glutamate buffer. Coverslips were then 
fixed with formaldehyde for 30 min at RT, changing the formaldehyde once at 10 min. The formaldehyde 
was quenched by washing twice and incubating in IF quench media for 10 min. Cells were then washed 
twice and incubated with IF blocking buffer for 15 min at RT. Coverslips were then incubated with 2xFYVE 
or PX Domain Alexa-Fluor probes at 1:200 in IF blocking buffer for 1 h at RT. Coverslips were washed twice 
with IF blocking buffer prior to dipping into ddH2O and mounting onto microscope slides with prolong® 
gold mounting solution.  
2.10.4 Live Cell Imaging  
For live cell imaging experiments, cells were seeded onto glass bottom dishes (627870 – Greiner Bio One) 
a minimum of 16 h prior to allow cells to settle flat onto coverslips. Treatments were carried out utilising 
phenol red free DMEM or EBSS to reduce background fluorescence and buffered with 20 mM Hepes 
pH 7.4 to prevent acidification of the media in the absence of CO2. Imaging was carried out by widefield 
deconvolution microscopy (Deltavision Elite, GE Healthcare) in a heated environment chamber using 
softWoRx® 5.0 (Applied Precision, GE Healthcare) for image acquisition and deconvolution.  
2.10.5 Immunofluorescence Quantitation 
Immunofluorescence experiments were quantified by NIS Elements (Nikon) or by Fiji (Schindelin et al. 
2012) for parameters described in figure legends. Co-localisation experiments were quantified by 
determining the Manders’ coefficients (Manders et al. 1993). 
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2.11 Statistical Analysis 
Statistical analysis and post-hoc tests were carried out as described in figure legends using GraphPad 
Prism® v5.0. The statistical significance of data is denoted on graphs by asterisks (*) where * = p < 0.05, 
** = p < 0.01, *** = p <0.001 or n.s = not significant. 
2.12 CLS Services 
Some materials and procedures described in this section were provided by departments within the 
College of Life Sciences, University of Dundee. All cDNA constructs and in-house antibodies were produced 
by the Division of Signal Transduction Therapy (DSTT). DNA sequencing and the majority of DNA maxi 
preps were carried out by DNA Sequencing & Services. LB broth and plates were provided by Central 
Technical Services. Live cell imaging was carried out utilising equipment in the Centre for Advanced 
Scientific Technologies (CAST). Mass spectrometry samples were ran by the MRC Proteomics and Mass 
Spectrometry team.  
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3 Phosphorylation of UVRAG by mTOR 
 
3.1 Introduction 
 
Intracellular trafficking is fundamental for many aspects of cellular function (1.1.3). Through 
continued study, new proteins and functions continue to emerge which highlight the diverse 
nature of trafficking. Increasing complexity however demands efficient control mechanisms, as 
a lack of regulation has the propensity to drive disease. This is most strikingly represented by 
the demonstration that alterations in endocytic genes are ~2-5 fold more likely to cause 
monogenic disease compared to other human genes (Sigismund et al. 2012).  While many 
studies have identified proteins or regulation mechanisms that are uniquely required for 
individual trafficking pathways, it is essential to recognise that these distinct trafficking 
pathways are intricately linked with one another and hence further research is required to fully 
understand the consequences of alterations in one pathway relative to another. For example, 
the lysosome acts as the terminal destination for several trafficking pathways such as 
macroautophagy that when induced causes a rapid increase in the delivery of intracellular 
material to the lysosome. For this to proceed efficiently requires mechanisms to ensure 
lysosomes remain ‘primed’ and able to digest incoming material whilst at the same time 
recycling components. Precisely how other intracellular pathways are regulated to adjust for 
this remains unclear. Work examining the transcription factor TFEB has shown it is critical for 
the upregulation of lysosomal genes and also increases bulk-flow endocytosis following 
autophagy induction, however this response can take several hours and it is likely that more 
immediate steps may be required (Sardiello et al. 2009). The VPS34 complex is essential for 
endocytosis as well as autophagy induction; it could therefore be an immediately attractive 
target to trigger a change in pathway balance until later acting transcriptional processes such as 
TFEB take effect.  
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For this reason the VPS34 complex was examined to determine whether the induction or 
suppression of autophagy modified the complex in any manner that may lead to regulation of 
other trafficking pathways.  
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3.2 Results 
 
3.2.1 UVRAG is Phosphorylated in a Nutrient Dependent Manner 
 
To explore possible regulation mechanisms the VPS34 complex was examined under nutrient 
rich conditions or during an autophagic response. Autophagy was induced either by nutrient 
deprivation (EBSS) or via direct chemical inhibition of mTOR with KU0063794 (García-Martínez 
et al. 2009) in U2OS, Hela and Mouse Embryonic Fibroblasts (MEFs, see Figure 3.1A). Nutrient 
depletion and inhibitor treatment blocked mTOR activity as demonstrated by the mobility shift 
of 4E-BP1 indicating dephosphorylation in addition to the reduction in ULK1 S757 
phosphorylation, both known substrates of mTORC1. Furthermore the kinase activity of ULK1 is 
enhanced as judged by an increase in ATG13 S318 phosphorylation, indicating the induction of 
an autophagic response. Upon examination of the VPS34 complex no notable change was 
observed in any component except for the protein UVRAG, which exhibited a mobility shift in 
the presence of nutrients. As a mobility shift by SDS-PAGE can be indicative of post-translational 
modifications, cell lysates from MEFs grown in nutrient rich conditions were utilised to 
determine if UVRAG was modified by phosphorylation. Incubation of cell lysate with λ 
phosphatase, which has broad non-specific phosphatase activity (Zhuo et al. 1993), abolished 
the observed mobility shift but this was prevented in the presence of phosphatase inhibitors 
(Figure 3.1B). This demonstrates that UVRAG undergoes phosphorylation in the presence of 
nutrients. To further examine the requirement of nutrients for UVRAG phosphorylation, MEFs 
were incubated in the presence of serum alone, amino acids alone, serum and amino acids or 
with neither. As is shown in Figure 3.1C, both amino acids and serum together elicited the 
greatest mobility shift. Incubation of either alone results in a partial shift in comparison to 
without nutrients or with mTOR inhibition. In addition the use of a specific VPS34 kinase inhibitor 
(VPS34-IN1) does not impair the UVRAG mobility shift suggesting it is not dependent upon VPS34 
complex activity (Examination of VPS34-IN1 specificity and action is shown in Chapter 6).  
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Figure 3.1 - UVRAG is phosphorylated under nutrient rich conditions. 
(A)  Cel ls  were treated for 1 h  (MEFs) or 2 h (U2OS and Hela) in complete media (+AA), 1uM 
KU0063794 (KU) or starvation media (EBSS).  (B)  MEF cell  lysates from cells treated for 1 h in 
complete media (+AA) were split into three and treated with lambda phosphatase as indicated. 
(C)  Wild-type MEFs were incubated for 1  h in the presence of  serum and amino acids (complete 
media),  amino acids only (serum starve media),  serum only (EBSS + 10  % FBS),  without serum or 
amino acids (starvation media),  treated with 1  µM KU0063794 (KU) or 1µM VPS34 -IN1 for 1 h 
prior to lysis.  (A-C) All samples were lysed in 0.5  % NP-40 lysis buffer.  
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 To examine the loss of UVRAG phosphorylation in a time-dependent manner during nutrient 
deprivation, MEFs were monitored across multiple time-points (Figure 3.2A). A complete 
downshift of UVRAG was observed by 45 min which interestingly correlated with that of the 
mTOR substrate 4E-BP1. Replacement of nutrients (serum and amino acids) caused a rapid 
reappearance of UVRAG and mTOR substrate phosphorylation within 15 min. The mTOR 
ATP-competitive inhibitor KU0063794 caused a more rapid inhibition of ULK1 S757 and UVRAG 
phosphorylation within 10 min when added to cells in nutrient rich conditions (Figure 3.2B). 
Removal of the inhibitor by washout allowed rapid re-phosphorylation by 5 min. The 
phosphorylation of UVRAG therefore correlates with nutrient status in an mTOR dependent 
manner, as the presence of nutrients alone is not sufficient for UVRAG phosphorylation if mTOR 
is specifically inhibited. The difference in recovery of UVRAG or mTOR substrate phosphorylation 
following nutrient depletion compared to mTOR inhibition is likely due to the requirement for 
signalling to occur prior to mTOR reactivation. In comparison the upstream signalling remains 
intact in the presence of KU0063794 and mTOR activity therefore rapidly recovers following drug 
washout. 
The loss of UVRAG phosphorylation correlates with autophagy induction as both nutrient 
depletion and mTOR inhibition induce autophagy as indicated by an increase in LC3-II flux, 
demonstrated by the addition of the lysosomal inhibitor Bafilomycin A1 (BafA1; Figure 3.2C&D). 
The mTOR inhibitor KU0063794 inhibits both mTORC1 and mTORC2 as it binds to the ATP 
binding domain of mTOR (García-Martínez et al. 2009). It was of interest to establish whether 
UVRAG phosphorylation is dependent specifically on mTORC1 or mTORC2, therefore selective 
mTORC1 inhibitor rapamycin was used (Sarbassov et al. 2004). A partial decrease in the UVRAG 
mobility shift was observed upon rapamycin treatment whilst mTORC2 activity was unaffected 
as shown by AKT S473 phosphorylation (Figure 3.2E). The inhibition of mTORC1 by rapamycin is 
very selective but not complete for all substrates; p70 T389 phosphorylation was ablated 
completely but 4E-BP1 was only partially down-shifted (Choo et al. 2008). Recent work has 
demonstrated that rapamycin has differential effects upon mTORC1 substrates dependent upon 
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their interaction strength, with phosphorylated serines generally more resistant than threonines 
to rapamycin inhibition (Kang et al. 2013). It is difficult to determine whether the remaining 
partial mobility shift in UVRAG is due to rapamycin insensitivity (as with 4E-BP1) or whether this 
suggests a role for mTORC2 mediated phosphorylation. To determine whether mTORC2 was 
implicated in UVRAG phosphorylation, Rictor deficient MEFs which are unable to form mTORC2 
were utilised. No difference in the UVRAG mobility shift was observed with Rictor -/- MEFs. 
Rapamycin treatment induced a partial downshift in UVRAG similar to wild-type MEFs that was 
fully abolished with the mTORC1 and 2 inhibitor KU0063794 (Figure 3.2F). This suggests that 
mTORC2 is not implicated in UVRAG phosphorylation and that mTORC1 activity is responsible. 
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Figure 3.2 - Characterisation of UVRAG phosphorylation in response to nutrients 
(A) Wild-type MEFs were washed a nd incubated in starvation media (EBSS)  for 1  h and then 
changed to complete media (+AA) for 1  h, time-points were taken as indicated. (B)  Wild-type 
MEFs were treated with 1  µM KU0063794 (KU) for 30 min, cel ls  were washed twice and 
incubated in complete me dia for 5 min with time-points taken as indicated. (C) Wild-type MEFs 
were grown either in complete media (+AA), starvation media (EBSS) or treated with 1  µM 
KU0063794 (KU) in the presence or absence of 100  nM Bafilomycin A1 (BafA1).  (D)  Quantitation 
of (C),  bars represent mean LC3-II  ± SEM of n = 4 independent experiments. Stat ist ical analysis 
was carried out by one-way analysis of variance using Dunnett’s mult iple comparison test and 
comparing to the +AA control where * = p < 0.05, ** = p < 0.01 or n.s  = not s ignificant (E) Wild-
type MEFs were incubated in complete media (+AA), starvation media (EBSS),  treated with 1 µM 
KU0063794 (KU) or treated with 100 nM or 1 µM Rapamycin as indicated for 1 h. (F)  RICTOR +/+ 
and -/-  MEFs were incubated in complete media  (+AA) and treated with 1 µM KU0063794 or 100 
nM Rapamycin for 1 h. (A-F) All  samples were lysed in 0.5  % NP-40 lysis buffer.  
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3.2.2 mTOR Mediates UVRAG Phosphorylation 
 
The data presented here thus far suggests a dependence upon mTORC1 or its downstream 
effectors for the phosphorylation of UVRAG under nutrient rich conditions. Given the previously 
established direct inhibitory role of mTORC1 phosphorylation of ULK1 in the regulation of 
autophagy (1.2.5). It was examined whether mTORC1 could also directly phosphorylate UVRAG. 
The mTORC1 or mTORC2 complexes can be selectively isolated by immunoprecipitation (IP) of 
mTOR complex specific components, for example RAPTOR (mTORC1), SIN1 or RICTOR (mTORC2). 
As demonstrated in Figure 3.3A, an endogenous mTOR IP was able to immunoprecipitate both 
mTORC1 and mTORC2 but endogenous RAPTOR or RICTOR IPs were complex specific. In 
comparison to direct mTOR IP, IP of RAPTOR yielded less mTOR, however a critical factor for 
substrate phosphorylation is recognition and binding. mTORC1 activity is directed by binding 
substrates through RAPTOR (Hara et al. 2002) and as such, IP of RAPTOR demonstrated superior 
phosphorylation of the mTORC1 substrate p70-S6Kinase (p70) in vitro in comparison to IP of 
mTOR (Figure 3.3B). To examine whether mTORC1 can directly phosphorylate UVRAG or other 
components of the VPS34 complex, an in vitro kinase assay was carried out. Endogenous 
mTORC1 was immunoprecipitated via RAPTOR and incubated with GST-UVRAG, GST-ATG14L or 
FLAG-BECLIN1 (Figure 3.3C). As a control GST-p70 D236A was also included in the in vitro kinase 
assay. GST-p70 D236A is mutated in the critical kinase DFG motif that orientates the γ-phosphate 
of ATP for transfer to substrates (Hanks & Hunter 1995), therefore preventing kinase activity. 
This ensures that incorporation of 32P γ-phosphate into GST-p70 cannot occur via 
autophosphorylation and therefore any phosphorylation observed purely represents the activity 
of other kinases. A strong phosphorylation of GST-UVRAG was observed in comparison to GST-
p70 D236A; additionally GST-ATG14L was weakly phosphorylated whilst FLAG-BECLIN1 
demonstrated no modification. Critically, phosphorylation of p70 or UVRAG was severely 
ablated if the assay was carried out in the presence of KU0063794 (Figure 3.1Figure 3.3D), 
suggesting the incorporation of 32P is dependent on mTOR kinase activity. To examine whether 
mTORC2 could phosphorylate UVRAG in vitro, endogenous RAPTOR or RICTOR were 
75 
 
 
immunoprecipitated and assayed against GST-p70 D236A, GST-UVRAG or GST-Serum and 
glucocorticoid induced protein kinase 1 (SGK1) K127A (Figure 3.3E). SGK1 is an established 
mTORC2 target phosphorylated at S422 in the hydrophobic motif and mutation of the ATP 
binding domain K127A is known to ablate kinase activity (Kobayashi & Cohen 1999; García-
Martínez & Alessi 2008). UVRAG and p70 were phosphorylated when incubated in vitro with 
mTORC1 but not with mTORC2. UVRAG is therefore only phosphorylated in vitro by mTORC1 
and not mTORC2. It should be noted that SGK phosphorylation could not be observed by 
autoradiography but could be detected by use of phospho-specific antibodies. An increase in 
SGK S422 phosphorylation was observed with mTORC2 in comparison to IgG, confirming that 
mTORC2 was active. However, SGK1 S422 phosphorylation was also observed with mTORC1; 
previous data has demonstrated that mTORC1 can phosphorylate SGK at S422 in vitro but 
mTORC2 is the key kinase in the cellular environment (Hong et al. 2008). 
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Figure 3.3 – UVRAG and mTOR in vitro kinase assay 
(A)  Antibodies raised against RAPTOR (S682B), RICTOR (S654B) or mTOR (S673B) were used 
respectively to immunoprecipitate mTORC1, mTORC2 or both from HEK293 cells.  (B)  mTOR (M) 
and RAPTOR (R) were immunoprecipitated from HEK293 cells and used f or an in vitro  kinase assay 
with GST-p70 D236A. (C)  mTORC1 was selectively  immunoprecipitated from HEK293 cel ls  using a 
RAPTOR antibody and uti l ised for an in vitro  kinase assay. mTORC1 was incubated with GST -p70 
D236A, GST-UVRAG, GST-ATG14L or FLAG-BECLIN1 in the presence or absence of  1  µM KU0063794. 
(D)  Quantitat ion of (C),  bars represent mean substrate 32P incorporation ± SEM of n  = 4 
independent experiments.  Statist ical analysis  was carried out by two -way analysis of variance 
using Bonferroni’s post -test where *** = p < 0.001. (E)  RAPTOR or RICTOR antibodies were used 
for immunoprecipitation of  mTORC1 and mTORC2 from HEK293 cells for in vitro kinase assay 
analysis with GST-UVRAG, GST-p70 D236A and GST-SGK K127A. (A-E)  Al l  samples were lysed in 
mTORC lysis buffer.   
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3.2.3 Identification of UVRAG Phosphorylated Residues 
 
To determine the location of phosphorylation sites on UVRAG two approaches were undertaken. 
MEFs stably expressing FLAG-UVRAG were grown in nutrient rich conditions or treated with 
KU0063794 and immunoprecipitated using FLAG agarose. Additionally, GST-UVRAG was 
incubated in vitro with endogenous mTOR and phosphorylated in a non-radioactive kinase assay 
in the absence or presence of KU0063794. In each experiment samples were separated by SDS-
PAGE, the UVRAG band was excised for protease digestion and used for phospho-peptide 
analysis by mass spectrometry. Phosphorylated peptides identified between experiments are 
detailed in Table 10. Five unique singly phosphorylated peptides were identified from FLAG-
UVRAG immunoprecipitated from cells. Three of these sites were abolished upon mTOR 
inhibition. Two major single phosphorylated peptides were identified from GST-UVRAG 
following in vitro kinase assay with mTOR that were both sensitive to KU0063794. Notably, these 
phospho-peptides were also identified upon FLAG-UVRAG IP. The two common peptides were 
K543-K559 (S548 or S549 or S550 predicted phosphorylation site) and K564-R595 (S571 
predicted site). A third L514-R542 (T518 or S522 predicted site) peptide was observed, however 
this was only observed in a half of experiments and usually presented with a low ion score. The 
extracted-ion chromatograms (XICs) for K543-K559 and K564-R595 peptides from the in vitro 
kinase assay are shown in Figure 3.4A&B. In both XICs, the phosphorylated peptide species was 
only observed following a kinase reaction with mTOR, and not in the presence of KU0063794 or 
with an IgG control IP. To determine the precise residues phosphorylated within UVRAG, a 
radioactive kinase assay was carried out with endogenous mTORC1 and GST-UVRAG. Trypsin 
was used to digest UVRAG and peptides were separated by liquid chromatography as shown in 
Figure 3.4C. The incorporation of 32P was too low to allow Edman degradation to identify 
phosphorylated residues (Edman & Begg 1967), however two distinct radioactive peaks were 
eluted by liquid chromatography which may suggest there are two major phosphorylated 
peptides within UVRAG following an in vitro kinase assay. Repeating the non-radioactive in vitro 
kinase assay of UVRAG with mTORC1 (IP: RAPTOR) or mTORC2 (IP: RICTOR) and analysis by mass 
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spectrometry demonstrated that the phosphorylated K543-K559 peptide was only seen with 
mTORC1. No phospho-peptides were identified following kinase assay reaction with mTORC2, 
further suggesting that mTORC2 does not phosphorylate UVRAG (Figure 3.4D). Analysis of GST-
UVRAG phosphorylated in vitro by mTOR was repeated with several proteases (Trypsin, 
Chymotrypsin and ASP-N) to increase the sequence coverage of UVRAG. Approximately 92 % of 
the total UVRAG sequence was identified by mass spectrometry (Figure 3.5A) and two distinct 
phosphorylated peptide peaks were seen by liquid chromatography (Figure 3.4C). Taken 
together the above data clearly indicates that mTORC1 mediates phosphorylation at two distinct 
sites. The domain structure of UVRAG is represented in Figure 3.5B with an alignment of Human 
UVRAG 501-620, the region where phosphorylated residues were identified. Mass spectrometry 
was unable to accurately predict which residue of S548-550 is phosphorylated, however the 
S550 and S571 residues both are positioned with a +1 leucine residue which is favourable for 
mTOR mediated phosphorylation sites (Figure 3.5C)(Hsu et al. 2011). 
 
Possible 
Site 
Peptide (P-site) UVRAG IP  
(from Cells) 
mTOR Kinase Assay 
(in vitro) 
+AA KU0063794 Control KU0063794 
S498 R.QSSIFGGADVGFSGGIPSPDKGHR.K + P + + n.p n.p 
S508/S509 R.ASSENERLQYK.T + P + n.p n.p n.p 
T518/S522 R.LQYKTPPPSYNSALAQPVTTVPSMGETER.K + P + + Φ Φ 
S548-S550 R.KITSLSSSLDTSLDFSK.E + P + n.p + n.p 
S571 R.KGEDLVGSLNGGHANVHPSQEQGEALSGHR.A 
+ P 
+ n.p + n.p 
Table 10 – UVRAG Phosphorylated Peptides 
List  of phosphorylated identified in UVRAG immunoprecipitat ion or in v itro  kinase assays in the 
presence or absence of mTOR inhibitor KU00 63794. Identif ied peptide for each site is shown with 
the predicted phosphorylated  residue.  (+) Denotes that peptide w as identified and 
phosphorylated, (n.p)  peptide was identified but not phosphorylated or (Φ) peptide was identif ied 
but not consistently phosphorylated across experiments.  
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Figure 3.4 – Extracted Ion Chromatograms (XICs) of phosphorylated peptides. 
(A-B) mTOR (S683B) was immunoprecipitated from HEK293 cel ls  and incubated with GST -UVRAG 
in a non-radioactive kinase assay in the presence or absence of 1  µM KU0063794.   Peptides were 
analysed by mass spectrometry fo llowing protein digest.  XIC of  phosphorylated peptides 
identif ied (A) K543-K559 and (B) K564-R595.  (C) mTOR immunoprecipitated from HEK293 cel ls  was 
used to carry out a radioactive kinase assay with GST -UVRAG. UVRAG was c leaved by tryptic digest 
and peptides were separated by l iquid chromatography whilst  monitoring counts per minute (cpm)  
of eluted fract ions. (D) RAPTOR (S260D) or RICTOR (S654B) was immunoprecipitated from HEK293 
cells  and incubated with GST -UVRAG in a non-radioactive kinase assay in the presence or absence 
of 1 µM KU0063794. Peptides were analysed by mass spectrometry fo llowing protein digest,  the 
XIC of phosphorylated K543 -K559 is  shown.   
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Figure 3.5 - Mass Spectrometry UVRAG Coverage. 
(A) Ful l GST-UVRAG sequence (1-237 = GST).  Peptides covering residues highlighted in red were 
identif ied by mass spectrometry, 94% of  GST -UVRAG was identified (92% of  UVRAG).  (B) Domain 
structure of UVRAG showing the proline r ich region (PRR), C2 Doma in (C2) and coi led-coi l domain 
(CCD). Al ignment of UVRAG amino acids 501 -620 (Human) between species, black boxes signify  
conserved residues whilst  grey represents s imilar residues. Identif ied phosphorylat ion sites 
indicated with an asterisk (*).  Alignment  was carr ied out using ClustalW alignment software 
(EMBL-EBI) with sequences from UniProt (www.uniprot.org).  (C)  Consensus sequence for mTORC1 
directed phosphorylat ion from (Hsu et al .  2011) .  
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To confirm whether phosphorylation does occur at S548-550 or S571 residues, the serine 
residues were mutated to alanine residues that cannot be phosphorylated as they lack a 
hydroxyl group. The GST-UVRAG alanine mutants were incubated in vitro with endogenous 
mTORC1 that was immunoprecipitated via RAPTOR. Mutation of S548, S549 and S550 all to 
alanine (AAA) caused reduced phosphorylation in vitro. This was also seen with S550A but not 
S549A or S548A (Figure 3.6A), suggesting that S550A is the phosphorylated residue of the K543-
K559 peptide. Mutation of UVRAG S571A also caused a decrease in phosphorylation and change 
in mobility. Expressing UVRAG with S550A and S571A together resulted in an additive loss of 32P 
incorporation (Figure 3.6B), reducing levels to ~30 % as is also seen when using the mTOR 
inhibitor KU0063794 (Figure 3.6C). This suggests that S550 and S571 are the primary mTORC1 
mediated phosphorylation sites. The residual 32P incorporation of UVRAG was insensitive to the 
mTOR inhibitor KU0063794 and consequently may result from the activity of contaminating 
kinases. 
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Figure 3.6 - UVRAG Alanine Mutants in vitro Kinase Assay 
(A+B)  HEK293 cells were lysed in mTORC lysis  buffer and mTORC1  was immunoprecipitated using 
a RAPTOR antibody (S260D) and incubated with GST -UVRAG and alanine site mutations 
(wt= wild-type, AAA = S548A+S549A+S550A, DblA = S550A + S571A) in an in vitro  k inase assay. (C) 
Quantitation of  (B),  bars represent mean substra te 32P incorporation ± SEM of n = 4 independent 
experiments. Stat istical analysis was carried out by one -way analysis of variance and Dunnett’s 
multiple comparison test to  the wild -type control where *  = p < 0.05 and *** = p < 0.001  
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3.2.4 Characterisation of UVRAG Phosphorylation Sites 
 
The mutation of S550A and S571A prevented UVRAG phosphorylation in vitro, however the 
mutation to alanine residues may disrupt site recognition by mTOR. To confirm that UVRAG was 
phosphorylated at S550 and S571, specific phospho-antibodies to each site were raised in sheep 
and purified by the Division of Signal Transduction Therapy (DSTT), University of Dundee. This 
allowed further examination and characterisation of these phosphorylation sites in cells 
endogenously.  
GST-UVRAG wild-type or S571A phosphorylated in vitro by endogenously immunoprecipitated 
mTORC1 was recognised by the S550 phospho-specific antibody but as expected the S550A and 
S550A+S571A mutants were not recognised (Figure 3.7A). Exogenous FLAG-UVRAG 
immunoprecipitated from MEFs under nutrient rich conditions was also recognised by the S550 
phospho-specific antibody; this was ablated upon nutrient starvation or if FLAG-UVRAG S550A 
was immunoprecipitated instead (Figure 3.7B). Analysis of cell lysates from several cell lines using 
the S550 phospho-specific antibody also demonstrated that endogenous UVRAG was 
phosphorylated at S550 in a nutrient dependent manner in multiple cell lines and between 
species (Figure 3.7C). Incubation of MEFs in serum and amino acid free media caused a loss of 
S550 phosphorylation with similar kinetics to that of 4E-BP1 (Figure 3.7D). Development of a S571 
phospho-specific antibody confirmed that the S571 site is also phosphorylated in response to 
nutrients. IP of GFP-UVRAG clearly shows S550 and S571 phosphorylation in the presence of 
nutrients but not upon nutrient starvation or upon mutation of S550A and S571A (Figure 3.7E). 
The use of phospho-specific antibodies therefore clearly corroborates earlier experiments that 
S550 and S571 of UVRAG were phosphorylated in response to nutrients. 
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Figure 3.7 – Development of UVRAG S550 and S571 phospho-antibodies 
(A) HEK293 were lysed in mTORC lysis  buffer and mTORC1 was immunoprecipitated using a RAPTOR 
antibody (S260D).  mTOR was incubated with  GST-UVRAG or alanine site mutants (DblA = 
S550A+S571A) as a substrate in a non -radioactive kinase assay. Samples were blotted using a S550 
phospho-specif ic antibody (S323D). (B) U2OS cells stably expressing FLAG -UVRAG wild-type or 
S550A mutant were incuba ted in complete media (+AA) or starvation media (EBSS)  for 2  h. Anti-
FLAG agarose was used to immunoprecipitate FLAG -UVRAG and blotted as shown. (C) Cells were 
incubated in complete media (+AA) or starvation media (EBSS) for 1  h (MEFs) or 2 h (HEK293, 
U2OS, Hela) and blotted as shown. (D)  Wild-type MEFs were washed and incubated in starvation 
media (EBSS) for 1  h and then changed to complete media (+AA) for 45  min, time-points were 
taken as indicated. (E) U2OS cells stably expressing GFP -UVRAG wild-type or S550A+S571A mutant 
were incubated in complete media (+AA) or starvation media (EBSS) for 2  h. Anti-GFP sepharose 
was used to immunoprecipitate GFP and blotted as shown. (B-E)  All  samples were lysed in 0.5  % 
NP-40 lysis buffer.  
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3.2.5 Cellular Distribution of Phosphorylated UVRAG 
 
Following identification and confirmation of mTOR regulated phosphorylation sites in UVRAG, 
the effect upon interaction with canonical binding partners was examined. Two distinct VPS34 
complexes are present within mammalian cells (Figure 3.8A) and it is possible that 
phosphorylation of UVRAG may alter complex formation. Endogenous VPS34 was 
immunoprecipitated and showed equal UVRAG binding between nutrient rich conditions or 
during autophagy induction by mTOR inhibition or nutrient starvation (Figure 3.8B). Importantly, 
UVRAG demonstrated a clear mobility shift confirming that phosphorylation was not occluding 
the protein from interacting with the VPS34 complex. Similarly, direct IP of endogenous UVRAG 
did not show any difference in VPS34 complex stoichiometry between phosphorylation states 
(Figure 3.8C). IP of exogenous mCherry-S-BECLIN1, GFP-RUBICON or mCherry-S-ATG14L (Figure 
3.8D-F) from MEFs similarly showed no change in the stoichiometry of the complex between 
conditions. No UVRAG was detected following IP of ATG14L under any treatment as expected 
due to their mutually exclusive binding to the same coiled-coil domain of BECLIN1 (Itakura et al. 
2008). Equally no ATG14L was observed in complex with UVRAG or RUBICON as has previously 
been demonstrated (Matsunaga et al. 2009). Excluding the IP of ATG14L, in all instances the 
phosphorylated form of UVRAG interacted under nutrient rich conditions and exhibited no 
change in component stoichiometry indicating that phosphorylation does not occlude or 
enhance binding of UVRAG or other canonical components to the VPS34 complex. Despite 
previously published work suggesting UVRAG interacts with Endophilin B1 (Takahashi et al. 
2007), it was not possible to confirm interaction with UVRAG under nutrient rich or depleted 
conditions (Figure 3.8G).   
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Figure 3.8 - Phosphorylated UVRAG is not occluded from the VPS34 complex 
(A)  Schematic representation of the two predominant mammalian VPS34 complexes. MEFs were 
incubated in complete media (+AA),  starvation media (EBSS)  or treated with 1  µM KU0063794 (KU) 
for 1 h prior to lysis  in 0.5  % NP-40 lysis buffer. S-tag sepharose, GFP sepharose, Protein -G 
sepharose or FLAG agarose were used as appropriate to IP (B)  VPS34 (S672B), (C) UVRAG (S323D),  
(D)  mCherry-S-BECLIN1, (E) GFP-Rubicon or (F) mCherry-S-ATG14L. (G)  Wild-type MEFs were 
incubated in complete media (+AA) or starvation media (EBSS) for 1  h and lysed in CHAPs lysis  
buffer. UVRAG was IP’d (S323D) and blotted as indicat ed.   
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3.2.6 Pursuit of Novel UVRAG Interacting Proteins 
 
Changes in UVRAG complex formation were further examined by size-exclusion chromatography 
(SEC) on a Sephadex G6 column. Whilst there was no change in established VPS34 complex 
components (Figure 3.8), it is possible that previously uncharacterised interactions may be 
altered upon UVRAG phosphorylation; if this is true then this could affect the UVRAG-VPS34 
complex molecular weight and elution profile by SEC. MEFs were grown in nutrient rich or 
nutrient depleted conditions and then analysed by SEC. As is shown in Figure 3.9, UVRAG 
co-fractionated with VPS34 and BECLIN1 across a wide elution peak with little change between 
cell treatments. ATG14L was found in a higher weight peak with small amounts of BECLIN1 and 
VPS34, but this partially shifted to a lower weight peak, correlating with more VPS34, upon 
autophagy induction. No obvious change in the fractionation profile of UVRAG was evident, 
however given the wide elution peak it would be difficult to determine changes in the interaction 
of low molecular weight proteins. 
To attempt to identify possible uncharacterised UVRAG interacting proteins, GST-UVRAG 
wild-type or S548A/S549A/S550A (S548-550A) were immunoprecipitated from MEFs under 
nutrient rich conditions and separated by SDS-PAGE. Peptides were generated by protease 
digestion and analysed by mass spectrometry to identify co-immunoprecipitating proteins. A 
curated list of identified proteins are shown in Table 11, a full list can be found in Appendix A. 
Many proteins were conserved between both samples including VPS34, VPS15 and RAPTOR. In 
addition peptides from tubulin, motor proteins and clathrin coat components were found in 
both samples. Several proteins unique to each pull-down were identified that will require further 
examination to confirm the interaction and whether binding occurs in a phosphorylation 
dependent manner.  
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Figure 3.9 - Gel filtration of UVRAG 
(A)  Wild-type MEFs were incubated in complete media (+AA) or starvation media (EBSS) for 1  h 
and separated by gel f i l trat ion on a Superose 6 column. Estimated molecular weight of fract ions 
was determined by gel  f i ltration chromatography standards. (*) Represents a non -specific band. 
(B)  The distr ibution of each protein between fract ions was analysed by densitometry and plotted.  
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REF 
WILD-TYPE UVRAG S548-550A UVRAG 
GENE NAME 
Score Peptides Coverage Score Peptides Coverage 
Q9P2Y5 3391 253 71% 6405 434 72% UVRAG UV radiation resistance-associated 
gene protein 
P68363 1150 53 54% 2010 85 62% TUBA1B Tubulin alpha-1B chain 
Q9BVA1 589 28 46% 2046 88 58% TUBA2B Tubulin beta-2B chain 
Q8N122 173 13 9% 227 19 14% RPTOR Regulatory-associated protein of 
mTOR 
P63167 170 5 37% 161 5 37% DYNLL1 Dynein light chain 1, cytoplasmic 
Q99570 135 16 9% 193 15 10% PIK3R4 Phosphoinositide 3-kinase 
regulatory subunit 4 
P53675 102 8 4% 95 5 1% CLTCL1 Clathrin heavy chain 2 
Q8NEB9 68 6 6% 78 4 3% PIK3C3 Phosphatidylinositol 3-kinase 
catalytic subunit type 3 
P33176 65 8 8% 119 5 5% KIF5B Kinesin-1 heavy chain 
Q9UBP0 32 4 3% 39 6 6% SPAST Spastin 
O95071 132 9 3% - UBR5 E3 ubiquitin-protein ligase UBR5 
P61981 108 3 8% - YWHAG 14-3-3 protein gamma 
Q15836 94 3 24% - VAMP3 Vesicle-associated membrane 
protein 3 
Q9Y277 52 4 10% - VDAC3 Voltage-dependent anion-selective 
channel protein 3 
Q8TEB1 - 312 14 22% DCAF11 DDB1- and CUL4-associated factor 
11 
O14654 - 185 13 12% IRS4 Insulin receptor substrate 4 
Q13263 - 176 10 8% TRIM28 Transcription intermediary factor 
1-beta 
P53618 - 69 7 6% COPB1 Coatomer subunit beta 
Table 11 – Curated List of UVRAG Interacting Proteins 
Reference for identif ied proteins is  from UniProt,  protein score refers to assigned score by 
MASCOT software. Proteins represent co -immunoprecipitat ing proteins of GST -UVRAG wild-type 
or S550A. Full l ist  can be found in Appendix A and Appendix B.  
 
As an alternate approach to enrich for proteins which may selectively interact with the 
phosphorylated region of UVRAG alone, biotinylated peptides corresponding to S536-S583 of 
human UVRAG with S550 and S571 both or singly phosphorylated were obtained (DSTT, 
University of Dundee). The peptides were incubated with cell lysate from HEK293 or MEFs grown 
in nutrient rich conditions and immunoprecipitated with streptavidin agarose to identify 
potential phosphorylation specific interactors by mass spectrometry. As is shown in Table 12 the 
highest scoring interactors of phosphorylated peptides were 14-3-3 proteins, whilst no unique 
proteins were found to co-immunoprecipitate with the non-phosphorylated peptide.  
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Table 12 - Curated list of UVRAG biotin peptide interactors 
Reference for identified proteins is  from UniProt,  protein score refers to assigned score by 
MASCOT software. No unique peptides were identif ied in the non -phosphorylated peptide with 
more than two unique peptides. F ul l uncurated list is shown in Appendix C and Appendix D.  
 
 
The interaction of 14-3-3 proteins was identified both by biotin peptide and whole protein 
immunoprecipitation. To examine whether 14-3-3 proteins could interact, GFP-UVRAG 
wild-type or S550A+S571A was immunoprecipitated and immunoblotted using a pan 14-3-3 
antibody that recognises all isoforms. Whilst 14-3-3 appears to interact, this did not appear to 
occur in a phosphorylation sensitive manner as binding was still observed in the phosphorylation 
site mutant at a similar level to wild-type protein following normalisation (Figure 3.10). Although 
the phosphorylation of UVRAG does not alter the binding of the most well established VPS34 
complex binding partners, it is possible that the phosphorylation of UVRAG may instead localise 
the VPS34 complex to a distinct location and this was examined further.   
REF SCORE PEPTIDES 
(UNIQUE) 
GENE NAME IP 
IDENTIFIED 
P62259 2097 26 (20) 1433E 
 
14-3-3 protein epsilon Phospho 
Q9CQV8 1770 23 (16) 1433B 
 
14-3-3 protein beta/alpha Phospho 
P61982 1631 25 (19) 1433G 14-3-3 protein gamma Phospho 
P68510 1547 19 (16) 1433F 14-3-3 protein eta Phospho 
P63101 1233 19 (14) 1433Z 14-3-3 protein zeta/delta Phospho 
P68254 696 18 (12) 1433T 14-3-3 protein theta Phospho 
P07901 358 6 (5) HS90A Heat shock protein HSP 90-alpha Phospho 
P58252 146 8 (5) EF2 Elongation factor 2 Phospho 
P63038 89 3 (3) CH60 60 kDa heat shock protein, mitochondrial Phospho 
P52480 78 4 (1) KPYM Pyruvate kinase isozymes M1/M2 Phospho 
P16381 74 3 (2) DDX3L Putative ATP-dependent RNA helicase Pl10 Phospho 
Q61753 67 3 (2) SERA D-3-phosphoglycerate dehydrogenase Phospho 
P17182 61 4 (2) ENOA Alpha-enolase Phospho 
P20029 2568 38 (33) GRP78 78 kDa glucose-regulated protein Both 
P17879 366 7 (5) HS71B Heat shock 70 kDa protein 1B Both 
P38647 1290 20 (15) GRP75 Stress-70 protein, mitochondrial Both 
P11499 155 6 (3) HS90B Heat shock protein HSP 90-beta Both 
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Figure 3.10 - Interaction of UVRAG with 14-3-3 proteins 
Wild-type MEFs stably expressing wild -type (wt) or S550A+S571A (DblA)  GFP -UVRAG were 
incubated in complete media (+AA) or starvation media (EBSS) for 1  h and lysed in 0.5  % NP-40 
lysis buffer. UVRAG was immunoprecipitated with GFP sepharose and blotted as indicated. Blot 
was analysed by densitometry and the level of 14 -3-3 co-immunoprecipitat ing normalised to GFP -
UVRAG was plotted.  
 
MEFs were homogenised in the absence of detergent and separated by density centrifugation 
using a gradient of 10-45 % iodixanol. This allows the separation of cellular components based 
upon their isopycnic point, a technique that is commonly used to differentially separate cellular 
organelles (Graham et al. 1994). Movement of the UVRAG-VPS34 complex to a distinct cellular 
location upon phosphorylation may therefore be demonstrated by differences in its isopycnic 
point. Comparison of nutrient rich or nutrient deprived MEFs however displayed very little 
change in separation of UVRAG, RUBICON, ATG14L or BECLIN1 (Figure 3.11). A large proportion 
of total VPS34 however was present in low-density fractions that was distinct from the majority 
of BECLIN1, UVRAG, RUBICON or ATG14L. This may represent early endosomes as this correlates 
with the distribution of the early endosome marker EEA1. Upon nutrient starvation the VPS34 
distribution shifts to match that of other VPS34 complex components in denser fractions that 
may represent late endosomes or lysosomes as indicated by the fractionation profile of mTOR. 
Critically, UVRAG appears to remain in the same fractions regardless of phosphorylation state, 
but this does not exclude the possibility of a change in localisation between two compartments 
with similar isopycnic points.  
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Figure 3.11 - Density gradient separation of VPS34 complex components 
(A) Wild-type MEFs were incubated in complete media (+AA) or starvation media (EBSS) for 1  h 
and separated by iodixan ol density gradient, samples were blotted as indicated. (B)  The 
distr ibution of each protein between fractions was analysed by densitometry and plotted.     
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3.3 Discussion 
 
Data presented in this chapter demonstrates for the first time that UVRAG can be 
phosphorylated. Moreover the phosphorylation of UVRAG occurs in a nutrient sensitive manner 
directly by mTORC1 and this may represent part of a co-ordinated control mechanism of key 
autophagy regulators alongside the ULK1 kinase complex.  
Correlation with the activity of mTOR can be undoubtedly seen when assessing UVRAG 
phosphorylation upon incubation in serum or amino acids alone compared to combined 
treatment (Figure 3.1C). This clearly demonstrates the requirement of both growth factor and 
amino acid pathways for the synergistic activation of mTORC1 and phosphorylation of 
substrates. Induction of autophagy by nutrient deprivation or mTOR inhibition ablated the 
mobility shift in UVRAG. The inhibitor KU0063794 is a potent and selective ATP-competitive 
inhibitor of mTORC1 and mTORC2 with an IC50 of ~10 nM. Screening against a panel of 76 protein 
or 7 lipid kinases in vitro at 1 µM and 10 µM demonstrates little off-target inhibition (García-
Martínez et al. 2009), this gives confidence that the blockage of UVRAG phosphorylation by 
KU0063794 is due to mTOR or a downstream mTOR effector and not an inhibitor off-target 
effect. Other structurally distinct dual mTOR inhibitors such as Torin1 are also available that 
could be utilised to further confirm the specificity of UVRAG phosphorylation by mTOR (Thoreen 
et al. 2009). 
Incubation of mTORC1 but not mTORC2 in vitro causes direct phosphorylation of UVRAG. 
Typically mTORC1 substrates are recognised and bound through the regulatory component 
RAPTOR to allow phosphorylation. Immunoprecipitation of UVRAG identified several peptides 
from the RAPTOR protein suggesting that UVRAG interacts with the mTORC1 complex (Table 
11). Interestingly a specific TOR signalling (TOS) motif has been identified in p70 and 4E-BP1 that 
mediates RAPTOR binding and mTOR phosphorylation (Schalm & Blenis 2002). Similar TOS 
motifs have more recently been found for other mTORC1 substrates such as HIF-1α and PRAS40 
(Land & Tee 2007; Oshiro et al. 2007). The motifs identified to date are shown in Figure 3.12, 
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the most commonly observed motif to date is F.[-].Φ.[-].Φ where F represents phenylalanine, [-] 
represents negatively charged residues and Φ represents hydrophobic residues (Aasland et al. 
2002). Mutation of the phenylalanine in all identified TOS motifs completely abolishes RAPTOR 
binding and mTORC1 phosphorylation (Schalm & Blenis 2002). Examination of UVRAG sequence 
however does not appear to have a matching motif with the closest being FEREK or FYTDL. 
Knowledge to date of the TOS motif however is still preliminary and only based upon several 
characterised substrates, many other notable mTORC1 substrates including ULK1 and TFEB do 
not possess a standard TOS motif. TOS motifs so far have primarily been based upon a conserved 
phenylalanine (F) residue at position 0, however it is possible that other hydrophobic aromatic 
amino acids such as tyrosine (Y) could function in place of F. Furthermore the negatively charged 
([-]) residues could potentially be replaced by serine or threonine residues, with phosphorylation 
introducing a negative charge. This raises the exciting possibility that RAPTOR binding could be 
subject to an additional layer of regulation by other kinases phosphorylating the TOS motif, 
though presence of a serine or threonine at these positions remains to be shown. Further 
understanding of the RAPTOR recognition motifs in other mTORC1 substrates will allow 
refinement of the TOS motif and may help identify which region of UVRAG is critical for binding. 
Alternatively the binding location of RAPTOR could be determined by fragmentation analysis of 
UVRAG. 
Incubation of endogenous mTORC1 in vitro with BECLIN1, ATG14L and UVRAG reveals that only 
UVRAG is strongly phosphorylated in comparison to p70. No phosphorylation is evident with 
BECLIN1 and ATG14L displays a weak phosphorylation. Phosphorylation in vitro was prevented 
in the presence of KU0063794 indicating this was mediated by mTOR kinase activity. Yuan et al. 
(2013) have previously demonstrated that ATG14L could be a direct mTORC1 substrate, 
however this was reliant on tagged and over-expressed RAPTOR and mTOR. In the present 
investigation using an endogenous mTORC1 assay, ATG14L was weakly phosphorylated in 
comparison to p70 D236A or UVRAG. For this reason UVRAG was solely focused upon as the 
data suggested this was likely to be an endogenous substrate of mTORC1. 
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Figure 3.12 - TOR signalling (TOS) motif 
Current known TOS mot ifs are l isted alongside their containing protein with the prevalence of  
each residue in the motif demonstrated. To date TOS motifs have been identif ied in p70 S6K 
(Schalm & Blenis 2002) , 4E-BP1 (Schalm et al.  2003) , eIF3f (Csibi et a l.  2010) ,  PRAS40 (Oshiro et 
al.  2007), HIF-1α (Land & Tee 2007) ,  HEXOKINASE-II  (HK-II)  (Roberts et  al .  2014) ,  PHOSPHOLIPASE 
D2 (PLD2)  (Ha et al.  2006)  and SIRTUIN1 (Back et al .  2011) .  
 
Analysis by mass spectrometry identified two UVRAG phospho-peptides that were regulated in 
an mTORC1 dependent manner both in cells and following an in vitro kinase assay (Table 10). 
Large scale proteomic experiments have previously predicted S498, T518 and S548 as potential 
UVRAG phosphorylation sites (Yu et al. 2011), in this study S498 and T518 were identified but 
not found to be regulated in an mTOR dependent manner (Table 10). The K543-K559 phospho-
peptide corresponding to S548-S550 was identified to be mTOR dependent, S550 is the most 
favourable mTOR site by consensus sequence (Figure 3.5C) and indeed mutation analysis 
demonstrated that S550 is the phosphorylated residue (Figure 3.6). S498 or S508 and T518 or 
S522 may represent inputs from distinct unknown kinases that may also modulate UVRAG 
function and will require further investigation. Focus was placed upon S550 and S571 as these 
phosphorylated peptides were consistently identified by mass spectrometry with high scores in 
an mTOR dependent manner. Whilst higher peptide scores may simply indicate the peptide is 
more favourable for identification by mass spectrometry, mutation of S550A and S571A caused 
a complete downshift in UVRAG mobility and reduced 32P incorporation by ~70 % (Figure 3.6) 
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indicating that these represent major phosphorylation sites in UVRAG. Use of the mTOR kinase 
inhibitor KU0063794 also reduces 32P incorporation by ~70 %, suggesting that these two sites 
fully represent mTOR target residues and the remaining phosphorylation occurs due to the 
presence of contaminating kinases. Due to the fragility of the endogenous mTORC1 complex, IP 
has to be carried out under weak lysis and wash conditions with CHAPS detergent (Kim et al. 
2002) which may increase the propensity for non-specific contaminants.  
The location of the identified phosphorylation sites leads to ambiguity over possible functional 
roles as all sites fall within the C-terminal region of UVRAG with no known domain structure. 
The majority of characterised UVRAG protein interactions and functions have been correlated 
with specific protein domains.  The coiled-coil domain (CCD, 200-275) for example is the critical 
mediator of VPS34 complex binding by interacting with a CCD in BECLIN1 (Liang et al. 2006). 
Phosphorylation of UVRAG does not impede or enhance this interaction as no variation in 
BECLIN1 binding was observed (Figure 3.8). UVRAG has also been implicated in binding to the 
N-BAR containing protein Endophilin-B1 (Bif-1) via interaction of an N-terminal proline rich 
region (PRR) with the SH3 domain of Bif-1 (Takahashi et al. 2007). Membrane insertion of N-BAR 
domains is sufficient to generate membrane curvature and has been linked to enhancing 
autophagosome formation (Farsad et al. 2001). Attempts to resolve an interaction by 
immunoprecipitation of endogenous UVRAG (antibody raised against whole protein) in the same 
lysis buffer however proved unsuccessful (Figure 3.8D), even under nutrient starvation where 
the Bif-1 association is reported enhanced (Takahashi et al. 2007). Identification of UVRAG and 
Bif-1 binding was only demonstrated by exogenous expression of Myc-Bif-1 and FLAG-UVRAG in 
HEK293T cells. A further independent study resolved an interaction between endogenous 
UVRAG and HA-Bif-1 (Wong et al. 2011). A true endogenous-endogenous interaction has 
therefore not truly yet been demonstrated. It is possible that the binding of Bif-1 and UVRAG is 
weak or transient in nature that is not retained upon IP. The PRR may act to bind other proteins, 
non-repetitive PRRs such as that in UVRAG are favourable for SH3 domain interactions that are 
contained in a multitude of proteins. Many of these are membrane-associated proteins and are 
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often associated with signalling transduction pathways (Williamson 1994). UVRAG also contains 
a C2 domain that are classically associated with Ca2+ interaction and membrane binding (Nalefski 
& Falke 1996). The co-ordination of calcium can allow phospholipid binding (Sutton et al. 1995) 
and UVRAG has been shown to interact with PI(3)P for localisation to the endoplasmic reticulum  
as part of the ER tethering complex (He et al. 2013). The C-terminal region has more recently 
been identified to interact with several proteins; residues 275-442 for example has been shown 
to bind the centrosomal protein CEP63 or ER protein RINT-1 whilst residues 442-699 interact 
with DNA-dependent protein kinase (DNA-PK) (He et al. 2013; Zhao et al. 2012). Binding to CEP63 
or DNA-PK is not reported to require the BECLIN1-VPS34 complex for function. Further 
investigation is required to examine whether binding to these components is affected by UVRAG 
phosphorylation state. 
Separation of cell lysates by density centrifugation or gel filtration did not display any change in 
the distribution of UVRAG between phosphorylation states. As reported previously however, 
ATG14L did appear in higher molecular weight fractions than UVRAG demonstrating differences 
in complex specific binding (Matsunaga et al. 2009) although this was abolished upon autophagy 
induction. The wide elution peak of UVRAG meant that changes in a possible interaction upon 
phosphorylation may be easily masked. To look directly for interacting proteins, UVRAG wild-
type or S548-550A was immunoprecipitated and analysed by mass spectrometry. BECLIN1 was 
unable to be identified likely due to the antibody heavy chain present at a similar molecular 
mass, however both VPS34 and VPS15 were detected. Interestingly peptides corresponding to 
RAPTOR were also identified in both samples, confirming the involvement of mTORC1 with 
UVRAG. Tubulin components were highly represented upon UVRAG IP in comparison to a GST 
control IP and may represent the association of vesicles moving along microtubules given its 
established role in membrane trafficking. The detection of peptides belonging to motor proteins 
such as dynein or kinesin however was significantly lower (Table 11). The high score for many 
tubulin components may in part be explained by the reported binding of UVRAG to the 
centrosome and CEP63 (Zhao et al. 2012), however neither γ-tubulin nor CEP63 was identified. 
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CEP63 has a similar mass to BECLIN1 and it is possible it may also have been masked by detection 
of antibody heavy chain peptides instead.  Interestingly the v-SNARE vesicle-associated 
membrane protein 3 (VAMP3) was identified in only the wild-type immunoprecipitation. VAMP3 
in combination with t-SNAREs can mediate vesicle fusion at the plasma membrane, this has been 
shown to be important in the recycling of integrins for cell motility and also the fusion of 
granules (lysosome related organelles) from platelets (Riggs et al. 2012; Polgár et al. 2002). 
VAMP3 is also required for functional retrograde trafficking of mannose-6-phosphate receptors 
from late endosomes to the trans-golgi network (TGN) (Ganley et al. 2008). Given the low score 
and number of peptides however this will need further analysis to confirm interaction with 
UVRAG. DCAF11 and IRS4 were found uniquely in the UVRAG S550A+S571A mutant 
immunoprecipitation, further experiments are required to examine whether these represent 
genuine interactions and how they may regulate or interplay with UVRAG function. 
To try to improve resolution of phosphorylation specific interacting proteins and reduce 
non-specific binding, biotin peptides corresponding to Human UVRAG S536-S583 and 
encompassing both mTORC1 phosphorylation sites were generated (Schulze & Mann 2004). 
Reducing the whole protein down to a specific peptide region can enrich for proteins that may 
specifically interact (Gururaja et al. 2003; Hinsby et al. 2004). Synthesis of phosphorylated 
peptides is also advantageous as it ensures a near homologous phosphorylation state which may 
help identify interactions, whereas immunoprecipitation of whole protein will likely also contain 
those that are not phosphorylated at particular residues. The main drawback from the use of 
peptides however is that the small region may not be sufficient to bind genuine interactors if it 
is from a region lacking key interacting residues (Schulze & Mann 2004). Use of phosphorylated 
biotin peptides mainly identified 14-3-3 isoforms (Table 12). 14-3-3 proteins are able to 
modulate many signalling pathways through their ability to bind phosphorylation sites, thereby 
preventing them from mediating interactions or fulfilling other functions (Muslin et al. 1996). 
Analysis of immunoprecipitated UVRAG however demonstrated poor binding of 14-3-3 that was 
not regulated in a phosphorylation sensitive manner (Figure 3.10). The binding of 14-3-3 may 
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not be an important interaction for in vivo UVRAG, however UVRAG peptides in vitro are ideal 
binding targets for 14-3-3 proteins based upon the residues surrounding each phosphorylated 
serine residue(Yaffe et al. 1997). Very few other proteins were identified by peptide IP and it is 
possible that 14-3-3 proteins act to compete off other interactions due to their affinity for the 
phosphorylation motif. Another approach may be to selectively deplete 14-3-3 isoforms from 
cell lysates prior to immunoprecipitation, however this also risks losing other potentially 
important proteins.  
In conclusion, the protein UVRAG is phosphorylated by mTORC1 during nutrient rich conditions 
and this is abolished upon induction of autophagy. ULK1 and VPS34 are the two primary inducers 
of autophagy downstream of mTOR and it is exciting that they may be regulated co-ordinately 
with one another. UVRAG remains in complex with VPS34 and does not facilitate any detectable 
binding of additional components or alter localisation in a manner that impacts upon its 
isopycnic point. The binding of UVRAG to the VPS34 complex however is known to increase lipid 
kinase activity. The primary consequence of mTORC1 mediated phosphorylation of ULK1 is a 
reduction in protein kinase activity to prevent autophagy induction (Ganley et al. 2009; Jung et 
al. 2009). It may also be possible that mTOR analogously manipulates VPS34 kinase activity via 
phosphorylation of UVRAG. Additionally post-translational modification of other VPS34 
interactors BECLIN1 and ATG14L has previously been shown to regulate lipid kinase activity 
(Russell et al. 2013; Xia et al. 2014; Yuan et al. 2013). A further examination of VPS34 activity 
following phosphorylation is therefore critical and is addressed in the following chapter. 
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4 Regulation of VPS34 Kinase Activity by 
mTOR 
 
4.1 Introduction 
 
Phosphatidylinositol kinases (PIKs) regulate cellular signalling via creation of discrete enriched 
pools of phosphoinositides that recruit effector proteins to drive cellular responses. The 
phosphatidylinositol 3-kinases (PI3Ks) have been the subject of particularly intense study due to 
their implication in growth factor signalling, a frequently mutated pathway in disease (Samuels 
et al. 2004). Notably class I PI3K’s (PIK3C1) activity is very low and dependent upon growth factor 
signalling via receptor tyrosine kinases to induce rapid and significant increases in lipid kinase 
activity (Stephens et al. 1993). By comparison VPS34 (PIK3C3) does not demonstrate substantial 
activity changes on the same scale, instead the VPS34 and VPS15 dimer is constitutively active 
(Stack et al. 1995). Several stimuli have been identified in recent years that are able to modulate 
VPS34 kinase activity, however the level of activity change is typically 2-4 fold and noticeably 
much smaller than activity changes observed in PIK3C1. Slight changes in activity however are 
not inconsequential due to the very nature of phospholipid signalling, the presence of a small 
enriched pool of phospholipid is sufficient to recruit cellular effectors in a spatial and temporal 
manner that is critical for correct cellular function. PI(3,5)P2 for example represents only 0.04 % 
of the total cellular phosphatidylinositol (PI) but inhibition impairs a diverse set of trafficking 
pathways (McCartney et al. 2014). Additionally, blocking the formation of one phosphoinositide 
species can lead to knock-on effects for other lipid species, as many are inter-converted from 
one species to the next by sequential phosphorylation or phosphatase activity (Figure 1.6).  
The binding of regulatory components such as BECLIN1 and UVRAG have been show to increase 
VPS34 activity (Kihara, Noda, et al. 2001; Liang et al. 2006). Several VPS34 interactors have also 
been reported to be regulated by post-translational modifications that lead to VPS34 activity 
changes. Notably BECLIN1 is reported to be phosphorylated and ubiquitinated, both of which 
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enhance ATG14L-BECLIN1-VPS34 kinase activity and autophagy induction (Russell et al. 2013; 
Xia et al. 2013). Given that UVRAG is known to modulate VPS34 activity upon complex binding 
and that phosphorylation of other VPS34 components have been shown to regulate activity, it 
is possible that UVRAG phosphorylation by mTOR may also act to regulate kinase activity and 
this was therefore examined further. Additionally, AMPK is reported to co-ordinately regulate 
the activity of both ULK1 and VPS34 (Kim et al. 2011; Kim et al. 2013), given that mTORC1 is 
established to regulate ULK1 activity this may represent an analogous control mechanism that 
also alters VPS34 activity.  
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4.2 Results 
 
4.2.1 VPS34 activity is regulated by UVRAG phosphorylation. 
 
Endogenous or recombinant VPS34 can be assayed in vitro to determine lipid kinase activity. 
Liposomes created from the VPS34 substrate phosphatidylinositol were incubated in the 
presence of 32P γ-ATP and Manganese (Mn2+) (Volinia et al. 1995; Whitman et al. 1988); lipid 
kinase activity of VPS34 catalyses the transfer of γ-phosphate to position three of the inositol 
ring to create phosphatidylinositol-3-phosphate (PI(3)P) (Schu et al. 1993). The size and 
consequent curvature of lipid vesicles is an important determinant for the binding of membrane 
interacting proteins, including VPS34 via the myristoylation of VPS15 (Herman et al. 1991; 
Madsen et al. 2010). Accordingly, PI was extruded through a polycarbonate membrane to form 
liposomes with a maximal diameter of 100 nm to reduce substrate variability and improve 
experimental consistency.   
Endogenous UVRAG-BECLIN1-VPS34 complex was selectively analysed by immunoprecipitation 
of UVRAG. This ensured that UVRAG-bound VPS34 activity was analysed and did not include 
ATG14L-BECLIN1-VPS34 or unbound VPS34. The UVRAG-BECLIN1-VPS34 kinase activity was 
examined during nutrient rich conditions or upon autophagy induction by nutrient starvation or 
mTOR inhibition (KU0063794). A significant drop in VPS34 activity of ~50 % was observed in 
U2OS cells upon autophagy induction (Figure 4.1A), similarly wild-type MEFs demonstrated a 
decrease in UVRAG-BECLIN1-VPS34 activity upon nutrient starvation (Figure 4.1B). In 
comparison the activity of mCherry-S-ATG14L-BECLIN1-VPS34 was examined in MEFs and 
nutrient starvation displayed no significant change in activity (Figure 4.1C) indicating that the 
response to nutrient starvation observed is specific to the UVRAG-BECLIN1-VPS34 complex. The 
UVRAG-BECLIN1-VPS34 lipid kinase activity therefore correlates with changes in the UVRAG 
phosphorylation state with increased activity when S550 and S571 are phosphorylated.  
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Figure 4.1 – Endogenous VPS34 activity in response to nutrient status 
(A+B)  Cells were incubated in complete media (+AA), starvation media (EBSS) or treated with  
1 µM KU0063794 for 1 h (MEFs) or 2 h (U2OS)  before lysis.  Endogenous UVRAG was 
immunoprecipitated (S323D) and co - immunoprecipitated VPS34 was assayed in vitro .  (C)  mCherry-
S-ATG14L MEFs were incubated in complete media (+AA) or starvation media (EBSS)  for 1  h before 
lysis.  ATG14L was immunoprecipitated by S -protein sepharose and assayed for co -
immunoprecipitating VPS34 activ ity. For (A-C)  samples were lysed in 0.5% NP-40 lysis buffer. Bars 
in each graph represent mean normalised VPS34 activ ity ± SEM for n = 3 indep endent experiments.   
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To examine whether the kinase activity of VPS34 is directly linked to UVRAG phosphorylation, 
cells stably expressing near endogenous levels of wild-type or S550A+S571A UVRAG were 
generated. GFP-UVRAG was immunoprecipitated from MEFs or Hela cells and canonical binding 
partners were examined to ensure VPS34 complex binding was not impaired (Figure 4.2). 
Mutation of S550A+S571A had no effect on BECLIN1 or VPS34 binding as was previously 
predicted (Figure 3.8).  
 
 
Figure 4.2 - UVRAG S550A + S571A mutant cells 
Wild-type MEFs (A)  or  Hela cells (B)  stably expressing GFP-UVRAG wild-type (wt),  S550A+S571A 
(DblA)  or non-transfected (NT) were incubated in complete media (+AA) or starvation media (EBSS) 
for 1 h (MEFs) or 2 h (Hela).  Cells were lysed in 0.5  % NP-40 lysis buffer and GFP-UVRAG was 
immunoprecipitated with anti -GFP sepharose beads and immunoblotted for associated VPS34 
complex proteins.  
 
U2OS cells expressing FLAG-UVRAG wild-type or S550A+S571A were immunoprecipitated and 
assayed for associated VPS34 activity in the presence or absence of nutrients. FLAG-UVRAG 
wild-type displayed a similar change in activity to that of endogenous UVRAG,  however 
mutation of S550A+S571A abolished the VPS34 activity increase observed in the presence of 
nutrients (Figure 4.3A). Mutation of a serine residue to an aspartate can mimic the properties 
of phosphorylation as it also introduces a negative charge. Analysis of FLAG-UVRAG 
S550D+S571D bound VPS34 did not display enhanced activity that could be expected if it were 
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to mimic the phosphorylation phenotype, however it matched that of S550A+S571A (Figure 
4.3B). This suggests that whilst unable to mimic the effects of phosphorylation, mutation to a 
non-phosphorylatable residue still abolishes the increase in complex activity.  Investigations 
utilising MEFs stably expressing GFP-UVRAG also confirmed that mutation of S550A+S571A 
abolished the enhanced complex activity under nutrient rich conditions (Figure 4.3C).  
 
Figure 4.3 - UVRAG S550A+S571A mutant VPS34 kinase activity 
(A) U2OS cel ls stably expressing FLAG-UVRAG wild-type or S550A+S571A were incubated in 
complete media (+AA) or starvation media (EBSS) for 2  h.  UVRAG was immunoprecipitated with 
FLAG agarose and co-immunoprecipitated VPS34 activ ity was assayed in vitro .  (B)  Quantitation of  
(A),  bars represent the mean normalised VPS34 activity ± SEM for a minimum of  n = 4 independent  
experiments.  (C)  MEFs stably expressing GFP-UVRAG wild-type or S550A+S571A were incubated in 
complete media (+AA) or starvation media (EBSS) for 1  h.  UVRAG was immunoprecipitated with 
GFP sepharose and co- immunoprecipitated VPS34 activity  was assayed in vitro.  Bars represent 
mean normalised VPS34 activity  ±  SEM for n = 3 independent experiments.  (B+C)  Stat istical 
analysis  was carr ied out by two -way analysis of variance and Bonferroni’s post -test.  
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4.2.2 Reconstitution of the VPS34 complex in vitro 
 
To rule out the possibility of unknown cellular components influencing the VPS34 complex 
activity, such as additional binding proteins, a recombinant VPS34 assay was attempted. The 
VPS34 complex was to be reconstituted in vitro and phosphorylated directly with endogenous 
mTORC1 to reduce external variables. Attempts to reconstitute the VPS34 complex in vitro 
however were unsuccessful due to poor complex formation and high non-specific binding. 
His-BECLIN1 alone could bind to GST beads non-specifically in the absence of GST-UVRAG whilst 
the addition of GST-UVRAG did not enhance binding further (Figure 4.4A). Alternatively 
GST-BECLIN1 was able to successfully bind MBP-UVRAG but His-VPS34-VPS15 was occluded 
from binding GST sepharose (Figure 4.4B). Interestingly the addition of His-VPS34-VPS15 
enhanced the binding of MBP-UVRAG to GST-BECLIN1 but did not bind itself. It may be that 
these proteins require co-expression to form a functional complex. Alternately it is possible that 
the presence of tags utilised for protein purification could be detrimental to binding, therefore 
multiple tag combinations of recombinant proteins were attempted, but without success (data 
not shown). 
Although unclear, assuming the phosphorylation of UVRAG did not facilitate binding of 
additional components then the increase in activity could potentially be derived from 3D 
structural changes in the VPS34 complex that impact upon substrate recognition or the ATP 
hydrolysis rate of VPS34. To determine whether phosphorylation of UVRAG could interact or 
alter binding with specific VPS34 complex components, biotinylated peptides from UVRAG were 
utilised. Non-phosphorylated or S550+S571 phosphorylated peptides were incubated with 
His-VPS34-VPS15, His-VPS34, GST-BECLIN1 or GST-UVRAG. A control peptide of the same charge 
and length was used for comparison. The phosphorylated UVRAG peptide had a stronger 
interaction with recombinant proteins than the non-phosphorylated peptide, however this was 
also observed with the control phosphorylated peptide. The presence of negative charge alone 
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appears to be favourable for peptide-protein interaction regardless of the sequence and it has 
been demonstrated that charged proteins are more likely to interact in a system (Xu et al. 2013). 
 
 
Figure 4.4 - Recombinant VPS34 complex formation 
(A) Recombinant GST-UVRAG (DU36724) and His-BECLIN1 (DU40738) or (B) Recombinant MBP-
UVRAG (DU40944), His-VPS34-VPS15 (DU8692) and GST-BECLIN1 (DU40130)  were incubated in 
0.5 % NP-40 lysis  buffer and immunoprecipitated with GST -Sepharose. (C)  B iotinylated peptides 
corresponding to human UVRAG S536 -S583 or control peptide were incubated in 0.5  % NP-40 lysis  
buffer separately with His -VPS34 (DU3303)  or His-VPS34-VPS15, His-BECLIN1 or GST-UVRAG. 
Peptides were immunoprecipitated with streptavidin agarose and analysed by western blot for 
interaction of recombinant proteins.  
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4.2.3 Detection of cellular PI(3)P levels 
 
Data obtained in vitro indicated that UVRAG phosphorylation at S550+S571 increased VPS34 
lipid kinase activity by ~2 fold (Figure 4.3). It is important to ascertain whether the activity 
change in vitro is replicated by cellular changes in the level of the product PI(3)P, particularly as 
UVRAG-BECLIN1-VPS34 represents a sub-population of total VPS34 within the cell. The cellular 
PI(3)P level can be estimated by taking advantage of the specific binding properties of FYVE 
domains. The FYVE domain of HRS exclusively binds to PI(3)P and the binding affinity can be 
improved by expression of a double (2xFYVE) domain (Gaullier et al. 1998) . The 2xFYVE domain 
was stably expressed in U2OS cells with a GFP tag, allowing PI(3)P rich membranes to be 
represented by GFP-positive puncta (Gillooly et al. 2000). However, the expression of 
GFP-2xFYVE within cells may have adverse effects due to competition with endogenous PI(3)P 
interacting proteins such as EEA1 (Byfield et al. 2005). This can impair cellular function, 
therefore, U2OS cells expressing a very low level of GFP-2xFYVE were isolated by single cell 
cloning to minimise potential artificial cellular effects of probe expression. The punctate 
expression of GFP-2xFYVE was examined between nutrient rich conditions or autophagy 
induction either by nutrient depletion or by mTOR inhibition. Additionally the PI3K inhibitor 
wortmannin was used as a positive control to inhibit PI(3)P production (Arcaro & Wymann 1993; 
Stack & Emr 1994). No significant change in puncta was observed between conditions except for 
wortmannin treatment that abolished membrane binding resulting in a diffuse cytosolic location 
(Figure 4.5). This could suggest that UVRAG phosphorylation state has no effect upon cellular 
PI(3)P levels, contrasting the evidence determined in vitro (Figure 4.1). However as described 
above the expression of an intracellular PI(3)P probe could potentially have adverse effects even 
at a low expression level and additionally expression that is too low may only label a subset of 
PI(3)P structures. For these reasons PI(3)P levels were determined by staining following 
formaldehyde fixation. Recombinant PI(3)P binding domains were purified and conjugated to 
fluorophores allowing use on fixed cells similar to antibodies.  
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Figure 4.5 – GFP-2xFYVE Staining 
(A) Images of U2OS cells stably expressing a GFP -2xFYVE (HRS) PI(3)P binding probe.  Cells were 
washed and incubated in complete media (+AA), starvation media (EBSS),  treated with 1  µM 
KU0063794 or 10 µM Wortmannin for 2  h prior to formaldehyde fixat ion (B)  Quantitat ion of (A),  
bars represent mean puncta per cel l ±  SEM for n = 3 independent experiments. Signif icance was 
determined by one-way analysis  of variance and Dunnet’s multiple comparison post -test.   
 
The PX domain from p40phox selectively binds PI(3)P (Kanai et al. 2001); the PX domain 
conjugated to Alexa Fluor® 555 was a kind gift from N.Ktistakis, Babraham Institute, Cambridge,  
and was utilised for preliminary experiments. The PX domain was subsequently expressed and 
purified from bacteria prior to conjugation to Alexa Fluor® 594 (Referred hereafter as PX-594). 
U2OS cells expressing low levels of GFP-2xFYVE were grown in nutrient rich or depleted 
conditions and stained with the PX-594 conjugate following fixation. Direct comparison of the 
two PI(3)P binding domains demonstrated specific PX-594 positive structures that were not 
labelled with GFP-2xFYVE, particularly in central regions between the cell periphery and nucleus 
(Figure 4.6A). The punctate staining observed with each probe was not present in cells treated 
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with wortmannin (Figure 4.5 & Figure 4.7), indicating that the binding of each probe was PI(3)P 
dependent. This demonstrated that the GFP-2xFYVE stably expressed in U2OS cells (Figure 4.5) 
was not fully representative of cellular PI(3)P levels. Upon nutrient deprivation and UVRAG 
dephosphorylation, a ~2 fold decrease in total PX-594 staining was observed that matched 
VPS34 in vitro activity data in comparison to GFP-2xFYVE (Figure 4.6B&C). 
 
Figure 4.6 - Comparison of PI(3)P Binding Probes. 
(A) U2OS cel ls expressing GFP-2xFYVE were incubated in complete media (+AA) or starvation 
media (EBSS) for 2  h and f ixed with formaldehyde by freeze -thaw. Cells were stained using PX -594 
and analysed by microscopy. Arrows indicate examples of  distinct  PX-594 punctate structures. 
(B+C) Quantitation of  (A),  bars represent mean value ± SEM for n  = 3 independent experiments. 
Significance was determined by one-way analysis of variance and Dunnet’s mult iple comparison 
post-test to the +AA sample whe re ** = p < 0.01,  *** = p < 0.001 and n.s =  not significant.   
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The co-localisation of PX-594 was assessed with multiple PI(3)P binding proteins. The early 
endosome markers EEA1 and GFP-WDFY2 bind to PI(3)P via their FYVE domains and displayed 
significant co-localisation with PX-594 (Figure 4.7,Figure 4.8A) (Hayakawa et al. 2006; Simonsen 
et al. 1998). In comparison, the early endosomal marker APPL1 interacts with Rab5 in the 
absence of PI(3)P (Zoncu et al. 2009) and displayed very low co-localisation with PX-594 (Figure 
4.8B), thereby demonstrating the selectivity of PX-594 for PI(3)P positive endosomal 
membranes. Other FYVE domain containing PI(3)P effectors involved in endocytosis showed 
co-localisation, such as RUFY1 that is present on Rab4 and Rab14 positive endosomes (Figure 
4.9A) (Fukuda et al. 2011; Yamamoto et al. 2010) . The motor protein adaptor FYCO1 that is 
partially dependent upon PI(3)P for membrane binding also displayed small amounts of PX 
domain co-localisation (Figure 4.9B)(Pankiv et al. 2010). The PX Domain therefore labels a wide 
selection of known PI(3)P positive compartments.  
 
Figure 4.7 - PX Domain and EEA1 Co-localisation 
U2OS cells were incubated in complete media (+AA),  starvation media (EBSS) or treated with 
wortmannin (10µM) for 2  h and then fixed by freeze thaw. Cel ls were stained with PX -594 and 
anti-EEA antibody using AlexaFluor® 488 secondary antibody.  
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Figure 4.8 - PX Domain co-localisation with WDFY2 and APPL1 
U2OS cells (A)  control  or (B)  transfected with GFP-WDFY2 were incubated in complete media (+AA) 
or starvation media (EBSS)  for 2  h and then fixed by freeze thaw. Cel ls  were staine d with PX-594 
and (A)  anti -GFP or (B) anti-APPL1 using AlexaFluor® 488 (AF -488) secondary antibody. Arrows 
indicate example regions of  co -local isation.  
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Figure 4.9 - PX Domain and RUFY1 and FYCO1 
U2OS cel ls were incubated in complete media (+AA) or starvation media (EBSS) for 2  h and then 
fixed by freeze thaw. Cells were stained with PX -594 and (A)  anti-RUFY1 or (B) anti-FYCO1 using 
AlexaFluor® 488 (AF-488)  secondary antibody. Arrows represent examples of co-localisat ion.  
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It may appear counter-intuitive that cellular PI(3)P levels dropped upon nutrient starvation, 
particularly as nutrient starvation is a potent inducer of autophagy and that this is dependent 
upon VPS34 PI3K activity (Kihara, Noda, et al. 2001). The induction of autophagy and formation 
of PI(3)P at initial omegasome structures can be monitored by the translocation of the double-
FYVE domain containing protein 1 (DFCP1) from the ER (Axe et al. 2008). U2OS cells expressing 
GFP-DFCP1 were utilised to examine the formation of DFCP1 puncta upon nutrient starvation 
(Figure 4.10). Upon autophagy induction either by nutrient starvation or mTOR inhibition, the 
level of punctate structures increased in number and in size (Figure 4.10) concomitantly with a 
decrease in global cellular PI(3)P levels (Figure 4.6C). Treatment with the PI3K inhibitor 
wortmannin prevented DFCP1 puncta forming, indicating this was dependent upon PI(3)P. 
Whilst global PI(3)P levels drop upon nutrient starvation, the staining of DFCP1 clearly 
demonstrates that the PI(3)P at autophagosomal structures increases. 
 
Figure 4.10 - DFCP1 Puncta Increase upon Autophagy Induction 
(A) U2OS cel ls stably expressing GFP-DFCP1 were grown in complete media (+AA), starvation 
media (EBSS),  treated with 1  µM KU0063794 or 10  µM Wortmannin for 2  h prior to  formaldehyde 
fixation. (B+C) Graphs represent the mean (A)  DFCP1 puncta per cell or (B)  DFCP1 puncta radius 
± SEM from n = 3 independent experiments. Statist ics were carried out by one -way analysis of  
variance uti l ising Dunnett’s post -test to compare to +AA control.  *  = p < 0.05, *** = p < 0.001, n.s  
= not s ignificant.  
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4.2.4  Nutrient status governs cellular PI(3)P levels 
 
To examine the role of UVRAG and its phosphorylation further, endogenous UVRAG was 
depleted by RNA interference (RNAi). Reverse transfection of MEFs with a previously reported 
siRNA targeting the protein coding region (ORF1) of UVRAG (Liang et al. 2006) caused a 
significant knockdown of UVRAG within 24h and a peak response at ~48 h (Figure 4.11A&B). 
Stable transfection of a shRNA targeted against the same region also significantly reduced 
endogenous UVRAG levels (Figure 4.11C). Other shRNA sequences generated against a separate 
protein coding region (ORF2) or 5’ untranslated region (5’UTR) also caused knockdown of 
endogenous UVRAG but not as efficiently as ORF1 (Figure 4.11C). 
 
Figure 4.11 - UVRAG siRNA treatment 
(A)  Wild-type MEFs were transfected with 50 -150 nM control or UVRAG ORF1 siRNA (Table 9)  by 
either forward or reverse transfection and lysed and 36 hours post -transfection.  (B)  Wild-type 
MEFs were reverse transfected with 50  nM ORF1 siRNA and lysed at time-points indicated. (C)  
Wild-type MEFs were stably transfected by retroviru s with the shRNA indicated (Table 7),  NT = 
non-transfected, UV = FLAG-UVRAG over-expression.  High and Low refers to  western blot 
exposure.  (A-C)  All  samples were lysed in 0.5  % NP-40 lysis buffer.  
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Figure 4.12 - Effect of UVRAG and nutrient status on cellular PI(3)P levels 
(A)  U2OS cells were transfected with 50  nM control  or ORF1 siRNA (Table 9),  40 h post-transfection cel ls  were incubated in complete media (+AA), starvation media 
(EBSS)  or treated with 1  µM KU0063794 for 2  h and f ixed by freeze-thaw before staining with PX-594.  (B-D)  Quantitat ion of experiment carried out as in (A)  for (B) 
MEFs, (C)  U2OS and (D) Hela. Bars represent mean fold change in PX Domain staining ± SEM of  n=3 independent experiments.  Stat istical analysis was ca rried out by 
two-way analysis of variance with Bonferroni’s post -test.  
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The total level of PX domain staining in U2OS, Hela and MEF cells was examined before and after 
endogenous UVRAG knockdown. In addition cells were examined between nutrient rich 
conditions, nutrient depletion or upon mTOR inhibition. Comparison of cell lines demonstrated 
that cellular PI(3)P levels were lower upon nutrient starvation or mTOR inhibition. In addition, 
knockdown of UVRAG resulted in lower cellular PI(3)P levels during nutrient rich conditions but 
equivalent to control siRNA upon nutrient starvation or mTOR inhibition (Figure 4.12). The level 
of cellular PI(3)P therefore correlates with UVRAG phosphorylation state between cell lines and 
UVRAG is required for the stimulation seen under nutrient rich conditions. MEFs stably 
expressing siRNA resistant GFP-UVRAG wild-type or S550A+S571A were next examined to 
determine whether the nutrient stimulated VPS34 activity was dependent upon UVRAG 
phosphorylation sites. During nutrient rich conditions, knockdown of UVRAG reduced cellular 
PI(3)P levels similar to that observed during starvation; expression of GFP-UVRAG wild-type was 
able to rescue this phenotype whilst GFP-UVRAG S550A+S571A did not (Figure 4.13). The levels 
of PI(3)P were consistent upon nutrient starvation or mTOR inhibition regardless of UVRAG 
expression. 
This data strongly implicates the importance of phosphorylation at S550 + S571 as critical 
regulatory sites by mTOR. Phosphorylation at these residues has been demonstrated to increase 
the VPS34-UVRAG complex activity in vitro and also causes a detectable change in cellular PI(3)P 
levels. Having observed significant changes in the levels of PI(3)P, the precise role of this in 
cellular function remains to be elucidated.      
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Figure 4.13 – Effect of UVRAG S550A+S571A Upon Cellular PI(3)P 
(A)  Wild-type MEFS or those stably expressing siRNA resistant GFP -UVRAG wild-type or 
S550A+S571A were reverse transfected with 100 nM control or ORF1 siRNA. 40  h post-
transfection, cel ls were incubated in complete media (+AA), starvation media (EBSS) or treated 
with 1 µM KU0063794 for 1  h, f ixed by freeze-thaw and stained with PX-594. (B)  Quantitation of 
(A),  bars represent mean fold change of  PX Domain staining ± SEM of  n=4 independent 
experiments. Statist ical analysis was carried out using two -way analysis of variance and 
Bonferonni’s post -test where * = p < 0.05 and n.s = not significant .  
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4.3 Discussion 
 
The data presented in this chapter for the first time demonstrate that the phosphorylation of 
UVRAG directly impacts upon intrinsic VPS34 lipid kinase activity. Furthermore, modulation of 
VPS34 activity by phosphorylation of UVRAG results in a significant global cellular change in 
PI(3)P level that may consequently alter cellular function.  
Direct examination of endogenous UVRAG-BECLIN1-VPS34 complex activity in vitro 
demonstrates a decrease in activity upon nutrient starvation (Figure 4.1A&B). A reduction in 
VPS34 activity of ~2.5 fold in vitro has previously been observed upon IP of VPS34 or BECLIN1 
during amino acid starvation (Byfield et al. 2005; Russell et al. 2013). Analysis of VPS34 or 
BECLIN1 will likely contain multiple sub-complexes and the proportion of this that is UVRAG-
BECLIN1-VPS34 is unclear. A previous report has suggested that ~50 % of VPS34 is bound to 
BECLIN1 and that UVRAG will likely represent a smaller proportion (Kihara, Kabeya, et al. 2001). 
In contrast, IP of BECLIN1 co-purified with equivalent stoichiometry of VPS15, VPS34 and UVRAG 
suggesting a stable ‘core’ VPS34-BECLIN1-UVRAG complex, whereas levels of ATG14L and 
Rubicon were lower (Zhong et al. 2009). Given that VPS34, BECLIN1 or UVRAG IP all demonstrate 
a comparable decrease in activity upon nutrient deprivation it would be expected that this 
occurs via regulation of a common component. Indeed an analogous situation is present 
whereby phosphorylation of VPS34 by AMPK has been reported to decrease activity upon 
glucose starvation (Kim et al. 2013). Binding of ATG14L however prevented inhibitory VPS34 
phosphorylation by AMPK but the effect upon UVRAG containing complexes was not fully 
examined. The increased activity of UVRAG-BECLIN1-VPS34 during nutrient rich conditions was 
directly dependent upon UVRAG S550 and S571 phosphorylation as mutation to alanine residues 
abolished this activity (Figure 4.3).  
It seems counter-intuitive that the PI(3)P levels decrease upon nutrient starvation due to the 
requirement of VPS34 activity for autophagy induction (Petiot et al. 2000). Multiple VPS34 
complexes are present in the cell and it is the ATG14L containing complex that has primarily 
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been implicated in autophagy induction (Kihara, Noda, et al. 2001). Importantly, the ATG14L 
complex is present at a much lower level than the UVRAG complex, estimates from yeast suggest 
ATG14L is expressed ~15 fold less than BECLIN1 (Kihara, Noda, et al. 2001). The contribution of 
PI(3)P from ATG14L containing complexes will therefore be a relatively small proportion of total 
cellular PI(3)P. Indeed analysis of DFCP1 translocation to the omegasome demonstrated a 
dramatic increase upon autophagy induction indicating that the autophagy specific pool of 
PI(3)P was increased (Figure 4.10). ATG14L complex activity did not change upon mTOR 
inhibition, suggesting that the regulatory mechanism that reduces VPS34 activity upon 
starvation is not present in this complex (Figure 4.1C). An earlier report has suggested that 
ATG14L-BECLIN1-VPS34 activity is negatively regulated by mTORC1 kinase activity (Yuan et al. 
2013). The examination of ATG14L complex activity in this current study utilises exogenous 
mCherry-S-ATG14L that may reduce phosphorylation stoichiometry and mask regulatory 
changes. It is worth noting however that in vitro kinase reactions of endogenous mTORC1 with 
ATG14L carried out in this study did not demonstrate strong phosphorylation (Figure 3.3). 
Regulation of ATG14L complex activity may not be essential to induce autophagy, rather it is 
suggested that the localisation of the complex to sites of autophagosome formation is critical 
for autophagosome generation (Fan et al. 2011; Sun et al. 2008). Data shown in (Figure 3.9) 
demonstrates a change in the ATG14L elution pattern by SEC upon autophagy induction, which 
may resemble an important regulatory change to allow a very localised pool of PI(3)P 
generation.  
Precisely how the phosphorylation in a separate component of the VPS34 complex can directly 
affect the lipid kinase activity is intriguing. Assuming the lack of additional protein interactions, 
it is possible to speculate that introduction of two negative residues causes a global 3D structural 
change in UVRAG and possibly the whole complex. Site-specific phosphorylation of disordered 
protein regions has been shown to impact upon secondary and tertiary structure (Garza et al. 
2010). Indeed, phosphorylation of S550 and S571 cause large mobility shifts in the native protein 
by SDS-PAGE that may be in part due to structural changes. Introducing a global structural 
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change in the VPS34 complex may act to improve lipid substrate or ATP binding, which 
subsequently improves kinase efficiency. Another possibility could be the manipulation of 
RUBICON binding. RUBICON binds to the VPS34 complex by extensive contacts with UVRAG and 
also interacts with VPS34 through a RUN domain to negatively regulate kinase activity (Sun et 
al. 2010; Zhong et al. 2009). The introduction of negatively charged residues onto UVRAG by 
phosphorylation could potentially disrupt RUN domain interactions with VPS34 without 
displacing RUBICON from the complex. Interestingly, RUBICON binding reduces UVRAG complex 
activity to ~25 % (Sun et al. 2010). Expression of a ΔRUN RUBICON mutant that cannot interact 
with VPS34 alleviates UVRAG inhibition to ~50 %, a two-fold change that is similar to the 
observed mTOR phosphorylation induced activity change (Sun et al. 2010). Furthermore, 
RUBICON has no apparent ancestral homologue in S. cerevisiae (Matsunaga et al. 2009) and 
similarly the unstructured C-terminal domain of UVRAG is absent from the S. cerevisiae homolog 
vps38. Use of UVRAG biotin peptides did not show selectivity for peptide sequence, however it 
clearly demonstrated the binding affinity and preference of proteins for negatively charged 
peptides (Figure 4.4C). The phosphorylation of S550 and S571 could thereby represent an evolved 
mechanism to alleviate RUBICON mediated inhibition via the RUN domain, subsequently 
increasing VPS34 kinase activity. This could allow rapid regulatory changes in VPS34 activity 
without the requirement for displacement of RUBICON from the complex, allowing further fine 
tuning of VPS34 complex activity. Critically, the molecular mechanism of S550 and S571 
phosphorylation is entirely speculative without further understanding of the VPS34 complex. 
Crystal structure determination will be key to identifying how components interact and 
predicting possible C-terminal domain interactions of UVRAG.  
Attempts to reconstitute the reaction in vitro were unsuccessful through the inability to form a 
complete complex (Figure 4.4A&B). It is possible that efficient formation may require 
co-expression or that the combination of tags result in steric hindrance that prevents efficient 
binding, particularly due to larger tags such as GST or MFP. Purification of recombinant proteins 
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expressing small (FLAG, V5) or cleavable (TEV, Prescission) tags would likely improve the ability 
to efficiently form complexes.  
Changes in VPS34 complex activity in vitro clearly correlated with cellular PI(3)P levels. 
Examination of GFP2xFYVE expression demonstrated that not all PI(3)P positive structures were 
being labelled efficiently in comparison with PX-594 (Figure 4.6). PX-594 co-localised with 
multiple known PI(3)P effectors and also demonstrated a drop in overall intensity upon nutrient 
starvation. Previous work has also shown that PI(3)P drops upon amino acid starvation with a 
GST-2xFYVE domain or PI(3)P antibody (Nobukuni et al. 2005; Yuan et al. 2013). The use of PI(3)P 
detecting 2xFYVE or PX domains still has limitations; not all cellular PI(3)P will be labelled via this 
method as some will be occluded from recognition and interacting due to binding of endogenous 
PI(3)P effector proteins. Analysis of the whole cell lipid composition by mass spectrometry would 
allow the total level of phosphoinositide species relative to one another to be observed. The loss 
of PI(3)P can potentially have knock-on consequences by impeding the sequential conversion to 
PI(3,5)P2 that is catalysed by PIKFYVE (Sbrissa et al. 1999; Ikonomov et al. 2001). Analysis of 
multiple phosphoinositide species would allow greater understanding of how each is regulated 
in response to nutrient starvation. Alternately, the level of PI(3,5)P2 could be examined by use 
of mucolipin1 that specifically recognises and binds this phospholipid (Dong et al. 2010).  
Depletion of UVRAG causes a decrease in cellular PI(3)P (Figure 4.12), which is perhaps not 
surprising considering that the binding of UVRAG to VPS34 and BECLIN1 in mammalian cells is 
reported to increase lipid kinase activity by ~2-4 fold (Liang et al. 2006; Sun et al. 2010). It is 
surprising however that this is equivalent to the level of PI(3)P observed upon nutrient starvation 
in cells containing UVRAG, suggesting that under these conditions the presence and binding of 
UVRAG does not alter PI(3)P formation. In yeast the impact of vps38/UVRAG is more modest, 
suggesting ~20 % increase in vps34 activity upon binding (Kihara, Noda, et al. 2001). Importantly 
the stimulation of VPS34 activity observed requires UVRAG and its phosphorylation as mutation 
of S550 and S571 to alanine blocks the activity increase in the presence of nutrients.  
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Therefore the phosphorylation of UVRAG drives an increase in VPS34 activity that occurs 
independently of other complex components. The phosphorylation may cause a structural 
rearrangement that leads to an increase in lipid kinase activity and significant cellular changes 
in phospholipid composition. The precise consequences of phosphorylation need to be further 
examined to understand the role it plays in trafficking. Given the requirement of PI(3)P in 
trafficking processes, it could be assumed that higher levels of PI(3)P may assist or improve 
trafficking in the presence of nutrients. The cellular response to alterations in PI(3)P is therefore 
further examined in the following chapter.  
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5 Functional consequences of UVRAG 
Phosphorylation 
 
5.1 Introduction 
 
As shown in previous chapters phosphorylation of UVRAG by mTOR caused an increase in VPS34 
activity and raised cellular PI(3)P levels (Figure 4.13). To determine possible functional 
consequences of this regulatory event requires analysis of PI(3)P  and UVRAG dependent 
pathways. 
The importance of PI(3)P within cells has predominantly been linked to endocytosis, with 
multiple stages that are regulated by PI(3)P formation. The production of PI(3)P at early 
endosomal structures for example plays a key role in recruiting the FYVE domain containing 
protein EEA1 (Simonsen et al. 1998), EEA1 then acts as a tether to assist with endosome fusion 
(Christoforidis et al. 1999). VPS34 has also been linked to the formation of intraluminal vesicles 
(ILVs) that define late endosomes or multi-vesicular bodies (MVBs). The formation of ILVs occurs 
in a PI(3)P dependent manner and it is thought to be a key regulatory step In defining whether 
receptors are to be degraded or recycled back to the plasma membrane (Futter et al. 2001). The 
formation of PI(3)P is also essential as a substrate for PIKFYVE to produce PI(3,5)P2 that is also 
required for efficient endosome maturation (Jefferies et al. 2008). Aside from endocytosis, 
VPS34 mediated formation of PI(3)P is also required for the induction of autophagy. The 
formation of PI(3)P at omegasome sites recruits the FYVE domain containing proteins DFCP1 and 
WIPI1 and leads to autophagosome formation (Polson et al. 2010). The ATG14L-VPS34 complex 
is essential for autophagosome formation (Matsunaga et al. 2010), although previous data has 
suggested that UVRAG may also enhance autophagy induction (Liang et al. 2006). 
Given the requirement of PI(3)P for trafficking pathways, it is possible that stimulation of VPS34 
by mTOR enhances a distinct pathway or multiple pathways in a manner that assists with cellular 
function. Several assays of intracellular trafficking were therefore undertaken to determine 
whether the increase in PI(3)P relates functionally to differences in a pathway.   
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5.2 Results 
 
5.2.1 Autophagy Induction is unaffected by UVRAG phosphorylation 
 
To examine the function of UVRAG phosphorylation, cells stably expressing GFP-UVRAG 
wild-type or S550A+S571A were utilised for analysis following depletion of the endogenous 
protein by RNAi. Whilst primarily the ATG14L containing complex has been linked with 
autophagy induction, UVRAG has also been implicated in assisting with autophagosome 
formation and maturation through binding to Bif-1 and mediating fusion of formed 
autophagosomes with the lysosome (Liang et al. 2006; Liang et al. 2008). Due to the requirement 
of mTOR activity for phosphorylation at UVRAG S550 and S571, mutation of these residues to 
alanine should have no effect during an autophagic response as mTOR is inhibited. During 
nutrient rich conditions UVRAG is phosphorylated and this may affect the rate of basal 
autophagic flux. Induction of autophagy in MEFs either by mTOR inhibition or by nutrient 
depletion was noted by an increase in the level of LC3-II formation. Upon comparison to MEFs 
expressing either of two unique shRNA constructs, no significant difference in the level of LC3-II 
was observed (Figure 5.1A-D). Expression of GFP-UVRAG wild-type or S550A+S571A did not 
demonstrate any significant difference with control cells, suggesting that neither UVRAG nor the 
phosphorylation state impacted upon the induction of autophagy (Figure 5.1E-G). Addition of 
the lysosomal inhibitor Bafilomycin A1 between cell lines triggered an equivalent increase in 
LC3-II levels upon depletion of UVRAG, this indicated that LC3-II was constantly being degraded 
via the lysosome and that autophagosome fusion with lysosomes was not impaired (Figure 5.1).  
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Figure 5.1 - LC3 Flux is unaffected by UVRAG phosphorylation 
(A)  Wild-type MEFS or those stably expressing (B) ORF1 shRNA or (C) 5’UTR shRNA (Table 9)  were 
grown in complete media (+AA), starvation media (EBSS) or treated with 1  µM KU0063794 (KU) 
for 1 h in the presence or absence of  50  nM Baf ilomycin A1 (BafA1). NT denotes non -transfected 
cells.  (D)  Quantitation of A-C where bars represent mean normalised LC3 -II  values ± SEM of n = 4 
independent experiments. MEFs stably expressing siRNA resist ant GFP-UVRAG (E)  wild-type or (F) 
S550A+S571A were reverse transfected with 100  nM control or ORF1 UVRAG siRNA (Table 9) .  Cel ls 
were grown in complete media (+AA) or starvation media (EBSS) for 1  h in the absence or presence 
of 50 nM Baf ilomycin A1 (BafA1). (G)  Quantitat ion of E&F where bars represent mean normalised 
LC3-II  values ± SEM of  n = 3 independent experiments. Bafilomycin addition is represented by ( -)  
or (+) (A-F) All samples were lysed in 0.5  % NP-40 lysis buffer. (D+G) Statist ics were calculated by 
two-way analysis of variance and the p -value for each is shown. wt  = wild-type, DblA = 
S550A+S571A  
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5.2.2 EGFR Degradation is unaffected by UVRAG phosphorylation 
 
The requirement of UVRAG for the trafficking and degradation of the epidermal growth factor 
receptor (EGFR) was next examined. The EGFR is present at the cell surface where binding of 
epidermal growth factor (EGF) causes EGFR dimerisation and activation of intrinsic tyrosine 
kinase activity (Schlessinger 1988). Autophosphorylation of the cytoplasmic C-terminal domain 
allows binding of downstream effectors to convey growth factor signalling (Lowenstein et al. 
1992). Constitutive EGFR signalling by pathway mutations or upregulation plays a pivotal role in 
cell transformation and progression of multiple carcinomas, it is therefore essential that cells 
are able to terminate signalling efficiently (Wells et al. 1990). EGFRs are primarily internalised 
via clathrin mediated endocytosis (CME) but also by non-clathrin endocytosis (NCE) and are 
trafficked to the lysosome for degradation (Sigismund et al. 2008). The rate of EGFR degradation 
is commonly used as a marker for analysing the rate of endocytosis as a difference at a single 
step in the process can cause a measurable change in degradation via the lysosome. 
The level of EGFR expression was examined between MEFs, Hela and U2OS cells following 
differing periods of serum starvation. Serum starvation causes EGFRs to accumulate at the 
plasma membrane, which is essential to bind EGF. Hela cells displayed very high levels of EGFR 
in comparison to MEFs or U2OS. The levels of EGFR decreased in U2OS following serum 
starvation and thus they were not used for further analysis as the protein level was too low to 
monitor (Figure 5.2A). To examine the rate of EGFR endocytosis and degradation the growth 
media on cells was changed following serum starvation to complete media including EGF and 
cycloheximide to inhibit protein translation of further EGFRs (Ennis & Lubin 1964). Additionally 
the selective mTOR inhibitor KU0063794 was included to assess the impact of mTOR activity 
upon EGFR degradation. Within two hours ~80 % of the total EGFR pool was degraded in MEFs, 
however, no significant difference was observed upon inhibition of mTOR activity and 
subsequently UVRAG phosphorylation (Figure 5.2B).  The role of UVRAG in EGFR degradation 
was examined further by depletion of endogenous UVRAG in MEFs by RNAi.  
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Figure 5.2 - EGFR Degradation with mTOR inhibition and UVRAG depletion 
(A)  MEFs, Hela and U2OS cells were serum starved for the times indicated in serum starve media.  
(B)  MEFs were serum starved for 2  h prior to addit ion of  50  ng/ml EGF and 30  µg/ml cycloheximide 
with or without 1  µM KU0063794 in complete media.  (C)  MEFs were reverse transfected with 
50 nM control or ORF1 UVRAG siRNA. At ~40  h post-transfection cells were serum starved for 2  h 
prior to addition of 50  ng/ml EGF and 30 µg/ml cycloheximide in complete media. (A-C)  Al l  samples 
were lysed in 0.5  % NP-40 lysis buffer at t ime-points indicated.  Graphs represent the EGFR protein 
level normalised to α -tubulin and subsequently plotted as a percentage of t ime 0  h EGFR ± SEM 
of n = 3 independent experiments. Statist ics were determined by Student’s t -test comparing each 
time-point between treatments where *  = p < 0.05.  
 
Targeting of UVRAG by siRNA demonstrated a modest increase in rate of degradation at earlier 
time-points and was significantly different at 30 minutes (Figure 5.2C). This is in contrast to 
previously published data (Liang et al. 2008; Thoresen et al. 2010 - see discussion). Use of an 
mTOR inhibitor will affect a multitude of downstream targets that could also impact upon 
trafficking functions and lead to opposing effects. MEFs expressing siRNA resistant GFP-UVRAG 
wild-type or S550A+571A were utilised to examine possible differences due to UVRAG 
phosphorylation specifically. No significant change was observed in MEFs when rescued with 
the S550A+S571A mutant in comparison to GFP-UVRAG wild-type (Figure 5.3A). Examination of 
Hela cells displayed significantly faster degradation with S550A+S571A at 60 minutes compared 
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to control siRNA cells. These findings however were not significant in comparison to the wild-
type rescue (Figure 5.3B). The use of the mTOR inhibitor KU0063794 is further demonstrated to 
have no effect upon EGFR degradation upon treatment of UVRAG wild-type or S550A+S571A 
rescue cells (Figure 5.3C). The protein expression level of EGFR did not demonstrate any 
significant changes dependent upon UVRAG status (Figure 5.3D).  
 
Figure 5.3 - EGFR Degradation is unaffected by UVRAG S550A+S571A 
(A-C) GFP-UVRAG wild-type or S550A+S571A were stably expressed in (A)  MEFs  or (B+C) Hela cel ls,  
NT = Non-transfected. All cells were reverse transfected w ith 100 nM UVRAG ORF1 siRNA or 
control siRNA where indicated and util ised for experiments at ~40  h post-transfection. Cel ls were 
serum starved for 2  h in serum starvation media.  At time 0 cell  media was changed to complete 
media including 50 ng/ml EGF,  30  µg/ml cycloheximide and 1  µM KU0063794 (where indicated). 
Cel ls  were lysed in 0.5  % NP-40 lysis buffer at each t ime -point.  (A+B)  Graphs represent mean EGFR 
level  normalised to α -tubulin and plotted as a percentage of t ime 0 ± SEM for n = 3 independent 
experiments. (D)  Quantitation of EGFR levels in Hela cells from (B+C), bars represent mean EGFR 
level at time 0 relat ive to control s iRNA ± SEM of n = 3 independent experiments.  
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5.2.3 Transferrin Recycling is unaffected by UVRAG phosphorylation 
 
Uptake of the EGFR does not exclusively lead to degradation as differing levels of EGFR recycling 
also occurs dependent upon stimulatory conditions (Sigismund et al. 2005), it is important to 
examine whether the recycling pathway is affected. Transferrin receptors (TR) are exclusively 
internalised by CME and are almost entirely returned to the plasma membrane via Rab4 and 
Rab11 recycling endosomes, the trafficking of transferrin can be utilised to examine the recycling 
pathway (Daro et al. 1996; Ullrich et al. 1996). The transferrin receptor assists with cellular iron 
uptake by binding the iron storage protein transferrin, upon trafficking to the early endosome 
iron is released due to the decrease in pH;  the receptor and transferrin is then recycled to the 
plasma membrane to repeat this process (Dautry-Varsat et al. 1983).  
To examine the rate of TR recycling, Hela and U2OS cells were incubated in the presence of 
fluorescently conjugated transferrin to allow cellular uptake and distribution throughout the 
recycling pathway. Cells were then washed to remove excess transferrin and the rate of TR 
recycling was monitored in the presence or absence of the mTOR inhibitor KU0063794 (Figure 
5.4A&B). The loss of cell fluorescence represented the release of transferrin following successful 
TR recycling to the surface, re-uptake was reduced due to competition from high concentrations 
of non-fluorescent transferrin. UVRAG phosphorylation was inhibited upon addition of 
KU0063794 but no difference was observed in the rate of TR recycling in either Hela or U2OS 
cells, though the rate between cell lines was notably different (Figure 5.4C&D). MEFs stably 
expressing GFP-UVRAG wild-type or S550A+S571A were utilised to examine whether UVRAG 
phosphorylation specifically altered the rate of TR recycling. Within 30 minutes ~60 % of 
transferrin had been recycled in control MEFs. Depletion of endogenous UVRAG resulted in cells 
containing higher levels of fluorescent transferrin at time 0 (Figure 5.5A&C), suggestive of either 
higher rates of uptake or reduced recycling. Immunoblotting indicated that the level of 
transferrin receptor was increased upon treatment with UVRAG siRNA, particularly in cells 
lacking GFP-UVRAG rescue (Figure 5.5B). Normalisation of average cell intensity to TR protein 
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expression level demonstrated that the accumulation of fluorescent transferrin was 
proportional to receptor level, except for non-rescue UVRAG siRNA cells. Despite higher TR 
expression level the uptake and turnover rate was slower in UVRAG depleted cells. Control siRNA 
cells exhibited faster recycling than rescue cells, although crucially there was no difference 
between the wild-type or S550A+S571A mutant. This indicates that UVRAG is required for 
transferrin receptor recycling but that this is not dependent upon phosphorylation status.  
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Figure 5.4 - Transferrin Recycling is unaffected by mTOR inhibition 
(A)  U2OS cel ls  were incubated with 5  µg/ml Transferrin-594 conjugate for 1  h in complete media. 
Cel ls were washed and incubated in complete media with 100  µg/ml transferrin and 1  µM 
KU0063794 where indicated. Cells were formaldehyde f ixed at noted time -points and average ce ll  
f luorescence was determined. (B)  U2OS cells were treated as in (A),  lysed in 0.5  % NP-40 lysis  
buffer and immunoblotted as indicated. (C&D) Quantitation of experiment as in (A) with (C) U2OS 
or (D)  Hela cel ls.  Points represent average cell f luorescence normalised to t ime 0 ± SEM of n  = 3 
independent experiments.   
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Figure 5.5 - Transferrin Recycling is unaffected by UVRAG S550A+S571A 
(A)  MEFs or those stably expressing GFP -UVRAG wild-type or S550A+S571A were reverse 
transfected with 100  nM ORF1 siRNA. ~40  h post-transfection cells were incubated with 5  µg/ml 
Transferrin-594 conjugate for 1  h. Cells were washed and incubated in complete media with 
100 µg/ml transferr in and formaldehyde f ixed at t ime 0 or  30 min. (B)  MEFs transfected as in (A) 
were lysed in 0.5  % NP-40 lysis buffer and immunoblotted as indicated. (C)  Quantitat ion of (A),  
points represent average cell intensity normalised to time 0. (D)  Quantitat ion of  (A) following 
normalisat ion of  average cellular intensity relat ive to transferr in receptor expression in (B) .   
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5.2.4 Comparison of PI(3)P binding proteins 
 
Mutation of UVRAG S550A+S571A caused a ~2 fold decrease in cellular PI(3)P during nutrient 
rich conditions (Figure 4.13),  yet no striking phenotype in the rate of EGFR or TR trafficking was 
observed (Figure 5.2 to Figure 5.5). To query possible effects of PI(3)P loss, multiple interacting 
proteins from distinct cellular compartments were examined. U2OS cells were fractionated to 
examine the distribution of proteins between cytosol and membranes during nutrient rich 
conditions (high PI(3)P) or upon nutrient depletion or mTOR inhibition (low PI(3)P) (Figure 4.6). 
FYVE domain containing proteins from the early endosome (EEA1 – Rab5 interacting), recycling 
endosome (RUFY1 – Rab4/11 interacting), late endosome (FYCO1 – Rab7 interacting) or the PX 
domain containing protein (SNX1 – EGFR and multiple endosomal compartment interacting) all 
selectively bind PI(3)P and it is a requirement for their membrane localisation (Pankiv et al. 2010; 
Simonsen et al. 1998; Yamamoto et al. 2010; Zhong et al. 2002). Treatment with the PI3K 
inhibitor wortmannin blocked PI(3)P formation and consequently abolished membrane binding 
of EEA1, RUFY1, FYCO1 and SNX1 (Figure 5.6A&B). Reduction of PI(3)P by nutrient depletion or 
mTOR inhibition in comparison demonstrated no significant change in membrane binding of 
these proteins.(Figure 5.6A&B) . Analysis of RUFY1, FYCO1 and SNX1 by immunofluorescence 
did not display any reduction in puncta formation upon nutrient depletion and in some cases 
was possibly higher (Figure 5.6C), EEA1 was demonstrated previously (Figure 4.7). The reduction 
in PI(3)P upon nutrient depletion therefore does not impair the binding of these endocytosis 
markers nor does it significantly alter the rate of receptor trafficking (5.2.2, 5.2.3). 
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Figure 5.6 - Membrane Binding of PI(3)P Interacting Proteins 
(A+B)  U2OS cel ls were grown in complete media (+AA), starvation media (EBSS),  treated with 1  µM 
KU0063794 (KU) or treated with 10  µM Wortmannin (Wort) for 2  h. Cells were homogenised in 
membrane fract ionation buffer and the post -nuclear supernatant (P) underwent  
ultracentrifugation to spl it  into cytosol ic (C)  and membrane (M) fract ions.  (C)  U2OS cel ls were 
grown in complete media (+AA) or starvation media (EBSS)  and formaldehyde fixed.  Cel ls  were 
stained as indicated uti l ising Alexa Fluor® -594 secondary antibody.  
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5.2.5 Examination of additional UVRAG dependent processes 
 
In addition to autophagy and EGFR degradation, UVRAG has been reported to be implicated in 
several other processes. Previous studies examining the distribution of UVRAG by 
immunofluorescence have also demonstrated extensive co-localisation with multiple cellular 
organelles including the ER, Golgi, Endosomes, Lysosomes and mid-body during cytokinesis (He 
et al. 2013; Matsunaga et al. 2009; Thoresen et al. 2010). To determine possible effects of 
UVRAG phosphorylation processes linked to these distinct regions were examined.   
UVRAG is reported to interact with the ER-Tethering complex to assist Golgi-ER transport 
through the protein RINT-1, this interaction is significant as depletion of UVRAG or disruption of 
RINT-1 binding causes a loss of Golgi integrity leading to fragmentation (He et al. 2013). 
Examination of the cis-golgi marker GM130 (Nakamura & Rabouille 1995) in U2OS cells treated 
with UVRAG siRNA demonstrated fragmentation and dispersal as reported (Figure 5.7A). 
Expression of siRNA resistant GFP-UVRAG wild-type or S550A+S571A were both able to rescue 
this phenotype suggesting UVRAG phosphorylation does not affect Golgi integrity (Figure 5.7A). 
UVRAG has also been shown to localise with lysosome associated membrane protein 1 (LAMP1) 
(Matsunaga et al. 2009), a heavily glycosylated membrane protein that is found primarily in 
lysosomes (Carlsson et al. 1988). Depletion of endogenous UVRAG caused an increase in LAMP1 
positive structures under nutrient rich conditions (Figure 5.7B). Rescue with GFP-UVRAG wild-
type reversed this phenotype but mutation of S550A+S571A caused an accumulation of small 
LAMP1 positive structures (Figure 5.7B). Distinct phenotypes were observed upon UVRAG 
depletion and S550A+S571A mutation and thus the regulation of lysosomes were examined 
further. Analysis of other UVRAG functions such as that in cytokinesis are ongoing. 
 
 
137 
 
 
 
Figure 5.7 - GM130 and LAMP1 in UVRAG S550A+S571A U2OS cells 
(A+B)  U2OS cells or those stably expressing GFP -UVRAG wild-type or S550A+S571A were reverse transfected with UVRAG ORF1 siRNA (Table 9).  40 h post-transfection 
cells the growth media was changed and cells were incubated for 1  h in complete media. Cel ls were f ixed with formaldehyde and stained for endogenous (A) GM130 or 
(B) LAMP1 using Alexa Fluor®-594 secondary antibody. 
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5.2.6 UVRAG regulates LAMP1 positive structures 
 
The effect of autophagy induction either by mTOR inhibition or nutrient starvation on LAMP1 
structures was examined. The activation of autophagy leads to trafficking of autophagosomes 
towards the lysosome for fusion and degradation of interior contents, consequently LAMP1 
positive structures increase in size. Furthermore lysosomes move from the cell periphery to 
perinuclear locations that is thought to assist with autophagosome fusion (Korolchuk et al. 2011) 
. Analysis of endogenous LAMP1 in U2OS cells demonstrated an increase in average LAMP1 
object size upon autophagy induction (Figure 5.8A&B). Observation of live U2OS cells stably 
expressing LAMP1-GFP confirmed that LAMP1-GFP structures increased in size but decreased in 
number in a time-dependent manner following nutrient deprivation. Re-addition of nutrient rich 
media caused a rapid reversion of phenotype (Figure 5.8C). 
The effect of UVRAG upon LAMP1 was further explored in U2OS cells stably expressing 
GFP-UVRAG wild-type or S550A+S571A by incubation in presence or absence of nutrients (Figure 
5.9A). Knockdown of UVRAG resulted in larger lysosomes during nutrient rich conditions whilst 
rescue with siRNA resistant wild-type UVRAG caused a slight increase in the number of LAMP1 
objects that were slightly smaller on average, though neither were significant (Figure 5.9B&C). 
Expression of GFP-UVRAG S550A+S571A resulted in significantly increased number of LAMP1 
positive structures, more than twice that of control siRNA U2OS cells (Figure 5.9C).). The average 
LAMP1 object size increased upon starvation in all except the UVRAG S550A+S571A mutant that 
remained significantly smaller and demonstrated no change in size upon starvation (Figure 
5.9D).  Western blot of cells during growth conditions suggest an increase in the level of LAMP1 
expression upon UVRAG siRNA or rescue with UVRAG S550A+S571A (Figure 5.9D) 
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Figure 5.8 - Regulation of LAMP1 Structures By Nutrient Status 
(A) U2OS cells were grown in complete media (+AA), starvation media (EBSS) or treated with 1  µM 
KU0063794 for 2  h prior to formaldehyde f ixation and staining for endogenous LAMP1. (B)  
Quantitation of (A) where bars represent mean fold change in object number or object area ± SEM 
for n = 3 independent experiments (KU0063794 is prel iminary data from n  = 1) .  Statist ics were 
determined by Students paired t -test where * = p < 0.05. (C) LAMP1-GFP expressing U2OS cells 
were grown in immunofluorescence starvation media for 2  h, cel ls were then resupplemented with 
immunofluorescence complete media for  2  h.  Graph represents the mean fold change in number 
of LAMP1-GFP objects or s ize relative to time 0 for n  = 10 cells.   
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Figure 5.9 - LAMP1 Regulation By UVRAG 
(A)  U2OS cells or those stably expressing GFP -UVRAG wild-type or S550A+S571A were reverse 
transfected with 100 nM UVRAG ORF1 siRNA (Table 9) .  ~40 h post-transfection cells the growth 
media was changed and cells were incubated for 2  h in complete media (+AA) or starvation media 
(EBSS) . Cel ls were f ixed with formaldehyde and stained for endogenous LAMP1. (B+C) Quantitat ion 
of (A),  bars represent the mean fold change in (B)  number of objects or (C) object size ± SEM for 
n = 3 independent experiments. Signif icance was determined by one -way analysis of variance 
uti lising Dunnett’s post -test to compare each to the U2OS control s iRNA sample where *  = p < 
0.05. ** = p < 0.01, *** p = < 0.001, n.s = not s ignificant. (D)  Western blot of cells as in (A) grown 
in complete media (+AA) for 2  h 
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The depletion of UVRAG or mutation of UVRAG phosphorylation sites resulted in two distinct 
phenotypes. The localisation of GFP-UVRAG was examined by live cell imaging to confirm 
whether UVRAG was present at LAMP1 positive structures as had previously been reported 
(Matsunaga et al. 2009). U2OS cells that stably expressed GFP-UVRAG and LAMP1-mCherry were 
utilised to determine the extent of co-localisation, GFP-UVRAG displayed extensive 
co-localisation with mCherry-LAMP1 calculated by Manders co-localisation coefficient (Figure 
5.10)(Manders et al. 1993). The co-localisation of LAMP1-mCherry structures was lower with 
GFP-UVRAG S550A+S571 than GFP-UVRAG wild-type although not significant (p = 0.0968). This 
suggests that no difference in the proportion of GFP-UVRAG binding to LAMP1 structures is 
observed, but that more LAMP1 structures not containing GFP-UVRAG are present in phospho-
mutant cells. 
Following confirmation that UVRAG is present at LAMP1 structures, subsequent analysis was 
important to determine whether other components of the VPS34 complex were also present. 
Antibodies for immunoblotting VPS34 or BECLIN1 were utilised to examine co-localisation with 
LAMP1 structures, however, antibody binding proved poor for use by immunofluorescence (data 
not shown). Instead the localisation of the VPS34 product PI(3)P with LAMP1 structures was 
examined. PX-594 demonstrated a small proportion of co-staining with LAMP1 structures 
(Figure 5.11A), additionally known PI(3)P binding proteins including SNX1 and RUFY1 also 
demonstrated LAMP1 co-localisation suggesting that PI(3)P is present at LAMP1 structures 
(Figure 5.11B&C).  
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Figure 5.10 – GFP-UVRAG co-localises with LAMP1 
(A)  U2OS cel ls  stably expressing LAMP1 -mCherry and siRNA resistant GFP -UVRAG wild-type or 
S550A+S571A were reverse transfected with 10 0 nM ORF1 UVRAG siRNA (Table 9).  ~40 h post-
transfection cells were grown in immunofluorescence starvation media (EBSS) and images taken 
at 2 h. Arrows indicate regions of co -local isat ion. (B) Co-localisat ion of GFP-UVRAG and LAMP1-
mCherry was determined by Manders co -local isat ion coeffic ient (Manders et al.  1993)  ± SEM of 
n = 3 independent experiments. Statist ics were carried out by two -way analysis  of variance using 
Bonferroni’s post -test.  P-value for wild-type vs S550A+S571A is  shown. n.s = not significant  
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Figure 5.11 - PI(3)P Co-localises with LAMP1 
(A-C) U2OS cells were grown in complete media (+AA) or starvation media (EBSS)  for 2  h prior to  
freeze-thaw formaldehyde f ixation. Cel ls  were stained for LAMP1 and (A) PX-594, (B) RUFY1 or (C) 
SNX1 util is ing Alexa Fluor® 488 and 594 secondary antibodies as indicated (AF -488 / AF-594)  
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Figure 5.12 - mTOR and LAMP1 co-localisation 
(A)  U2OS cells were incubated in complete media (+AA) or starvation media (EBSS) for 2  h prior 
to formaldehyde f ixation. Cells were stained for endogenous LAMP1 and mTOR. (B)  Quantitation 
of co-local isation in (A) where bars repre sent mean Manders co- localisation values ± SEM of  n  = 3 
independent experiments.  Stat istics were determined by two -way analysis  of variance and 
Bonferroni’s post -test,  n.s = not s ignificant. P-value for +AA v EBSS is shown.  
Extensive work and literature implicates the requirement of lysosomal localisation for activation 
of the mTORC1 complex (1.3.2), this thereby raises the possibility that mTORC1 and the novel 
substrate UVRAG may co-habit the same cellular location. To confirm the localisation of mTOR 
at LAMP1 structures, U2OS cells were examined between conditions of growth or nutrient 
starvation (Figure 5.12A). The level of co-localisation between mTOR and LAMP1 was 
determined by Mander’s coefficient (Manders et al. 1993). mTOR exhibited extensive 
co-localisation with LAMP1 during nutrient rich and deplete conditions (Figure 5.12B). 
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Figure 5.13 - Effect of UVRAG on mTOR distribution 
U2OS cel ls or those stably expressing GFP -UVRAG wild-type or S550A+S571A were reverse 
transfected with 100 nM ORF1 siRNA (Table 9).  ~40 h post-transfection cel ls were incubated in 
complete media (+AA) for  1 h prior to formaldehyde f ixation and staining for endogenous mTOR.   
 
Depletion of endogenous UVRAG by RNAi resulted in large clustered mTOR structures that could 
be reverted by expression of GFP-UVRAG wild-type, expression of GFP-UVRAG S550A+S571A 
caused an increase in smaller structures (Figure 5.13). The staining of mTOR replicates that of 
LAMP1, which suggests that localisation of mTOR to the lysosome is not affected by UVRAG but 
reinforces previous data that lysosomal size is altered by UVRAG status (Figure 5.9A). 
The regulation of lysosomes has recently been noted to require the presence of phospholipids 
and has focused upon PI(4)P and PI(4,5)P2 as critical mediators (Rong et al. 2012; Sridhar et al. 
2013). During an autophagic response lysosomal membrane is recycled by a process known as 
autophagic lysosome reformation (ALR) to ensure consistent formation of competent 
lysosomes. This process that occurs during autophagy counter-intuitively depends upon 
mTORC1 activity (Yu et al. 2010). The process of ALR was therefore examined further.  
Following a period of starvation, mTOR is re-activated and is required by an unknown 
mechanism to trigger the budding of tubular structures from lysosomes., tubular structures 
extend until they are cleaved in a dynamin2 dependent manner (Schulze et al. 2013). The 
formation of tubules was examined in U2OS cells. A small number of tubules were observed to 
bud from LAMP1 structures under nutrient rich conditions (Figure 5.14A) whilst nutrient 
starvation increased the number and length of tubules. Interestingly, addition of the VPS34 
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inhibitor VPS34-IN1 (Characterised Chapter 6) to cells caused an even greater increase in tubular 
structures, suggesting that VPS34 and PI(3)P levels are linked to tubule formation and/or 
turnover.  
The requirement of active mTOR and indication that VPS34 is also required strongly suggests 
that UVRAG-VPS34 complex may be involved in lysosomal regulation. Further investigation is 
warranted to fully understand the requirement of UVRAG and VPS34 for the process of ALR. 
 
 
Figure 5.14 - LAMP1 Tubule Formation 
(A)  U2OS cells were grown in complete media (+AA) or starvation media (EBSS)  in the absence or 
presence of 1 µM VPS34-IN1 for 3 h. Cells were methanol f ixed and stained for endogenous LAMP1, 
arrows highl ight tubulated structures. (B+C) Quantitation of (A) where bars represent the mean 
(B)  tubule length (µm) or (C)  tubule number ± SD from n = 2 independent experiments.  
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5.3 Discussion 
 
The role of UVRAG phosphorylation in multiple trafficking processes has been examined and 
demonstrates a previously unanticipated requirement of VPS34 and PI(3)P for the regulation of 
lysosomes.   
VPS34 plays a fundamental role in the induction of autophagy demonstrated by a blockade of 
autophagic flux upon depletion in MEFs (Itakura et al. 2008). ATG14L is equally critical as it 
directs the VPS34 complex to pre-autophagosomal sites via a C-terminal targeting sequence (Fan 
et al. 2011). The role of UVRAG was originally reported to be required for autophagosome 
formation in HCT116 cells (Liang et al. 2006), more recent data however has suggested that 
UVRAG depletion has no effect upon autophagy (Itakura et al. 2008; Knævelsrud et al. 2010). 
Data presented here agrees with the latter study as no impairment in LC3 flux was observed 
upon depletion of endogenous UVRAG (Figure 5.1A-D), additionally mutation of UVRAG 
S550A+S571A had no significant effect upon LC3 flux (Figure 5.1E-G). This data is fitting with the 
function of vps34 in yeast, where vps38 is required for CPY trafficking but deletion has no effect 
upon autophagy induction (Kihara, Noda, et al. 2001). 
The process of receptor-mediated endocytosis has been shown to be dependent upon PI(3)P as 
depletion of VPS34 induced by conditional knockout or siRNA causes severe impairment of EGFR 
degradation (Jaber et al. 2012; Thoresen et al. 2010). Given that UVRAG depletion significantly 
reduces cellular PI(3)P Figure 4.12 it could be assumed that the trafficking rate would be 
decreased in a similar manner, analysis upon depletion of UVRAG by RNAi however has 
unusually shown to increase the rate of EGFR degradation at the 30 min time-point (Figure 5.2C). 
Previous published data utilising the same siRNA targeting sequence demonstrates conflicting 
results that depletion of UVRAG impairs EGFR degradation (Liang et al. 2008; Thoresen et al. 
2010), the reason for this disparity is unclear. EGFR degradation can be differentially regulated 
dependent upon stimuli and receptor expression level, although this is still not fully understood 
despite long-standing knowledge that distinct internalisation mechanisms exist (Lund et al. 
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1990; Yamazaki et al. 2002). More recently work has demonstrated that treatment with low 
doses of EGF causes CME mediated internalisation with the majority of receptors recycled back 
to the plasma membrane (Sigismund et al. 2005). Treatment with high concentrations of EGF 
(>20 ng/ml) in contrast cause ~40 % of EGFRs to undergo internalisation by non-clathrin 
endocytosis (NCE) and it is via this pathway that the majority of EGFR degradation occurs 
(Sigismund et al. 2008). An increase in EGFR degradation may therefore highlight an increased 
proportion of NCE occurring and reduced recycling. Indeed examination of the transferrin 
receptor, which exclusively utilises CME, demonstrates impaired recycling upon treatment with 
UVRAG siRNA (Figure 5.5). A partial defect in CME mediated recycling may consequently 
increase the proportion of NCE occurring upon EGFR stimulation and explain the increased level 
of degradation that is observed (Figure 5.2C). The role of UVRAG in CME and recycling requires 
further investigation and this could be explored by utilising the polyene macrolide Filipin that 
inhibits NCE (Schnitzer et al. 1994). The use of different cell lines may also be a source of disparity 
between results, comparison of the human cell lines U2OS and Hela in this study for example 
display clear differences in recycling rate (Figure 5.4). Care must be taken when utilising cell 
culture models given the propensity for aberrant endocytosis to drive cancer progression. 
Mutation of the tumour suppressor p53 for example is thought to occur in ~50 % of all cancers 
(Vogelstein et al. 2000) and research has demonstrated that this can cause enhanced EGFR and 
integrin trafficking that promotes growth and cell invasiveness (Muller et al. 2009). Multiple 
factors may therefore contribute to the discrepancy observed upon UVRAG depletion, 
importantly, no significant difference of EGFR degradation or transferrin recycling was observed 
between UVRAG wild-type or S550A+S571A (Figure 5.3, Figure 5.5D) that suggests mTOR 
regulation is not important for either pathway.  
Analysis of multiple PI(3)P interacting proteins representing distinct endosomal compartments 
demonstrated no change in membrane binding upon nutrient depletion or mTOR inhibition, by 
comparison use of the PI3K inhibitor blocked membrane binding (Figure 5.6A&B). Furthermore 
analysis by Immunofluorescence demonstrated no reduction difference in the formation of 
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punctate structures upon nutrient depletion (Figure 5.6C). As endocytic proteins demonstrated 
no difference in binding, other processes and cellular locations that UVRAG has been implicated 
in were examined.  
Interaction of UVRAG with the protein RINT-1 has been shown to be important for Golgi integrity 
(He et al. 2013). Whilst depletion of UVRAG caused fragmentation of the Golgi as determined 
by GM130 staining, no phenotype was observed following rescue with UVRAG wild-type or 
S550A+S571A. This is perhaps to be expected as the binding of RINT-1 to UVRAG is reported to 
be dependent upon UVRAG residues 270-442 (He et al. 2013), distinct from the mTOR mediated 
phosphorylation sites (Figure 3.5). A previous study indicated that UVRAG localises with LAMP1 
positive structures (Matsunaga et al. 2009), examination of LAMP1 by immunofluorescence 
demonstrated significant differences upon UVRAG depletion or expression of the S550A+S571A 
mutant (Figure 5.7B). Targeting of UVRAG by siRNA caused an accumulation of large LAMP1 
positive structures that appeared similar but not as severe as the vacuolar phenotype observed 
upon VPS34 kinase inhibition with wortmannin or VPS34 depletion (Futter et al. 2001; Zhou & 
Wang 2010). Similarly large swollen vacuoles are also observed in yeast by over-expression of 
the PI(3)P phosphatase MTMR3 (Walker et al. 2001). Blockade of PI(3,5)P2 formation by 
inhibiting PIKFYVE also yields a strikingly similar phenotype (Jefferies et al. 2008), it appears that 
PI(3,5)P2 is critical for maturation of endosomes and inhibition of PI(3)P or PI(3,5)P2 generation 
induces a similar phenotype. In comparison to loss of PI(3)P induced by the aforementioned 
mechanisms, depletion of UVRAG is still permissive for EGFR and LC3-II degradation suggesting 
that these structures remain acidic and functional (Figure 5.1 & Figure 5.2). However, it is 
possible that some endogenous protein remains due to incomplete siRNA knockdown. In 
contrast to the effect of UVRAG knock-down, expression of GFP-UVRAG S550A+S571A mutant 
displays a distinct phenotype of numerous small LAMP1 structures (Figure 5.7B).  
Following autophagy induction, lysosomes move to the perinuclear region and this is thought to 
assist with autophagosome fusion and lysosomal size increases (Figure 5.8)(Korolchuk et al. 
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2011). The size of lysosomes increased and were positioned at the perinuclear region in all cells 
upon nutrient starvation except for GFP-UVRAG S550A+S571A that exhibited significantly 
smaller LAMP1 structures throughout (Figure 5.9). The positioning of lysosomes depends upon 
both passive and active processes, recent research has demonstrated that smaller lysosomes 
(~500nm) undergo diffusion at approximately two and a half times faster than larger lysosomes 
(~1.2µm) (Bandyopadhyay et al. 2014). During nutrient starvation conditions lysosomes in 
control cells were on average twice the size of those in GFP-UVRAG S550A+S571A, passive 
diffusion may in part explain the diffuse cellular distribution observed upon mTOR site mutation 
(Figure 5.9). Lysosome transport between the cell periphery and perinuclear region is primarily 
regulated by the kinesin and dynein motor protein families, siRNA depletion or over-expression 
of these motor proteins can manipulate lysosome cellular location (Brown et al. 2005; Harada 
et al. 1998). Treatment of cells with the microtubule depolymerising agent nocodazole (Vasquez 
et al. 1997) causes a diffuse LAMP1 staining pattern similar to that observed in the GFP-UVRAG 
S550A+S571A mutant, which could indicate a defect in motor protein binding (Korolchuk et al. 
2011).  The kinesin family members KIF3, KIF5 and dynein have been demonstrated to regulate 
lysosome positioning, interestingly peptides corresponding to KIF5 (Kinesin-1) and Dynein were 
both identified upon mass spectrometry as interactors of GST-UVRAG (Appendix A & B). 
Peptides were identified upon immunoprecipitation of both UVRAG Wild-type and S550A 
mutant suggesting that S550 phosphorylation does not mediate or occlude binding. Further 
analysis is required to determine whether an endogenous interaction occurs and if mutation of 
both mTOR phosphorylation sites alters binding. Intriguingly the PI(3)P binding protein FYCO1 
has been demonstrated to act as an adaptor between autophagosomes, late endosomes or 
lysosomes and the motor protein kinesin to drive plus-end microtubule movement (Pankiv et al. 
2010). Binding to PI(3)P however may first require interaction with LC3 to allow FYVE domain 
interaction. Over-expression of FYCO1 was observed to increase lysosome fusion and the size of 
lysosome structures and as such it would be interesting to examine upon mutation of UVRAG 
S550A+S571A (Pankiv et al. 2010).  
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UVRAG has been reported to directly mediate lysosome fusion by interaction with VPS11 and 
VPS16 that form part of the core class C vacuolar protein sorting (Vps) complex (Liang et al. 
2008). Immunoprecipitation of GFP-UVRAG S550A however identified several unique peptides 
from VPS16 by mass spectrometry (Appendix B) suggesting that this interaction was not 
impeded by mutation of the S550 mTOR site. In addition experiments examining autophagy 
induction by LC3 flux (Figure 5.1) or endocytosis by EGFR degradation (Figure 5.3) were not 
significantly impaired indicating successful trafficking to the lysosome. The total level of LAMP1 
expression in GFP-UVRAG S550A+S571A cells was higher than control cells and it is possible that 
this acts as a compensatory mechanism to allow normal trafficking and degradation.  
Analysis of GFP-UVRAG and LAMP1-mCherry demonstrated extensive co-localisation and this is 
in agreement with a previous report that UVRAG is localised to LAMP1 structures (Figure 
5.10)(Matsunaga et al. 2009). A Difference in lysosomal phenotype between UVRAG rescue cells 
was clearly evident upon nutrient starvation, particularly in terms of lysosome size and 
distribution (Figure 5.10A). Several recently identified functions of UVRAG, such as the 
double-strand break repair pathway or RINT-1 interaction at the ER, have been determined to 
occur independently of the VPS34 complex (He et al. 2013; Zhao et al. 2012). Analysis of PX-594, 
RUFY1 and SNX1 staining with LAMP-1 demonstrated that regions of co-localisation did occur 
and suggested that PI(3)P is present at the lysosome, which may indicate the UVRAG is bound 
to the VPS34 complex at lysosomes (Figure 5.11). An important consideration however is that 
the PI(3)P present may be due to dephosphorylation of other lipid species or that this could be 
mediated by PI3K class 2 activity (Devereaux et al. 2013). Additionally newly synthesised LAMP1 
requires trafficking to the Golgi before continuing to endosomes and lysosomes (Cook et al. 
2004; Höning et al. 1996). Furthermore a small proportion of LAMP1 undergoes trafficking 
separately from the Golgi to the plasma membrane where endocytosis is required for LAMP1 to 
reach the lysosome (Rohrer et al. 1996). By navigating components of the endocytic trafficking 
system it is possible that some LAMP1 expression observed by immunofluorescence will not be 
representative of lysosomes but may co-localise with PI(3)P dependent structures, however this 
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is unlikely to be significantly accumulated. A recent proteomic experiment of an enriched 
lysosome fraction from rat liver identified several FYVE domain containing interacting proteins 
including FYCO1, FYVE-CENT, RUFY3 and ANKFY1; several SNX proteins were also identified that 
included SNX8, SNX16 and SNX17 (Chapel et al. 2013). The function of many of these proteins is 
currently uncertain and as such it will be important to examine whether they are indeed 
localised to lysosomes and if they may regulate lysosome function in a PI(3)P dependent 
manner. 
Immunofluorescence confirmed that mTOR exhibited extensive co-localisation with LAMP1 
positive structures in line with previous reports (Figure 5.12) (1.3.2).  Depletion of UVRAG or 
mutation of S550A+S571A did not prevent the formation of mTOR punctate structures, however 
the distribution and size of structures were visibly altered similar to that observed with LAMP1 
staining suggestive that mTOR remains localised to lysosomes (Figure 5.13). Separation of MEF 
lysates by iodixanol density gradient also showed that UVRAG and mTOR exhibit similar 
fractionation profiles indicating that mTOR and UVRAG are present at similar density 
compartments [Figure 3.11]. The cellular distribution of lysosomes can alter mTOR signalling by 
moving closer to downstream substrate proteins, forcibly directing lysosomes to the periphery 
by depletion of minus end directed microtubule motor proteins led to an increase in p70-S6K 
T389 phosphorylation (Korolchuk et al. 2011). The peripheral lysosomal distribution of UVRAG 
S550A+S571A cells may alter the level of downstream mTOR signalling and should be explored 
further.  
Comparison of LAMP1 staining between wild-type and S550A+S571A UVRAG rescue is 
particularly striking during nutrient starvation (Figure 5.10), however this is unusual as mTOR is 
inactive during autophagy and as such UVRAG will not be phosphorylated during this time. More 
recently however, the importance of mTORC1 activity for autophagic lysosome reformation 
(ALR) has become apparent (Yu et al. 2010). To continually mediate an autophagic response 
requires the ability to fuse and degrade autophagosome components whilst simultaneously 
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recycling membrane, catabolic products and replenishing the degradative ability of lysosomes. 
This is achieved by re-activation of mTOR following periods of starvation and is dependent on 
the efflux of nutrients from the lysosome (Rong et al. 2011). Tubular structures bud from LAMP1 
positive lysosomes and this is mediated in part by clathrin binding (Rong et al. 2012). Following 
extension tubules undergo scission mediated by Dynamin2 (Schulze et al. 2013). Formation of 
tubular LAMP1 positive ‘proto-lysosomes’ are then thought to undergo maturation to form 
functional lysosomes. ALR also increases the number or peripheral lysosomes which may assist 
signalling to mTORC1 substrates as mentioned previously (Korolchuk et al. 2011). 
Examination of LAMP1 in U2OS cells demonstrated the formation of tubular structures. Cells 
grown in nutrient rich conditions were tubulated but these rapidly underwent scission (Figure 
5.14). Starvation caused a more observable effect as tubules extended for much longer prior to 
cleavage from the main LAMP1 structure, inhibition of VPS34 using VPS34-IN1 caused severely 
extended LAMP1 tubules (Figure 5.14). This implicates PI(3)P directly as a regulator of the 
scission process. This is distinct from the small punctate staining observed upon UVRAG 
S550A+S571A mutation, however, it is possible that fixation may disrupt and affect the 
preservation of some of the tubules. It is therefore important to examine and compare tubule 
formation by live cell and is currently underway. 
Taken together the data presented in this chapter highlights a potentially unanticipated role of 
PI(3)P in the regulation of lysosomes. Moving forward, work will focus upon delineation of the 
relationship between PI(3)P and lysosome turnover. The impact of UVRAG S550A+S571A 
mutation upon tubule length and rate of scission in particular will be examined as this may be 
critical in driving the dispersed lysosome phenotype that is observed.  
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6 Characterisation of novel specific VPS34 
Inhibitors 
 
6.1 Introduction 
 
To date, further understanding of VPS34 has been hampered by a lack of specific tools that can 
help to delineate functional roles. Disruption of the VPS34 gene in yeast causes a 
temperature-sensitive growth defect that was important in establishing a link between Vps34p 
and protein sorting (Herman & Emr 1990). Further study in mammalian cells however has proven 
difficult due to the fundamental cellular requirement for VPS34, exemplified by embryonic 
lethality in homozygous VPS34 -/- mice (Zhou et al. 2011). Tissue specific knock-out of VPS34 
from sensory neurons generates mice that can survive gestation, however, all mice die within 2 
weeks exhibiting severe movement defects (Zhou & Wang 2010). Similarly homozygous deletion 
of VPS34 from cardiomyocytes causes death in mice between week five and week thirteen due 
to heart failure (Jaber et al. 2012). Depletion of VPS34 acutely by RNAi has also been utilised and 
implicated VPS34 as a possible upstream regulator of mTOR based upon decreased 
phosphorylation of mTORC1 substrates (Nobukuni et al. 2005; Byfield et al. 2005). There are 
several drawbacks regarding the use of RNAi that include the possibility of incomplete depletion 
of the endogenous protein that may be permissive for some functions. Additionally the use of 
lipofectamine as a transfection reagent has been linked to autophagy induction which may lead 
to erroneous results when examining the role of VPS34 (Mo et al. 2012). Furthermore siRNA 
depletion of VPS34 leads to significant loss of other canonical interaction partners including 
BECLIN1, ATG14L and UVRAG that may affect VPS34 independent roles of these proteins (Itakura 
et al. 2008; Thoresen et al. 2010; Devereaux et al. 2013). 
The use of ATP binding site inhibitors is a commonly used strategy for rapidly inhibiting kinase 
activity without affecting protein binding (Duong-Ly & Peterson 2013). Due to the conserved 
nature of the ATP binding site between kinases, many kinase inhibitors can act non-selectively 
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to bind and inhibit multiple kinases (Knight & Shokat 2005). Selectivity can be achieved and 
become therapeutically relevant as was demonstrated upon development of the first clinically 
approved kinase inhibitor Imatinib (Demetri & Mehren 2002). 
Inhibitor based studies of VPS34 to date have been reliant on the PI3K inhibitor wortmannin or 
LY294002 (Carpentier et al. 2013). Whilst able to inhibit VPS34 (Stack & Emr 1994), these 
inhibitors have a much greater potency against class I PI3Ks (Arcaro & Wymann 1993). A specific 
inhibitor of VPS34 is therefore required to fully explore lipid kinase function with minimal 
off-target effects. 
Recently developed inhibitors by Novartis, VPS34-IN1 and VPS34-IN2, are predicted to inhibit 
VPS34. This chapter examines the potency and specificity of these inhibitors towards VPS34 and 
the generation of cellular PI(3)P. 
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6.2 Results 
 
6.2.1 In vitro inhibition of VPS34 and VPS15 
 
VPS34-IN1 and VPS34-IN2 are structurally related bi-heteroaryl compunds that were originally 
reported in a patent by Novartis (WO 2012085815 A1), the structure of each is shown in Figure 
6.1A&B. The potency of VPS34-IN1 and VPS34-IN2 against recombinant VPS34 was determined 
by titration of each inhibitor to determine the concentration at which kinase activity was 
inhibited by 50 %, the IC50 (Sebaugh 2011). The activity of recombinant His-VPS34-VPS15 was 
determined by reaction with phosphatidylinositol liposomes in the presence of 32P γ-ATP and 
Mn2+ (Volinia et al. 1995; Whitman et al. 1988). VPS34-IN1 and VPS34-IN2 were both highly 
potent with IC50 values of 25 nM and 6 nM respectively (Figure 6.1C&D).  
A common drawback of ATP-binding kinase inhibitors is the propensity to inhibit multiple 
kinases due to similarities that exist within the ATP binding pocket (Karaman et al. 2008; Knight 
& Shokat 2005). To determine the selectivity of VPS34-IN1 and VPS34-IN2, multiple commercial 
protein and lipid kinase inhibitor profiling services were utilised to characterise the inhibitors as 
reported in Bago et al. (2014). A panel of 140 protein kinases and 20 lipid kinases were tested at 
the International Centre for Kinase Profiling, University of Dundee using 1 µM of each inhibitor. 
VPS34-IN1 & 2 were highly selective with little off-target inhibition of either lipid kinases or 
protein kinases. VPS34-IN1 exhibited greater selectivity reducing activity of only three protein 
kinases to ≤ 50 compared to six kinases with VPS34-IN2. The average activity across all protein 
kinases tested was 106 % or 82.4 % for VPS34-IN1 and VPS34-IN2 respectively, demonstrating 
further that the majority of kinases were unaffected and that VPS34-IN1 was slightly more 
selective (Bago et al. 2014).  
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Figure 6.1 - IC50 of VPS34-IN1 and VPS34-IN2 in vitro 
Chemical structure of the related compounds (A)  VPS34-IN1 and (B)  VPS34-IN2. (C)  Recombinant 
His-VPS34-VPS15 (DU8692)  was uti l ised for a  radioactive in vitro l ipid kinase assay with 
phosphatidyl inositol l iposomes. Lipid products were separated by thin layer chromatography and 
incorporation of  3 2P γ-phosphate was calculated by using a phospho imager.  (D)  Quantitat ion of 
(C),  points represent log inhibitor concentration relat ive to VPS34 kinase activity ± SEM from n=  3 
independent experiments. IC 50  curves were plotted by non-linear regression using Prism 5 .0.  
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The IC50 of VPS34-IN1 was tested against a further panel of 13 lipid kinases at ProQinase, Tumor 
Biology Center, Freiburg and 8 lipid kinases by AstraZeneca. VPS34-IN1 demonstrated extreme 
selectivity towards PIK3C3 over other PI3K isoforms and the IC50 was between 15-130 fold lower 
than the second most inhibited lipid kinase PIP5K1C (Bago et al. 2014). 
VPS34-IN1 and VPS34-IN2 are therefore highly potent and selective for VPS34 when tested in 
vitro and therefore the ability to inhibit cellular VPS34 was examined next. VPS34-IN1 & 2 were 
titrated from 0.01-10 µM in U2OS cells and the intensity of 2xFYVE-594 staining was used to 
determine cellular PI(3)P level. The level of response was comparable between inhibitors with 
~30 % and ~10 % PI(3)P staining remaining at 1 µM and 10 µM respectively. VPS34-IN1 and 
VPS34-IN2 can therefore potently inhibit PI(3)P production in cells. Further analysis is required 
to fully confirm that this impairs VPS34 functions within cells.  
 
 
159 
 
 
 
Figure 6.2 - Specific VPS34 Inhibitors block cellular PI(3)P production 
(A) U2OS cel ls  were treated for 1  h with the indicated concentration of inhibitor prior to freeze thaw formaldehyde f ixat ion and staining with 2xFYVE -594.  
(B)  Quantitation of (A),  bars represent cellular PI(3)P relative to DMSO control  ± SEM of n  = 3 independent experiments.   
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6.3 Discussion 
 
The data presented here demonstrates the potency and selectivity of the related compounds 
VPS34-IN1 and VPS34-IN2 for VPS34. The common drawback of previous VPS34 inhibitors has 
been the lack of selectivity over other PI3K classes (Stack & Emr 1994), this data now provides 
evidence for the first selective kinase inhibitor of VPS34.  
Data gathered in vitro suggests low nanomolar IC50 values for both compounds (Figure 6.1C&D), 
however to reduce PI(3)P formation by ~90 % requires cells to be treated with 10 µM of inhibitor 
(Figure 6.2). The reason for this disparity may be due to limitations in the permeability or uptake 
of the compound. However treatment of U2OS cells with VPS34-IN1 causes inhibition of PI(3)P 
formation within 1 minute that could not occur if the drug were not freely permeable (Bago et 
al. 2014), alternatively the remaining PI(3)P may be attributed to VPS34-independent sources. 
Class I PI3Ks produce PI(3,4,5,)P3 at the plasma membrane that undergoes sequential 
dephosphorylation via the SH2-containing inositol phosphatase (SHIP2) and inositol 
4-phosphatase (INPP4β) to form PI(3)P (Lioubin et al. 1996; Gewinner & Wang 2009). As inhibitor 
treatments were carried out on cells growing in nutrient rich media it is likely that class I PI3Ks 
were active. In addition the class II PI3Ks are able to phosphorylate phosphatidylinositol in vivo 
to form PI(3)P similar to VPS34 (Falasca et al. 2007) . Conditional knock-out of VPS34 from MEFs 
has been demonstrated to reduce PI(3)P levels by ~70 %, RNAi directed against class II PI3K α/β 
reduces the total level of PI(3)P further. It is estimated that up to 20 % of cellular PI(3)P may be 
generated via class II PI3Kα/β and this may play important functional roles alongside VPS34 
(Devereaux et al. 2013). The majority of VPS34 dependent PI(3)P is likely to be inhibited by 
treatment with 1 µM with the remaining likely to be generated from both class I (via 
dephosphorylation) and class II PI3Ks. It is important to characterise the effect of this inhibitor 
further in cells to confirm that it is sufficient to inhibit known VPS34 functions such as autophagy 
and endocytosis (Kihara, Noda, et al. 2001). 
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The ability to selectively inhibit VPS34 activity is an excellent tool that will allow VPS34 cellular 
function to be analysed more efficiently with fewer off-target effects, potentially avoiding 
artificial phenotypes. VPS34-IN1 has already proven beneficial for the study of VPS34, 
highlighting a potentially important and previously uncharacterised link between PI(3)P and the 
activation of serum and glucocorticoid-induced kinase 3 (SGK3) (Bago et al. 2014). Of particular 
interest will be further delineation of the reciprocal relationship between mTOR and VPS34, 
which has proved difficult to study so far with previous non-specific VPS34 inhibitors.  
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7 Discussion 
 
The data presented in this thesis highlights a novel and previously unanticipated role of mTOR 
in the regulation of lysosomes via phosphorylation of the protein UVRAG. This has been 
indicated through multiple lines of evidence. 
Data shown here has characterised UVRAG as a novel mTORC1 substrate that is phosphorylated 
at S550 and S571 (Figure 3.7). The phosphorylation of UVRAG has no discernible effect upon the 
stoichiometry or localisation of the UVRAG-VPS34 complex (3.2.5 and 3.2.6), however, it 
mediates a ~2 fold increase in VPS34 lipid kinase activity that can be detected in cells utilising 
recombinant PI(3)P binding domain probes (Figure 4.13). UVRAG exhibits extensive 
co-localisation at LAMP1 positive structures that are established (Flinn et al. 2010) and 
demonstrated to be co-localised with mTORC1 (Figure 5.12).  Mutation of the mTOR mediated 
phosphorylation sites in UVRAG induces a profound effect upon lysosomes, demonstrating 
increased small LAMP1 positive structures that are widely dispersed through the cytoplasm, 
even upon nutrient deprivation (Figure 5.9).  Lysosomal reformation is dependent upon mTOR 
kinase activity for turnover (Yu et al. 2010) and it is possible that this effect is mediated via 
UVRAG. 
The mechanism by which PI(3)P regulates lysosomes is unclear, however there are multiple 
possibilities that can be speculated upon and be subjected to further analysis. Treatment with 
the PIK3C3 inhibitor VPS34-IN1 rapidly causes a distended LAMP1 tubular phenotype similar to 
that observed upon inhibition of tubular scission (Schulze et al. 2013). It has previously been 
identified that Dynamin 2 is required for tubule scission at lysosomes and that use of the 
Dynamin inhibitor dynasore (Macia et al. 2006) rapidly induces a similar LAMP1 positive tubular 
phenotype (Schulze et al. 2013). The tubulated phenotype upon VPS34-IN1 administration 
would suggest that loss of PI(3)P or PI(3,5)P2 prevents tubule scission. PIKFYVE that utilises PI(3)P 
as a substrate to form PI(3,5)P2 (Figure 1.6) has previously been associated with lysosome 
maturation (Nicot & Fares 2006). In contrast to VPS34-IN1 treatment, prevention of PIKFYVE 
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activity by knock-out or by using the selective kinase inhibitor YM201636 causes accumulation 
of large late endosome/lysosome structures without tubule formation (Jefferies et al. 2008; 
Nicot & Fares 2006). Additionally, preliminary experiments suggest that treatment of either 
UVRAG wild-type or S550A+S571A rescue cells with YM201636 induces a similar swollen LAMP1 
positive phenotype (Data not shown). This would indicate that the requirement of PI(3,5)P2 
precedes the regulatory step mediated by UVRAG, but this requires further analysis for 
confirmation. Whilst data presented here suggests many smaller structures are formed in the 
UVRAG S550A+S571A mutant, it is possible that they also represent fragmented tubules as a 
consequence of the fixation method. Preliminary examination by live cell suggests that tubules 
formed in UVRAG S550A+S571 mutant cells may persist for longer before scission. 
Previous research examining the process of lysosomal reformation identified that PI4K and PI5K 
are localised to lysosomes and that this leads to formation of PI(4)P on lysosomes and PI(4,5)P2  
on budding tubular structures (Rong et al. 2012; Sridhar et al. 2013). PI(4,5)P2 is well established 
to mediate the recruitment of clathrin to the plasma membrane for endocytosis (Ford et al. 
2001) and it is assumed that membrane at lysosomes is turned over by an analogous mechanism 
(Rong et al. 2012). Dynamin is a small GTPase that forms a spiral around membranes and 
constricts by GTP hydrolysis to pinch off vesicles at the plasma membrane or lysosome tubules 
(Hinshaw & Schmid 1995; Schulze et al. 2013). Dynamin activity is modulated by 
phosphoinositides in vitro, however PI(4)P and  PI(4,5)P2 increased activity 1.5 and 3 fold 
respectively over PI(3)P (Yarar et al. 2008). Incubation of Dynamin with sorting nexin 9 (SNX9) 
synergises with multiple phosphoinositides to increase Dynamin activity further, in the presence 
of PI(3)P and SNX9 the activation of Dynamin is similar to that of PI(4,5)P2 (Yarar et al. 2008). 
SNX9 belongs to the sub-family of SNX-BAR proteins that are characterised by containing a 
SNX-PX domain and a C-terminal BAR domain; there are 12 SNX-BAR proteins and this includes 
SNX1, SNX18, and SNX33 (Weering et al. 2010). The PX and BAR domains act together as 
co-incident detectors of membranes as mutation of the BAR domain in SNX1 abolishes 
membrane localisation despite retaining phosphoinositide binding ability (Carlton et al. 2004). 
164 
 
 
SNX9 is able to tubulate lipids (Shin et al. 2008) and is required for efficient CME at the plasma 
membrane (Soulet & Yarar 2005). This in part is due to the ability of SNX9 to recruit Dynamin 2 
to tubular structures via SH3 domain-mediated interaction with the PRR in Dynamin (Lundmark 
& Carlsson 2004). Interestingly the PI3K inhibitor LY294002 (Vlahos et al. 1994) prevents tubular 
recycling from endosomes; removal of LY294002 causes rapid formation of tubular structures 
that subsequently recruit Dynamin 2 for tubule scission (Carpentier et al. 2013). This indicates 
that PI(3)P or PI(3,5)P2 is sufficient and necessary for the recruitment of effectors that mediate 
tubulation and scission. Data obtained with VPS34-IN1 by contrast promotes distended tubule 
formation that appears deficient in scission (Figure 5.14). It is possible that a SNX-BAR protein 
may still be recruited to lysosomes via interaction of the PX domain with PI(4)P or PI(4,5)P2 due 
to broad lipid binding ability (Yarar et al. 2007). At early endosomes however the recruitment of 
SNX-BAR proteins may be exclusively dependent upon PI(3)P or PI(3,5)P2 as they are thought to 
be the major phosphoinositide species at this location (Di Paolo & De Camilli 2006). This could 
potentially explain why tubules only form following removal of LY294002 (Carpentier et al. 
2013). Whilst a PX and BAR domain are required for lipid tubulation, an SH3 domain is essential 
for Dynamin 2 recruitment (Shin et al. 2008). Only SNX9, SNX18 and SNX33 from the SNX-BAR 
family contain SH3 domains (Weering et al. 2010). SNX18 is suggested to be functionally 
redundant with SNX9 to mediate CME with Adaptor protein-2 (AP-2) at the plasma membrane 
(Park et al. 2010). A separate study has indicated that SNX18 primarily functions via an analogous 
pathway but in combination with Adaptor protein 1 (AP-1) to mediate TGN to endosome 
trafficking (Håberg et al. 2008). The reported role of SNX18 in AP-1 trafficking (Håberg et al. 
2008) is particularly interesting, as it would suggest that separate SNX-BAR proteins can combine 
with differing Adaptor proteins to mediate distinct clathrin mediated budding events. As yet the 
role of SNX33 has not been established. Recently, a fifth adaptor protein complex (AP-5) has 
been identified based upon structural similarity with APs 1-4 (Hirst et al. 2011). AP-5 has been 
demonstrated to interact with SPG11 and SPG15 (Słabicki et al. 2010), two of the most 
frequently mutated proteins in hereditary spastic paraplegia (Boukhris et al. 2008; Hanein et al. 
165 
 
 
2008). Together SPG11 and SPG15 form a coat-like complex that localises to LAMP1 positive 
structures by immunofluorescence (Hirst et al. 2013) and SPG15 has been identified by mass 
spectrometry in purified lysosome fractions (Chapel et al. 2013). SPG15 is also known as 
Spastizin, zFYVE26 or FYVE-CENT, due to the presence of a FYVE domain. The mechanistic role 
of SPG15 thus far has been established as a key mediator of cytokinesis, the final step of mitosis 
following chromatid separation that divides the membrane and forms two daughter cells 
(Sagona et al. 2010). PI(3)P Is critical in this process as depletion of VPS34 causes cytokinesis 
arrest and increased formation of multinucleate cells, an effect that is replicated upon SPG15 
depletion (Sagona et al. 2010). Interestingly, knockdown of SNX9, SNX18 or SNX33 also cause 
cytokinesis failure and multinucleate cells formation (Ma & Chircop 2012). SPG15 is reported to 
immunoprecipitate with BECLIN1 and both BECLIN1 and UVRAG are demonstrated to localise to 
the midbody by immunofluorescence (Sagona et al. 2011; Thoresen et al. 2010). Importantly the 
localisation of SPG15 to LAMP1 structures is abolished by wortmannin suggesting it is recruited 
in a PI(3)P dependent manner (Khundadze et al. 2013). Additionally, a SPG15 knockout mouse 
model accumulates lysosomal enzymes (as seen in Figure 5.9D) and develops late-onset spastic 
paraplegia (Khundadze et al. 2013). Studies of the zebrafish SPG15 homologue souffle (Suf) 
identified that cortical granule maturation (a lysosome related organelle) is dependent upon Suf 
(Kanagaraj et al. 2014). Mutation of suf causes the accumulation of immature precursors that 
fail to pinch-off clathrin-coated buds, a phenotype that is also observed by inhibition of Dynamin 
with the inhibitor dynasore (Kanagaraj et al. 2014). Taken together this suggests that the 
recruitment of SPG15 to lysosomal structures occurs in a PI(3)P dependent manner and is critical 
for promoting scission and membrane turnover. Determining whether SPG15, Dynamin 2 and 
the SNX-BAR SH3 proteins are regulated downstream of UVRAG-dependent PI(3)P formation at 
the lysosome will be of critical importance. U2OS cell lines expressing Dynamin2-GFP, GFP-
SPG15 or GFP-SNX9 are being generated to examine their localisation by immunofluorescence 
upon lysosomal tubulation. The effect of UVRAG S550A+S571A mutation will then subsequently 
be examined to determine whether this affects protein localisation.  
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 The localisation of UVRAG to LAMP1 structures (Figure 5.10) is also interesting and it will be 
important to determine whether this is mediated directly via UVRAG or occurs via another 
component such as VPS15. UVRAG contains a C2 binding domain that has been demonstrated 
by lipid overlay to bind to PI(3)P, PI(4)P and PI(5)P (He et al. 2013). PI4K is present at the 
lysosome and forms PI(4)P (Sridhar et al. 2013) that could localise UVRAG via the C2 domain. 
Alternatively binding to PI(3)P would suggest a positive feedback loop for further recruitment of 
the UVRAG-VPS34 complex. This could be explored further by examining the localisation of 
UVRAG to LAMP1 structures in the presence of VPS34-IN1, additionally mutation of K78A/K82A 
in the UVRAG C2 domain abolishes phosphoinositide binding (He et al. 2013) and would 
determine whether recruitment is mediated by lipid binding.  
One of the most intriguing and fundamental questions is why UVRAG is an mTORC1 substrate? 
Traditionally, substrates of mTORC1 are phosphorylated to promote growth pathways such as 
protein synthesis by 4E-BP1 and p70 S6K (Hara et al. 1997; Price et al. 1992). Alternately 
phosphorylation by mTORC1 acts to repress catabolic pathways and functions as has been 
observed with ULK1 and TFEB (Ganley et al. 2009; Roczniak-Ferguson & Petit 2012). Data 
presented in this thesis indicates a role for UVRAG in lysosomal turnover and consequently it is 
interesting to consider how UVRAG phosphorylation could impact upon this in a context that 
may promote growth or inhibit catabolism. Whilst the impact of completely impaired lysosomal 
turnover is apparent upon SPG15 knockout, the consequence of UVRAG phosphorylation is less 
clear. Analysis of EGFR degradation (Figure 5.3) or transferrin receptor recycling (Figure 5.5) 
demonstrated no obvious difference upon UVRAG phosphorylation, although it is possible that 
defects are managed by increasing the total level of lysosomes. Lysosomal reformation is 
suggested to be important to maintain a competent pool of lysosomes (Yu et al. 2010), as such 
it may be important to test trafficking and degradation rates in UVRAG S550A+S571A cells 
following prolonged periods of stress that may indicate a deficiency in prolonged lysosome 
maintenance.  Given the intricate relationship of mTORC1 with the lysosome for activity (1.3.2), 
UVRAG phosphorylation may be important to maintain activation or promote downstream 
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substrate phosphorylation. Peripheral distribution of lysosomes is reported to assist with 
mTORC1 substrate phosphorylation (Korolchuk et al. 2011) and redistribution to the periphery 
also occurs during ALR upon mTOR activation (Yu et al. 2010). The Kinesin adaptor protein FYCO1 
drives positive directed transport to the periphery in a PI(3)P dependent manner (Pankiv et al. 
2010). FYCO1 has also been shown to reduce the formation of tubular lysosomes upon RNAi 
knockdown (Mrakovic et al. 2012). Increased production of PI(3)P at the lysosome upon UVRAG 
phosphorylation may act to enhance the association with FYCO1 and peripheral distribution and 
thereby promote mTORC1 signalling. However, mutation of UVRAG S550A+S571A elicits a 
diffuse punctate lysosomal staining upon fixation (Figure 5.9). This may represent other 
abnormalities that impede motor driven transport of lysosomes or may be a staining artefact of 
tubular structures. The effect of UVRAG upon basal mTOR signalling or recovery in ALR therefore 
requires further investigation. 
UVRAG may promote growth and survival by assisting with efficient cytokinesis as PI(3)P is 
required for this process (Sagona et al. 2010), work is currently underway to examine whether 
the phosphorylation of UVRAG alters the rate or efficiency of this process.  UVRAG has also been 
demonstrated to play a role distinct from the VPS34 complex in double-strand break repair 
pathways that is dependent upon interaction with DNA protein kinase (DNA-PK) via the protein 
KU-70 (Zhao et al. 2012). This interaction has been reported to occur under basal conditions 
however preliminary experiments have not been able to resolve an interaction with either 
UVRAG or VPS34 (data not shown). In addition SPG11 and SPG15 have been reported to interact 
with the helicase SPG48 and that SPG48 plays a role in double-strand break repair (Słabicki et al. 
2010). Whether there is a possible interlinking role between SPG15, SPG48 and UVRAG in DNA 
damage repair remains to be seen.  
The protein UVRAG therefore plays an important role in a myriad of cellular processes. Further 
work is still required to fully determine the functional consequences of lysosomal irregularities 
induced by UVRAG phosphorylation site mutations. Currently work has been dependent upon 
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the use of endogenous UVRAG siRNA and exogenous rescue constructs. This has certain 
limitations including residual incomplete knockout and limited time-frames for analysis. Work is 
ongoing to generate knock-in cell lines that express UVRAG S550A and S571A endogenously by 
utilising CRISPR site-specific nuclease technology (Cong et al. 2013). This would ensure 
endogenous protein comparison and improve data interpretation.  
 
 
Figure 7.1 – Proposed Model for the Role of Phosphoinositides in Lysosome Reformation 
The lysosome is regulated by multiple phosphoinositide species. PI4K forms PI(4)P that is  
sequential ly converted to PI(4,5)P 2  by PIP5K1B that is  important to recruit c lathrin to the growing 
bud/extension (Rong et al.  2012) . mTORC1 activity is  required for tubule formation and can 
phosphorylate UVRAG to increase PI(3)P production.  This has a positive effect  upon sc ission 
mediated by Dynamin 2 (Dyn2) v ia a currently unknown pathway or regulator.   
 
In conclusion, the VPS34 interacting protein UVRAG is phosphorylated in an mTOR dependent 
manner. Mutation of mTOR-mediated phosphorylation sites reduces VPS34 lipid kinase activity 
and consequently leads to aberrant LAMP1 staining, demonstrating a previously unanticipated 
link between the generation of PI(3)P and lysosome regulation. This study was originally intent 
on examination of VPS34 to identify regulatory mechanisms between intracellular trafficking 
pathways. Whilst the effect of UVRAG phosphorylation on trafficking rate is unclear, it has 
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unveiled a potentially fundamental aspect of lysosome regulation. This acts to redefine our 
current understanding of organelle identity and suggests that lysosomes in fact host multiple 
phosphoinositide species that are essential for function and regulation (Figure 7.1). Additionally 
this study adds further complexity to the current understanding of interactions between VPS34 
and mTOR by suggesting that mTORC1 acts upstream of VPS34 via phosphorylation of UVRAG. 
One of the key areas to examine next shall be how lysosome regulation impacts upon mTORC1 
signalling. mTOR and VPS34 feed into many similar pathways and this study has begun to reveal 
a reciprocal regulation of these two integral cellular components. This furthers our 
understanding of mTOR signalling and introduces additional implications for the utilisation of 
mTOR inhibitors in the clinic. The similarity of lysosome defect in UVRAG S550A+S571A mutants 
and SPG15 knockout is exciting and may suggest common elements. This study is the first to 
identify and characterise regulatory phosphorylation of the protein UVRAG and serves as a basis 
for future analysis. Further characterisation of UVRAG is essential for understanding its 
implicated role as a tumour suppressor and links to human disease, which could be critical for 
the development or improvement of future therapeutic strategies. 
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9 APPENDIX 
9.1 APPENDIX A 
 
Appendix A - – GST-UVRAG wild-type interacting proteins from experiment described in (Table 11), hits marked 
with an asterisk (*) are included on the curated list. 
REF  Score Peptides Coverage Gene Name 
Q9P2Y5 * 3391 253 71% UVRAG UV radiation resistance-associated gene protein 
P68363 * 1150 53 54% TUBA1B Tubulin alpha-1B chain 
Q9BVA1 * 589 28 46% TUBB2B Tubulin beta-2B chain 
Q13509  457 19 25% TUBB3 Tubulin beta-3 chain 
Q6S8J3  376 18 9% POTEE POTE ankyrin domain family member E 
Q02878  358 18 34% RPL6 60S ribosomal protein L6 
P26373  298 27 45% RPL13 60S ribosomal protein L13 
P12235  296 27 26% SLC25A4 ADP/ATP translocase 1 
P57721  284 9 15% PCBP3 Poly(rC)-binding protein 3 
P55884  214 12 10% EIF3B Eukaryotic translation initiation factor 3 subunit B 
Q6S8J3  203 8 3% POTEE POTE ankyrin domain family member E 
Q13200  198 12 7% PSMD2 26S proteasome non-ATPase regulatory subunit 2 
P42677  177 13 14% RPS27 40S ribosomal protein S27 
Q8N122 * 173 13 9% RPTOR Regulatory-associated protein of mTOR 
P63167 * 170 5 37% DYNLL1 Dynein light chain 1, cytoplasmic 
P83731  168 5 13% RPL24 60S ribosomal protein L24 
P62306  157 2 7%* SNRPF Small nuclear ribonucleoprotein F 
P13929  143 3 9% ENO3 Beta-enolase 
Q15019  135 7 14% Sep-02 Septin-2 
Q99570 * 135 16 9% PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 
O95071 * 132 9 3% UBR5 E3 ubiquitin-protein ligase UBR5 
P60900  132 2 5% PSMA6 Proteasome subunit alpha type-6 
P62829  126 12 37% RPL23 60S ribosomal protein L23 
P36542  115 6 11% ATP5C1 ATP synthase subunit gamma, mitochondrial 
P63220  113 7 33% RPS21 40S ribosomal protein S21 
Q13347  113 8 28% EIF3I Eukaryotic translation initiation factor 3 subunit I 
P61981 * 108 3 8% YWHAG 14-3-3 protein gamma 
P53675 * 102 8 4% CLTCL1 Clathrin heavy chain 2 
P10809  98 7 14% HSPD1 60 kDa heat shock protein, mitochondrial 
P60468  98 6 37% SEC61B Protein transport protein Sec61 subunit beta 
P14618  96 4 5% PKM2 Pyruvate kinase isozymes M1/M2 
Q9H853  95 5 21% TUBA4B Putative tubulin-like protein alpha-4B 
Q15836 * 94 3 24% VAMP3 Vesicle-associated membrane protein 3 
P62753  88 13 30% RPS6 40S ribosomal protein S6 
Q6S8J3  85 4 2% POTEE POTE ankyrin domain family member E 
Q14240  84 3 8% EIF4A2 Eukaryotic initiation factor 4A-II 
P05109  83 2 11% S100A8 Protein S100-A8 
Q14257  83 5 7% RCN2 Reticulocalbin-2 
O95816  81 8 19% BAG2 BAG family molecular chaperone regulator 2 
Q58FG0  81 6 13% HSP90AA5P Putative heat shock protein HSP 90-alpha A5 
Q96L21  79 6 16% RPL10L 60S ribosomal protein L10-like 
Q14157  77 3 4% UBAP2L Ubiquitin-associated protein 2-like 
O15027  76 5 3% SEC16A Protein transport protein Sec16A 
P12004  76 3 7% PCNA Proliferating cell nuclear antigen 
Q07020  76 7 11% RPL18 60S ribosomal protein L18 
O00410  75 2 2% IPO5 Importin-5 
P18124  74 4 20% RPL7 60S ribosomal protein L7 
P49207  74 6 16% RPL34 60S ribosomal protein L34 
P58546  73 2 14% MTPN Myotrophin 
P06703  71 2 8% S100A6 Protein S100-A6 
P46779  71 18 54% RPL28 60S ribosomal protein L28 
P62942  68 2 8% FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A 
Q8NEB9 * 68 6 6% PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 
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P33176 * 65 8 8% KIF5B Kinesin-1 heavy chain 
Q14839  65 3 1% CHD4 Chromodomain-helicase-DNA-binding protein 4 
P55209  64 4 11% NAP1L1 Nucleosome assembly protein 1-like 1 
P31943  62 4 8% HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 
P11586  59 9 9% MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 
P35580  59 8 3% MYH10 Myosin-10 
P39019  59 3 20% RPS19 40S ribosomal protein S19 
P14136  58 3 9% GFAP Glial fibrillary acidic protein 
P55795  58 4 5% HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 
O60282  57 3 3% KIF5C Kinesin heavy chain isoform 5C 
Q12840  57 3 3% KIF5A Kinesin heavy chain isoform 5A 
Q9Y490  57 6 2% TLN1 Talin-1 
P62263  56 3 15% RPS14 40S ribosomal protein S14 
P62424  56 14 32% RPL7A 60S ribosomal protein L7a 
P41252  55 5 1% IARS Isoleucyl-tRNA synthetase, cytoplasmic 
P55786  55 2 2% NPEPPS Puromycin-sensitive aminopeptidase 
Q9Y281  55 2 6% CFL2 Cofilin-2 
P35268  54 1 10% RPL22 60S ribosomal protein L22 
P55072  53 3 2% VCP Transitional endoplasmic reticulum ATPase 
Q15154  53 5 1% PCM1 Pericentriolar material 1 protein 
P23246  52 10 15% SFPQ Splicing factor, proline- and glutamine-rich 
P40429  52 8 17% RPL13A 60S ribosomal protein L13a 
Q5JNZ5  52 6 7% RPS26P11 Putative 40S ribosomal protein S26-like 1 
Q9Y277 * 52 4 10% VDAC3 Voltage-dependent anion-selective channel protein 3 
P61289  51 1 5% PSME3 Proteasome activator complex subunit 3 
A5A3E0  50 5 7% POTEF POTE ankyrin domain family member F 
Q92538  50 4 1% GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide 
exchange factor 1 
Q9UBP0 * 32 4 3% SPAST Spastin 
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9.2 APPENDIX B 
 
Appendix B - GST-UVRAG S550A interacting proteins from experiment described in (Table 11), hits marked with 
an asterisk (*) are included on the curated list. 
REF  Score Peptides Coverage Gene Name 
Q9P2Y5 * 6405 434 72% UVRAG UV radiation resistance-associated gene protein 
Q9BVA1 * 2046 88 58% TUBB2B Tubulin beta-2B chain 
P68363 * 2010 85 62% TUBA1B Tubulin alpha-1B chain 
Q13509  1461 48 30% TUBB3 Tubulin beta-3 chain 
Q05639  1173 69 32% EEF1A2 Elongation factor 1-alpha 2 
P68032  790 60 34% ACTC1 Actin, alpha cardiac muscle 1 
Q6S8J3  556 21 9% POTEE POTE ankyrin domain family member E 
Q71U36  389 16 30% TUBA1A Tubulin alpha-1A chain 
P55735  385 11 20% SEC13 Protein SEC13 homolog 
Q14257  345 17 29% RCN2 Reticulocalbin-2 
A6NKZ8  314 17 10%  Putative tubulin beta chain-like protein ENSP00000290377 
Q8TEB1 * 312 14 22% DCAF11 DDB1- and CUL4-associated factor 11 
Q6PEY2  287 16 24% TUBA3E Tubulin alpha-3E chain 
Q8NHW5  279 16 29% RPLP0P6 60S acidic ribosomal protein P0-like 
P62829  264 14 37% RPL23 60S ribosomal protein L23 
O95816  237 16 40% BAG2 BAG family molecular chaperone regulator 2 
P31943  236 12 18% HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 
P13929  232 5 7% ENO3 Beta-enolase 
Q8N122 * 227 19 14% RPTOR Regulatory-associated protein of mTOR 
Q9H853  220 6 10% TUBA4B Putative tubulin-like protein alpha-4B 
P42677  208 14 14% RPS27 40S ribosomal protein S27 
Q9H4B7  197 8 7% TUBB1 Tubulin beta-1 chain 
O95831  193 17 26% AIFM1 Apoptosis-inducing factor 1, mitochondrial 
Q99570 * 193 15 10% PIK3R4 Phosphoinositide 3-kinase regulatory subunit 4 
P10809  188 16 21% HSPD1 60 kDa heat shock protein, mitochondrial 
O14654 * 185 13 12% IRS4 Insulin receptor substrate 4 
P55884  179 4 5% EIF3B Eukaryotic translation initiation factor 3 subunit B 
Q13263 * 176 10 8% TRIM28 Transcription intermediary factor 1-beta 
P63167 * 161 5 37% DYNLL1 Dynein light chain 1, cytoplasmic 
P83731  160 13 32% RPL24 60S ribosomal protein L24 
P26373  158 18 36% RPL13 60S ribosomal protein L13 
P62306  151 3 9% SNRPF Small nuclear ribonucleoprotein F 
Q02878  149 6 22% RPL6 60S ribosomal protein L6 
P46736  143 3 3% BRCC3 Lys-63-specific deubiquitinase BRCC36 
Q96IX5  143 4 43% USMG5 Up-regulated during skeletal muscle growth protein 5 
P52597  126 13 17% HNRNPF Heterogeneous nuclear ribonucleoprotein F 
P33176 * 119 5 5% KIF5B Kinesin-1 heavy chain 
O15372  111 7 14% EIF3H Eukaryotic translation initiation factor 3 subunit H 
P46782  111 8 16% RPS5 40S ribosomal protein S5 
P14136  110 4 5% GFAP Glial fibrillary acidic protein 
Q6ZMR3  109 3 7% LDHAL6A L-lactate dehydrogenase A-like 6A 
Q13347  107 11 33% EIF3I Eukaryotic translation initiation factor 3 subunit I 
P62195  106 6 7% PSMC5 26S protease regulatory subunit 8 
Q16718  104 2 8% NDUFA5 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 5 
P60468  103 4 37% SEC61B Protein transport protein Sec61 subunit beta 
P43243  102 16 14% MATR3 Matrin-3 
P53675 * 95 5 1% CLTCL1 Clathrin heavy chain 2 
Q96EY1  93 4 6% DNAJA3 DnaJ homolog subfamily A member 3, mitochondrial 
Q6ZMR3  90 4 3% LDHAL6A L-lactate dehydrogenase A-like 6A 
P27635  86 15 35% RPL10 60S ribosomal protein L10 
Q15390  84 4 11% MTFR1 Mitochondrial fission regulator 1 
Q96L21  84 14 38% RPL10L 60S ribosomal protein L10-like 
Q13155  82 3 7% AIMP2 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 2 
O00743  80 7 17% PPP6C Serine/threonine-protein phosphatase 6 catalytic subunit 
Q8NEB9 * 78 4 3% PIK3C3 Phosphatidylinositol 3-kinase catalytic subunit type 3 
P05109  76 2 11% S100A8 Protein S100-A8 
P62942  76 2 8% FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A 
Q9P253  76 2 2% VPS18 Vacuolar protein sorting-associated protein 18 homolog 
P62249  72 8 30% RPS16 40S ribosomal protein S16 
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P04844  71 3 3% RPN2 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 
P53618 * 69 7 6% COPB1 Coatomer subunit beta 
Q12904  69 7 29% AIMP1 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1 
Q9Y5A9  66 2 2% YTHDF2 YTH domain family protein 2 
P62829  65 4 32% RPL23 60S ribosomal protein L23 
O00165  63 2 8% HAX1 HCLS1-associated protein X-1 
Q96S19  63 6 12% C16orf13 UPF0585 protein C16orf13 
O43175  60 4 6% PHGDH D-3-phosphoglycerate dehydrogenase 
Q14157  57 3 2% UBAP2L Ubiquitin-associated protein 2-like 
Q8TCT9  57 2 5% HM13 Minor histocompatibility antigen H13 
Q8NC51  54 1 3% SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 
P25705  52 12 15% ATP5A1 ATP synthase subunit alpha, mitochondrial 
P46779  52 13 45% RPL28 60S ribosomal protein L28 
P63220  52 3 33% RPS21 40S ribosomal protein S21 
P58546  51 1 14% MTPN Myotrophin 
Q9Y266  51 2 10% NUDC Nuclear migration protein nudC 
O15160  50 3 10% POLR1C DNA-directed RNA polymerases I and III subunit RPAC1 
O75190  50 4 9% DNAJB6 DnaJ homolog subfamily B member 6 
P36578  50 3 8% RPL4 60S ribosomal protein L4 
P49207  50 5 16% RPL34 60S ribosomal protein L34 
Q9Y2R0  45 4 17% CCDC56 Coiled-coil domain-containing protein 56 
Q8N4V1  44 2 18% MMGT1 Membrane magnesium transporter 1 
Q9NYH9  44 4 1% UTP6 U3 small nucleolar RNA-associated protein 6 homolog 
P46821  43 3 1% MAP1B Microtubule-associated protein 1B 
P78559  43 3 1% MAP1A Microtubule-associated protein 1A 
Q86U44  43 2 N/A METTL3 N6-adenosine-methyltransferase 70 kDa subunit 
Q9H269  43 1 1% VPS16 Vacuolar protein sorting-associated protein 16 homolog 
Q9UBP0 * 39 6 6% SPAST Spastin 
Q9BV73  31 2 0% CEP250 Centrosome-associated protein CEP250 
Q9NQT8  23 5 1% KIF13B Kinesin-like protein KIF13B 
Q9Y2H2  18 2  INPP5F Phosphatidylinositide phosphatase SAC2 
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9.3 APPENDIX C 
 
Appendix C – UVRAG non-phospho biotin peptide interacting proteins from experiment described in Table 12. all 
proteins with over 2 unique peptides shown. 
REF Score Peptides 
(Unique) 
Gene Name 
P20029 2568 96 (79) GRP78 78 kDa glucose-regulated protein  
P17879 366 10 (8) HS71B Heat shock 70 kDa protein 1B  
P38647 1290 47 (36) GRP75 Stress-70 protein 
P11499 155 6 (3) HS90B Heat shock protein HSP 90-beta 
Q61545 137 14 (3) EWS RNA-binding protein EWS  
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9.4 APPENDIX D 
 
Appendix D – UVRAG phospho biotin peptide interacting proteins from experiment described in Table 12, all 
proteins with over 2 unique peptides shown. 
 
 
REF Score Peptides 
(Unique) 
Gene Name 
P62259 2097 102 (78) 1433E 14-3-3 protein epsilon 
Q9CQV8 1770 88 (60) 1433B 14-3-3 protein beta/alpha  
P61982 1631 89 (65) 1433G 14-3-3 protein gamma  
P68510 1547 67 (56) 1433F 14-3-3 protein eta  
P63101 1233 50 (40) 1433Z 14-3-3 protein zeta/delta  
P68254 696 38 (25) 1433T 14-3-3 protein theta  
P20029 1419 58 (44) GRP78 78 kDa glucose-regulated protein  
P17879 258 7 (5) HS71B Heat shock 70 kDa protein 1B  
P38647 991 45 (31) GRP75 Stress-70 protein, mitochondrial  
P11499 463 20 (14) HS90B Heat shock protein HSP 90-beta  
P07901 358 11 (10) HS90A Heat shock protein HSP 90-alpha  
P08113E 130 7 (5) ENPL Endoplasmin  
Q61545 184 10 (4) EWS RNA-binding protein EWS  
P58252 146 9 (6) EF2 Elongation factor 2  
P63038 89 4 (3) CH60 60 kDa heat shock protein, mitochondrial  
P52480 78 5 (2) KPYM Pyruvate kinase isozymes M1/M2  
P16381 74 5 (2) DDX3L Putative ATP-dependent RNA helicase Pl10  
Q99PT1 71 2 (2) GDIR1 Rho GDP-dissociation inhibitor 1  
Q61753 67 4 (2) SERA D-3-phosphoglycerate dehydrogenase  
P17182 61 5 (2) ENOA Alpha-enolase  
E9Q557 56 17 (3) DESP Desmoplakin  
P01631 51 2 (2) KV2A7 Ig kappa chain V-II region 26-10  
P10630 47 2 (2) IF4A2 Eukaryotic initiation factor 4A-II  
Q8C120 33 6 (2) SH3R3 SH3 domain-containing RING finger protein 3  
Q8BIJ7 29 6 (2) RUFY1 RUN and FYVE domain-containing protein 1  
Q8VDD5 25 4 (2) MYH9 Myosin-9  
Q7TN37 22 4 (2) TRPM4 Transient receptor potential cation channel 
subfamily M member 4  
 
 
 
 
 
